<SEC-DOCUMENT>0001193125-18-233470.txt : 20180731
<SEC-HEADER>0001193125-18-233470.hdr.sgml : 20180731
<ACCEPTANCE-DATETIME>20180731172613
ACCESSION NUMBER:		0001193125-18-233470
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		7
FILED AS OF DATE:		20180731
DATE AS OF CHANGE:		20180731

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			TherapeuticsMD, Inc.
		CENTRAL INDEX KEY:			0000025743
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				870233535
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-207837
		FILM NUMBER:		18982128

	BUSINESS ADDRESS:	
		STREET 1:		6800 BROKEN SOUND PARKWAY NW
		STREET 2:		THIRD FLOOR
		CITY:			BOCA RATON
		STATE:			FL
		ZIP:			33487
		BUSINESS PHONE:		561-961-1911

	MAIL ADDRESS:	
		STREET 1:		6800 BROKEN SOUND PARKWAY NW
		STREET 2:		THIRD FLOOR
		CITY:			BOCA RATON
		STATE:			FL
		ZIP:			33487

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMHN, Inc.
		DATE OF NAME CHANGE:	20090930

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CROFF ENTERPRISES INC
		DATE OF NAME CHANGE:	19970915

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CROFF OIL CO
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>d579833d424b5.htm
<DESCRIPTION>FORM 424(B)(5)
<TEXT>
<HTML><HEAD>
<TITLE>Form 424(b)(5)</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Filed pursuant to Rule 424(b)(5)<BR>Registration No. 333-207837 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Arial Narrow"><FONT COLOR="#ff4338"><B>The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement is
not an offer to sell nor does it seek an offer to buy these securities in any jurisdiction where the offer or sale is not permitted. </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#ff4338"><B>Subject to Completion. Dated July&nbsp;31, 2018. </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Prospectus Supplement </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>to Prospectus dated
November&nbsp;17, 2015 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>$20,000,000 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g579833g0730230036492.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>TherapeuticsMD, Inc. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are offering
$20.0&nbsp;million of shares of our common stock, par value $0.001 per share, at an offering price per share of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our common stock is listed on the Nasdaq Global Select Market of The Nasdaq Stock Market LLC under the symbol &#147;TXMD.&#148; The last
reported sale price of our common stock on the Nasdaq Global Select Market on July&nbsp;30, 2018 was $5.52 per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:12pt; font-family:Times New Roman"><B>Investing in our
common stock involves a high degree of risk. See &#147;<A HREF="#psuppcov579833_1">Risk Factors</A>&#148; on page&nbsp;S-12 of this prospectus supplement, page 1 of the accompanying prospectus and in the documents we incorporate by reference in this
prospectus supplement to read about factors you should consider before buying shares of our common stock. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">This offering is being made
without an underwriter or a placement agent, and we will not be paying any underwriting discounts or commissions in connection with this offering. We will receive proceeds from the sale of these shares of $20.0&nbsp;million before deducting
customary offering expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Concurrently with this offering and pursuant to a separate prospectus supplement, we agreed to
sell&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock in an underwritten public offering, for aggregate gross proceeds of $65.0&nbsp;million, which we refer to herein as the
concurrent underwritten offering. The offering price per share in this offering will be the same as the offering price per share in the concurrent underwritten offering. We have granted the underwriters in the concurrent underwritten offering a <FONT
STYLE="white-space:nowrap">30-day</FONT> option to purchase up to an additional&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock at the public offering price, less underwriting
discounts and commissions. The closing of this offering is contingent upon the closing of the concurrent underwritten offering, but the closing of the concurrent underwritten offering is not contingent upon the closing of this offering. See
&#147;Plan of Distribution&#148; on page&nbsp;S-31 of this prospectus supplement for more information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and
Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the accuracy or adequacy of this prospectus supplement or the accompanying prospectus. Any representation to the contrary is a
criminal offense. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Delivery of the shares of common stock issued at the closing of this offering is expected to be made on or about
August&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Prospectus
Supplement dated&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="95%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><FONT STYLE="font-size:10pt"><B>Prospectus Supplement</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom579833_1">About this Prospectus Supplement</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-iii</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom579833_2">Prospectus Supplement Summary</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-1</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom579833_3">Risk Factors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-12</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom579833_4">Cautionary Statement About Forward-Looking Information</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-27</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom579833_5">Use of Proceeds</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-29</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom579833_6">Dilution</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-30</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom579833_7">Plan of Distribution</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-31</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom579833_8">Legal Matters</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-32</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom579833_9">Experts</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-32</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom579833_10">Where You Can Find More Information</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-32</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom579833_11">Incorporation of Certain Information by Reference</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-32</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Prospectus</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom579833_12">About this Prospectus</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">ii</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom579833_13">Risk Factors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom579833_14">Forward-Looking Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom579833_15">Our Company</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom579833_16">Ratio of Earnings to Fixed Charges</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom579833_17">Dilution</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom579833_18">Use of Proceeds</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom579833_19">Description of Common Stock</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom579833_20">Description of Preferred Stock</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom579833_21">Description of Debt Securities</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom579833_22">Description of Depositary Shares</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom579833_23">Description of Warrants</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom579833_24">Description of Purchase Contracts</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom579833_25">Description of Units</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom579833_26">Certain Provisions of Nevada Law and Our Charter and
Bylaws</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom579833_27">Legal Ownership of Securities</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom579833_28">Plan of Distribution</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom579833_29">Legal Matters</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom579833_30">Experts</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom579833_31">Where You Can Find More Information</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom579833_32">Incorporation of Certain Information by Reference</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have not authorized anyone to provide any information or to make any representations other than those contained or incorporated by
reference in this prospectus supplement, the accompanying prospectus or in any free writing prospectuses we have prepared. We take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may
give you. This prospectus supplement and the accompanying prospectus is an offer to sell only the shares offered hereby, but only under circumstances and in jurisdictions where it is lawful to do so. The information contained in this prospectus
supplement and the accompanying prospectus is current only as of the respective dates of such documents. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-ii </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom579833_1"></A>ABOUT THIS PROSPECTUS SUPPLEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Unless the context otherwise requires, all references in this prospectus supplement to &#147;TherapeuticsMD,&#148; &#147;TXMD,&#148;
&#147;Company,&#148; &#147;our company,&#148; &#147;we,&#148; &#147;us,&#148; or &#147;our&#148; refer to TherapeuticsMD, Inc., a Nevada corporation, and its subsidiaries, VitaMedMD, LLC, a Delaware limited liability company, BocagreenMD, Inc., a
Nevada corporation, and VitaCare Prescription Services, Inc., a Florida corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">This prospectus supplement and the accompanying
prospectus form part of a registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> that we filed with the Securities and Exchange Commission, or SEC, using a &#147;shelf&#148; registration process. This document contains two parts.
The first part consists of this prospectus supplement, which provides you with specific information about this offering. The second part consists of the accompanying prospectus, which provides more general information, some of which may not apply to
this offering. Generally, when we refer only to the &#147;prospectus,&#148; we are referring to both parts combined. This prospectus supplement may add, update, or change information contained in the accompanying prospectus. To the extent that any
statement we make in this prospectus supplement is inconsistent with statements made in the accompanying prospectus or any documents incorporated by reference herein or therein, the statements made in this prospectus supplement will be deemed to
modify or supersede those made in the accompanying prospectus and such documents incorporated by reference herein and therein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">This
prospectus supplement and the accompanying prospectus relate to the offering of shares of our common stock. Before buying any shares of our common stock offered hereby, we urge you to carefully read this prospectus supplement and the accompanying
prospectus, together with the information incorporated herein and therein by reference as described under the headings &#147;Where You Can Find More Information&#148; and &#147;Incorporation of Certain Information by Reference.&#148; These documents
contain important information that you should consider when making your investment decision. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">You should rely only on the information
contained in or incorporated by reference into this prospectus supplement, the accompanying prospectus and any free writing prospectus authorized by us. To the extent the information contained in this prospectus supplement differs or varies from the
information contained in the accompanying prospectus or any document filed prior to the date of this prospectus supplement and incorporated by reference, the information in this prospectus supplement will control. You should read this prospectus
supplement, the accompanying prospectus, the documents incorporated by reference into this prospectus supplement and the accompanying prospectus, and any free writing prospectus that we have authorized for use in connection with this offering, in
their entirety before making an investment decision. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The industry and market data and other statistical information contained in the
documents we incorporate by reference are based on management&#146;s own estimates, independent publications, government publications, reports by market research firms or other published independent sources and, in each case, are believed by
management to be reasonable estimates. Although we believe these sources are reliable, we have not independently verified the information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">TherapeuticsMD<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, vitaMedMD<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>,
and BocaGreenMD<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> are registered trademarks of our company. This prospectus supplement also contains trademarks and trade names of other companies. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-iii </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom579833_2"></A>PROSPECTUS SUPPLEMENT SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>The following summary of our business highlights some of the information contained elsewhere in or incorporated by reference into this
prospectus supplement or the accompanying prospectus. Because this is only a summary, however, it does not contain all of the information that may be important to you. You should carefully read this prospectus supplement and the accompanying
prospectus, including the documents incorporated by reference herein and therein, which are described under &#147;Incorporation of Certain Information by Reference&#148; in this prospectus supplement and under &#147;Incorporation of Certain
Information by Reference&#148; in the accompanying prospectus. You should also carefully consider the matters discussed in the section in this prospectus supplement entitled &#147;Risk Factors&#148; and in the accompanying prospectus, in our Annual
Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2017 and in other documents incorporated herein by reference. </I></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Our Company </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are a
women&#146;s health care company focused on creating and commercializing products targeted exclusively for women. Currently, we are focused on commercializing our recently U.S. Food and Drug Administration, or FDA, approved product, IMVEXXY&#153;
(estradiol vaginal inserts) for the treatment of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">moderate-to-severe</FONT></FONT> dyspareunia (vaginal pain associated with sexual activity), a symptom of vulvar and vaginal atrophy,
or VVA, due to menopause, and pursuing the regulatory approvals and <FONT STYLE="white-space:nowrap">pre-commercialization</FONT> activities necessary for commercialization of <FONT STYLE="white-space:nowrap">TX-001HR,</FONT> our <FONT
STYLE="white-space:nowrap">bio-identical</FONT> hormone therapy combination of 17&szlig;- estradiol and progesterone in a single, oral softgel drug candidate, for the treatment of moderate to severe vasomotor symptoms, or VMS, due to menopause in
menopausal women with an intact uterus, and our <FONT STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive system candidate <FONT STYLE="white-space:nowrap">in-licensed</FONT> from the Population Council. The new drug applications, or
NDAs, for <FONT STYLE="white-space:nowrap">TX-001HR</FONT> and our <FONT STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive system candidate have Prescription Drug User Fee Act, or PDUFA, target action dates for the completion of the
FDA&#146;s review of October&nbsp;28, 2018 and August&nbsp;17, 2018, respectively. IMVEXXY&#153; and <FONT STYLE="white-space:nowrap">TX-001HR</FONT> are designed to alleviate the symptoms of and reduce the health risks resulting from
menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort. More than 32 million women in the U.S. have symptoms of VVA due to menopause and more than 36 million women in the U.S. may experience VMS due to
menopause, representing potential total addressable markets for IMVEXXY<SUP STYLE="font-size:85%; vertical-align:top">TM</SUP> and TX-001HR, if approved, of approximately $20 billion and $25 billion, respectively. With our SYMBODA&#153; technology,
we are developing advanced hormone therapy pharmaceutical products to enable delivery of <FONT STYLE="white-space:nowrap">bio-identical</FONT> hormones through a variety of dosage forms and administration routes. In addition, we manufacture and
distribute branded and generic prescription prenatal vitamins. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g579833g0730230036773.jpg" ALT="LOGO">
 </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are a Nevada corporation. We maintain our principal executive offices at 6800 Broken
Sound Parkway NW, Third Floor, Boca Raton, Florida 33487. Our telephone number is (561) <FONT STYLE="white-space:nowrap">961-1900.</FONT> We maintain websites at <I>www.therapeuticsmd.com</I>, <I>www.vitamedmdrx.com</I> and
<I>www.bocagreenmd.com</I>. The information contained on our websites or that can be accessed through our websites does not constitute part of this prospectus supplement or the accompanying prospectus. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Recent Developments </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B><I>FDA Approval of IMVEXXY&#153;</I></B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On May&nbsp;30, 2018, we announced that the FDA had approved the 4 mcg and 10 mcg doses of IMVEXXY&#153; (estradiol vaginal inserts) for the
treatment of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">moderate-to-severe</FONT></FONT> dyspareunia (vaginal pain associated with sexual activity), a symptom of VVA, due to menopause. VVA is diagnosed in approximately 50% of
post-menopausal women. The 4 mcg dose of IMVEXXY&#153; represents the lowest approved dose of vaginal estradiol available. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On
July&nbsp;9, 2018, we initiated our early experience program for IMVEXXY&#153; with a limited launch of the 10 mcg dose to a targeted sample of healthcare providers throughout the country. In the first three weeks of our early experience program
(July 9 &#150; 27, 2018), approximately 1,363 healthcare providers have initiated at least one patient on treatment of the starter pack of IMVEXXY&#153; and sent in the <FONT STYLE="white-space:nowrap">follow-on</FONT> prescription for continuation
of treatment on the maintenance pack. We anticipate that the national launch of the 10 mcg dose of IMVEXXY&#153; will begin on August&nbsp;6, 2018 and that our <FONT STYLE="white-space:nowrap">Bio-Ignite</FONT> compounding pharmacy customers will
begin to receive IMVEXXY&#153; in late August 2018. We plan to launch the 4 mcg dose of IMVEXXY&#153; in September 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We believe the
patient engagement programs that we created and piloted around our prescription prenatal vitamin business have the potential to improve patient compliance for IMVEXXY<SUP STYLE="font-size:85%; vertical-align:top">TM</SUP>, compared to other products
in the VVA category. For example, in our prescription prenatal vitamin business, our patient engagement programs have achieved over 75% utilization of our co-pay assistance program, compared to an industry standard of 30%. We plan to use our patient
engagement programs to help patients manage out pocket costs IMVEXXY<SUP STYLE="font-size:85%; vertical-align:top">TM</SUP> and improve education regarding VVA, with the goal of increasing patient compliance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As part of the FDA&#146;s approval, we have committed to conduct a post-approval observational study to evaluate the risk of endometrial
cancer in post-menopausal women with a uterus who use a <FONT STYLE="white-space:nowrap">low-dose</FONT> vaginal estrogen unopposed by a progestogen such as IMVEXXY&#153;. In connection with the observational study, we will be required to provide
progress reports to the FDA on an annual basis. In addition, the FDA asked for post-approval information with respect to certain characteristics related to the product&#146;s specifications, which we expect to submit to FDA before the end of 2018.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B><I>License Agreement with Knight Therapeutics Inc.</I></B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On July&nbsp;30, 2018, we entered into a license and supply agreement, or the Knight License Agreement, with Knight Therapeutics Inc., or
Knight, pursuant to which we granted Knight an exclusive license to commercialize IMVEXXY&#153; and <FONT STYLE="white-space:nowrap">TX-001HR</FONT> in Canada and Israel. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of the Knight License Agreement, Knight will pay us a milestone fee upon first regulatory approval in Canada of each of
IMVEXXY&#153; and <FONT STYLE="white-space:nowrap">TX-001HR,</FONT> sales milestone fees based upon certain aggregate annual sales in Canada and Israel of each of IMVEXXY&#153; and <FONT STYLE="white-space:nowrap">TX-001HR</FONT> and royalties based
on aggregate annual sales of each of IMVEXXY&#153; and <FONT STYLE="white-space:nowrap">TX-001HR</FONT> in Canada and Israel. Knight will be responsible for all regulatory and commercial activities in Canada and Israel related to IMVEXXY&#153; and <FONT
STYLE="white-space:nowrap">TX-001HR.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We may terminate the Knight License Agreement if Knight does not submit all regulatory
applications, submissions and/or registrations required for regulatory approval to use and commercialize IMVEXXY&#153; and <FONT STYLE="white-space:nowrap">TX-001HR</FONT> in Canada and Israel within certain specified time periods. We also may
terminate the Knight License Agreement if Knight challenges our patents. Either party may terminate the Knight License Agreement for any material breach by the other party that is not cured within certain specified time periods or if the other party
files for bankruptcy or other related matters. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In connection with the Knight License Agreement, Knight entered into a subscription
agreement, or the Subscription Agreement, with us pursuant to which Knight agreed to purchase from us $20&nbsp;million of shares of our common stock concurrently with the closing of the first underwritten public offering of our
</P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
common stock to occur within 60 days following the date of the Knight License Agreement with gross proceeds to us of not less than $50&nbsp;million, at a price per share equal to the price per
share to the public in such public offering. In the event that such an offering does not close, Knight will, in lieu of such $20&nbsp;million investment, pay us a previously negotiated upfront license fee. An uncured breach of the Subscription
Agreement by Knight will give us the right to terminate the Knight License Agreement. Knight will be effectuating such purchase pursuant to the terms of this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Goldman Sachs&nbsp;&amp; Co. LLC is acting as underwriter in the concurrent underwritten offering.&nbsp;In connection with this offering,
Knight has agreed that, without our prior written consent, which cannot be given without Goldman Sachs &amp; Co. LLC&#146;s prior written consent, Knight will not offer or contract to sell any shares of our common stock until the date that is 90
days after the date of this prospectus supplement, after which date, the agreement will terminate and Knight will be released from its related obligations. Knight&#146;s agreement is subject to certain customary exceptions, including in respect of
bona fide gifts of shares.&nbsp;Additionally, provided that no public disclosure is required pursuant to the Securities Exchange Act of 1934, as amended, or the Exchange Act, Knight may, immediately and without restriction, sell or contract to sell
up to 50% of the shares of common stock acquired by Knight in this offering, as well as up to an additional 16.67% of such shares on or after each of the 30<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> day and the 60<SUP
STYLE="font-size:85%; vertical-align:top">th</SUP> day following the date of this prospectus supplement.&nbsp;See &#147;Plan of Distribution&#148; on page S-31 of this prospectus supplement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B><I>License Agreement with the Population Council</I></B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On July&nbsp;30, 2018, we entered into an exclusive license agreement, or the Council License Agreement, with the Population Council to
commercialize in the U.S. the Population Council&#146;s investigational segesterone acetate/ethinyl estradiol <FONT STYLE="white-space:nowrap">one-year</FONT> vaginal system for contraception. The <FONT STYLE="white-space:nowrap">one-year</FONT>
vaginal contraceptive system is in the shape of a ring and combines a novel progestin, segesterone acetate (Nestorone<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>), with a widely used estrogen (ethinyl estradiol) to prevent ovulation
for an entire year (13 cycles). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The NDA for the <FONT STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive system is
currently under review by the FDA and has a PDUFA target action date for the completion of the FDA&#146;s review of the NDA of August&nbsp;17, 2018. If approved, the <FONT STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive system would
be the first and only procedure-free, reversible prescription contraceptive to provide a full year of protection against unintended pregnancy while fully under a woman&#146;s control. If approved by its PDUFA target action date, we currently
estimate that the <FONT STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive system would be commercially available as early as the third quarter of 2019 with commercial launch as early as the fourth quarter of 2019 or first quarter of
2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Under the terms of the Council License Agreement, we are required to pay the Population Council milestone payments of
$20&nbsp;million within 30 days following approval by the FDA of the NDA for the <FONT STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive system and $20&nbsp;million within 30 days following the release of the first commercial batch of
the <FONT STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive system. The Population Council is also eligible to receive milestone payments and royalties from commercial sales of the <FONT STYLE="white-space:nowrap">one-year</FONT>
vaginal contraceptive system, as detailed below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We will assume responsibility for marketing expenses related to the commercialization of
the <FONT STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive system. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Council License Agreement includes exclusive
rights for us to negotiate <FONT STYLE="white-space:nowrap">co-development</FONT> of two other investigational vaginal contraceptive systems in development by the Population Council. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Population Council has previously developed long-acting, reversible contraception products including intrauterine devices, or IUDs, like
ParaGard<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> and Mirena<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>; implants like Norplant<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> and Jadelle<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP>; and the contraceptive vaginal ring for breastfeeding women Progering<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Contraceptive Market </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">An estimated 18&nbsp;million women in the U.S. want to avoid pregnancy and nearly half of all pregnancies that occur each year in the U.S. are
unintended. The U.S. market for prescription contraceptives generated more than $5&nbsp;billion in net sales in 2017 based on approximately 90&nbsp;million prescriptions. The U.S. market for prescription contraceptives includes oral contraceptives,
patches, rings, IUDs and implants. U.S. net sales of prescription oral contraceptives have fallen from approximately $3.5&nbsp;billion in 2012 to approximately $2.8&nbsp;billion in 2017, while during such time net sales of long acting reversible
contraceptives have grown from approximately $800&nbsp;million to approximately $1.5&nbsp;billion. According to the National Center for Health and Statistics, the use of long acting reversible contraceptives in the U.S. has increased nearly
five-fold in the last decade among women aged 15 to 44. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">NuvaRing, (etonogestrel/ethinyl estradiol vaginal ring), a monthly contraceptive
ring marketed by Merck, generated approximately $564&nbsp;million, $576&nbsp;million and $515&nbsp;million in net sales in 2017, 2016 and 2015, respectively, based on approximately 4.3&nbsp;million, 4.5&nbsp;million and 4.4&nbsp;million
prescriptions, respectively. We believe that the <FONT STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive system, if approved, will have significant competitive advantages to NuvaRing, and anticipated generic versions of NuvaRing,
including an anticipated price 40% lower than its current annual pricing, the ability to fill a <FONT STYLE="white-space:nowrap">one-year</FONT> prescription in one pharmacy visit and the lack of a requirement to refrigerate the ring. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Product </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The <FONT
STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive system is a combination of Nestorone with a widely used estrogen (ethinyl estradiol). Nestorone is a progesterone-derived unique natural progestin with high progestational potency and
antiovulatory activity and no androgenic, estrogenic or glucocorticoid effects at contraceptive doses. The active pharmaceutical ingredients are contained within a single ring that can prevent ovulation for an entire year with cyclical use (13
cycles). During each cycle, the <FONT STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive system is intended to be used following a 21/7 regimen, remaining in the vagina for three weeks (21 days) followed by one week (7 days) in which
the <FONT STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive system is removed from the vagina and placed in the accompanying case. The <FONT STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive system is composed of a
soft, flexible silicone elastomer. It is roughly 2<SUP STYLE="vertical-align:top">&nbsp;1</SUP>&#8260;<SUB STYLE="vertical-align:bottom">4</SUB> inches in diameter, and can be inserted and removed by the woman without the help of a healthcare
professional. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In a phase 3 acceptability study of 905 subjects, the <FONT STYLE="white-space:nowrap">one-year</FONT> vaginal
contraceptive system had overall satisfaction of 89% related to ease of use, side effects, expulsions/feeling the product and physical effect during sexual activity. The study also demonstrated high rates of adherence (94.3%) and continuation (78%).
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g579833g0730230036991.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We believe that the <FONT STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive system will
serve significant unmet needs in the U.S. contraceptive market for both patients and healthcare providers, if approved. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">For patients, if
approved, the <FONT STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive system would provide a single long-acting reversible birth control product that would not require a procedure for insertion at a doctor&#146;s office, empowering
women to be in complete control of their fertility and menstruation with a 21/7 regime. The <FONT STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive system would allow women to receive an entire year&#146;s worth of contraception with
a single annual pharmacy visit. In addition, if approved, we anticipate that the <FONT STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive system would be acceptable for nulliparous women, or women who have never given birth. Further,
the <FONT STYLE="white-space:nowrap">one-year</FONT> </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
vaginal contraceptive system is softer and more pliable than NuvaRing and, unlike NuvaRing, does not require refrigeration before being prescribed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We believe that the <FONT STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive system, if approved, may allow healthcare providers
to more easily follow medical standards of care and society guidelines to promote long-acting reversible birth control as first-line option. Existing long-acting reversible contraceptives, including IUDs and implants, require a procedure by a
healthcare provider for both insertion and removal and often require healthcare providers to buy, hold and manage inventory of the product. The <FONT STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive system, if approved, could be
prescribed by healthcare providers to a broader range of patients than many existing long-acting reversible contraceptive methods, including nulliparous women, without the need for providers to maintain inventory, since the prescription for the <FONT
STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive system would be filled at a pharmacy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The below chart sets certain
comparative information between the <FONT STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive system and currently-approved contraceptive products. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g579833txmd-riders.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Regulatory Status </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The NDA for the <FONT STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive system was submitted to the FDA by the Population
Council on August&nbsp;17, 2017 and has a PDUFA target action date for the completion of the FDA&#146;s review of the NDA of August&nbsp;17, 2018. The NDA for the <FONT STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive system is
supported by data from two pivotal phase 3 open-label safety and efficacy trials that were completed involving&nbsp;2,308&nbsp;healthy women at 27 sites in the U.S., Latin America, Europe, and Australia. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The phase 3 trials of the <FONT STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive system demonstrated efficacy consistent with
existing combination hormonal contraceptives, or CHCs, such as birth control pills, patches and hormonal rings. Approximately 1 to 3 women out of 100 women may get pregnant during the first year of use of the
<FONT STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive system, consistent with other CHCs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The phase 3 trials of the <FONT
STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive system also demonstrated safety consistent with existing CHCs. Consistent with other CHCs, women are at increased risk of a venous </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
thrombotic event, or VTE, when using the <FONT STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive system. Limited data are available on use of the
<FONT STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive system in women with a Body Mass Index, or BMI, greater than 29 because this population was excluded from the clinical trials after VTEs were reported. Consistent with other
CHCs, the most common adverse reactions are headache and nausea/vomiting and the most common adverse reactions leading to discontinuation are mild, and include:&nbsp;irregular bleeding, headache, vaginal discharge, and nausea/vomiting. We anticipate
that the <FONT STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive system will receive class labeling for CHCs, if approved. All CHCs carry a boxed warning that the product should not be used by patients who smoke cigarettes and are
over age 35. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We anticipate that the <FONT STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive system will be classified as a
&#147;new chemical entity,&#148; or NCE, by the FDA and thus have five years of regulatory exclusivity under the Drug Price Competition and Patent Term Restoration Act of 1984, otherwise known as the Hatch-Waxman Act, if approved. However, such
classification is not guaranteed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Council License Agreement </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Under the terms of the Council License Agreement, we are required to pay the Population Council milestone payments of $20&nbsp;million within
30 days following approval by the FDA of the NDA for the one year vaginal contraceptive system and $20&nbsp;million within 30 days following the release of the first commercial batch of the <FONT STYLE="white-space:nowrap">one-year</FONT> vaginal
contraceptive system. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">However, if a complete response letter or continuance of greater than 90 days is received by the Population Council
with respect to the <FONT STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive system or the <FONT STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive system is approved with additional post-marketing requirements or
commitments in excess of $1.0&nbsp;million, beyond the post-approval studies that may be required by the FDA noted below, then we or the Population Council may terminate the Council License Agreement, provided that we cannot agree with the
Population Council on a strategy to address such issues. If the <FONT STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive system is approved with shelf life of less than 18 months of stability or is not approved as an NCE that is
entitled to five years regulatory exclusivity in the U.S., then we may terminate the Council License Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are required to pay
the Population Council milestone payments of $40&nbsp;million upon cumulative net sales of the <FONT STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive system in the U.S. by us and our affiliates and permitted sublicensees of
$200.0&nbsp;million, $400.0&nbsp;million and $1.0&nbsp;billion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, we are required to pay the Population Council, on a
quarterly basis, step-based royalty payments based on annual net sales of the <FONT STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive system in the U.S. by us and our affiliates and permitted sublicensees as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="84%"></TD>
<TD VALIGN="bottom" WIDTH="15%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Annual Net Sales</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Royalty&nbsp;Rate</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less than or equal to $50.0&nbsp;million</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Greater than $50.0&nbsp;million and less than or equal to $150.0&nbsp;million</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Greater than $150.0&nbsp;million</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The annual royalty rate will be reduced to 50% of the initial rate during the
<FONT STYLE="white-space:nowrap">six-month</FONT> period beginning on the date of the first arms-length commercial sale of a generic equivalent of the <FONT STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive system that is launched by
a third party in the U.S., and thereafter will be reduced to 20% of the initial rate. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-6 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Population Council has agreed to perform and pay the costs and expenses associated with
four post-approval studies that may be required by the FDA for the <FONT STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive system. We have agreed to perform and pay the costs and expenses associated with a post-approval study that may
be required by the FDA to measure risk for venous thromboembolism, provided that if the costs and expenses associated with such post-approval study exceed $20&nbsp;million, half of such excess will offset against royalties or other payments owed by
us to the Population Council under the Council License. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We and the Population Council have agreed to form a joint product committee
responsible for overseeing activities under the Council License Agreement. We will be responsible for all aspects of promotion, product positioning, pricing, education programs, publications, sales messages and any additional desired clinical
studies for the <FONT STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive system, subject to oversight and decisions made by the joint product committee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Unless earlier terminated, the Council License Agreement will remain in effect until the later of the expiration of the <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">last-to-expire</FONT></FONT> of the Population Council&#146;s U.S. patents that are licensed to us, or the date following such expiration that follows a continuous period of six months
during which we and our affiliates have not made a commercial sale of the <FONT STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive system in the U.S. The Council License Agreement may also be terminated for certain breach and
bankruptcy-related events and by us on 180 days prior notice to the Population Council. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Population Council Contraceptive Ring Pipeline
</I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g579833g0730230037444.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As part of the Council License Agreement, we have the exclusive right to negotiate <FONT
STYLE="white-space:nowrap">co-development</FONT> and U.S. marketing rights for two other investigational vaginal contraceptive systems in development by the Population Council: a three-month contraceptive ring using Nestorone plus bio-identical
estradiol, which is currently in phase 2 clinical trials, and a new <FONT STYLE="white-space:nowrap">one-year</FONT> contraceptive ring using Nestorone plus ethinyl estradiol, which is designed as a life cycle management product for the <FONT
STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive system that we have licensed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Commercialization Strategy </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If the <FONT STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive system is approved by its PDUFA date, we currently estimate that
it would be commercially available as early as the third quarter of 2019, with commercial launch as early as the fourth quarter of 2019 or first quarter of 2020. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We intend to leverage our existing infrastructure, including our sales force, to commercialize the
<FONT STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive system, if approved, together with our recently-approved IMVEXXY<SUP STYLE="font-size:85%; vertical-align:top">TM</SUP> (estradiol vaginal inserts) and <FONT
STYLE="white-space:nowrap">TX-001HR</FONT> product candidate, if approved. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We believe that our existing sales force overlaps with over
80% of existing prescribers of the leading monthly contraceptive ring and that no additional sales representatives would be needed for us to </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-7 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
commercialize the <FONT STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive system, if approved. We intend to add a dedicated marketing team exclusively focused on the <FONT
STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive system. We also believe that we are uniquely positioned to market the <FONT STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive system, if approved, to the more than
60,000 annual vitaMedMD prenatal customers, who may proceed to contraception following pregnancy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We currently intend to price the <FONT
STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive system at parity or discount to current prescription contraceptive pricing levels and anticipate an annual wholesale acquisition cost, or WAC, of between $1000 and $1400, which
reflects a 40% decrease to the annual WAC of NuvaRing. We believe that the unique characteristics of the <FONT STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive system will assist us in pursuing favorable commercial payor coverage,
including only one pharmacy fill fee per year, an estimated savings of $33 annually per patient, and no office visit or procedure fees, an estimated savings of several hundred dollars annually per patient. However, obtaining and maintaining
favorable reimbursement can be a time-consuming and expensive process, and there is no guarantee that we will be able to negotiate or continue to negotiate reimbursement or pricing terms for our products, including the
<FONT STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive system, with payors at levels that are profitable to us, or at all. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, or the
ACA, mandates that private health plans provide coverage for women&#146;s preventative services, without imposing patient cost-sharing requirements, as recommended by the Health Resources and Services Administration, or HRSA. HRSA Guidelines require
private health plans to cover, without cost-sharing, at least one form of contraception, or product, in each of the methods, or classes, identified by the FDA for women in its Birth Control Guide, which currently includes 18 separate classes. For
classes with more than one type of treatment, private payors need only provide <FONT STYLE="white-space:nowrap">no-cost</FONT> coverage for one product in each class, and may use reasonable medical management to determine whether and to what extent
to cover other products in the class. We believe that if the <FONT STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive system is classified by the FDA as a &#147;vaginal system,&#148; and if the FDA determines that a &#147;vaginal
system&#148; constitutes a new class of birth control, this designation could allow for coverage of the <FONT STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive system by private health plans with no <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> cost for patients. However, the FDA may not designate the <FONT STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive system as a new class, and, even if the FDA does designate it as
a new class, it is possible that other <FONT STYLE="white-space:nowrap">FDA-approved</FONT> products could also be included in this new class. To the extent the <FONT STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive system is not the
only <FONT STYLE="white-space:nowrap">FDA-approved</FONT> product in a designated class of contraception, private payors may choose not to cover our <FONT STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive system, or may require
patient cost-sharing obligations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As part of the Council License Agreement, we have agreed to provide significantly reduced pricing to
federally designated Title X family planning clinics serving underrepresented women. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Population Council has previously entered into a
supply agreement with Crystal Pharma SAU for the supply of Nestorone, one of the active pharmaceutical ingredients for the <FONT STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive system, and a letter agreement with QPharma AB for the
optimization of the commercial manufacturing process for the <FONT STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive system. We intend to enter into agreements Crystal Pharma SAU and QPharma AB for the supply of Nestorone for, and the
manufacturing of, the <FONT STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive system, respectively, and the Population Council has agreed to use commercially reasonable efforts to assist us in doing so. However, either or both of
these contract manufacturers could decline to enter into similar agreements with us on the terms we anticipate, or at all. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I></I><B><I>Amendment to MidCap Credit Agreement</I></B><I> </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On July&nbsp;30, 2018, we entered into Amendment No.&nbsp;1 to that certain Credit and Security Agreement, or the Credit Agreement, by and
among our company, as borrower, our company&#146;s subsidiaries party thereto from time to time, each as a borrower, MidCap Financial Trust, as agent and as lender, and the additional lenders party thereto from time to time, in order to permit our
entry into the </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-8 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Council License Agreement.&nbsp;As part of the amendment, we are required to receive aggregate net cash proceeds of at least $75&nbsp;million from the issuance of our equity securities within
thirty days of entering into the Council License Agreement.&nbsp;Failure to complete this obligation will constitute an automatic event of default under the Credit Agreement. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-9 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The Offering </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Common stock offered by us</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Concurrent underwritten offering</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Concurrently with this offering, we are offering to sell&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock in the concurrent
underwritten offering. The closing of this offering is contingent upon the closing of the concurrent underwritten offering, but the closing of the concurrent underwritten offering is not contingent upon the completion of this offering. See
&#147;Plan of Distribution&#148; on page&nbsp;S-31 of this prospectus supplement.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Shares of common stock to be outstanding immediately after this offering and the concurrent
underwritten offering<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares, or
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares if the underwriters&#146; option to purchase additional shares in the concurrent underwritten offering is exercised in
full. The offering price per share in this offering will be the same as the offering price per share in the concurrent underwritten offering.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Use of proceeds</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">We intend to use the net proceeds from this offering and the concurrent underwritten offering to fund a portion of the costs for the commercial launch of our recently FDA approved product, IMVEXXY&#153; (estradiol vaginal
inserts) for the treatment of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">moderate-to-severe</FONT></FONT> dyspareunia (vaginal pain associated with sexual activity), a symptom of VVA, due to menopause, and to fund a portion of
the costs for <FONT STYLE="white-space:nowrap">pre-commercialization</FONT> and commercialization activities for <FONT STYLE="white-space:nowrap">TX-001HR,</FONT> our <FONT STYLE="white-space:nowrap">bio-identical</FONT> hormone therapy combination
of 17&szlig;- estradiol and progesterone in a single, oral softgel drug candidate, for the treatment of moderate to severe VMS due to menopause in menopausal women with an intact uterus, and our <FONT STYLE="white-space:nowrap">one-year</FONT>
vaginal contraceptive system candidate <FONT STYLE="white-space:nowrap">in-licensed</FONT> from the Population Council. We additionally intend to use a portion of the net proceeds from this offering and the concurrent underwritten offering for
working capital and general corporate purposes. We may also use a portion of the net proceeds from this offering and the concurrent underwritten offering to acquire or invest in businesses and products that we believe would complement our
women&#146;s health products and drug candidates. We can offer no assurance that the concurrent underwritten offering will close, and if it does not close, this offering will not be completed. Please see the section entitled &#147;Use of
Proceeds&#148; on page&nbsp;S-29 of this prospectus supplement.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><FONT STYLE="font-size:11pt"><B>Risk factors</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Investing in our common stock involves a high degree of risk. You should carefully read and consider the information set forth under &#147;Risk Factors&#148; on page&nbsp;S-12 of this prospectus supplement and page 1 of the
accompanying prospectus and in the documents incorporated by reference herein and therein to read about factors you should consider before buying shares of our common stock.</TD></TR>
</TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-10 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Common stock symbol</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Our common stock is listed on the Nasdaq Global Select Market under the symbol &#147;TXMD.&#148;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The number of shares of common stock to be outstanding immediately after this offering and the concurrent
underwritten offering is based on 216,834,059 shares outstanding on June&nbsp;30, 2018 and excludes the following as of that date: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">outstanding options representing the right to purchase a total of 25,210,899 shares of common stock at a weighted
average exercise price of $3.92 per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">outstanding warrants representing the right to purchase a total of 3,007,571 shares of common stock at a
weighted-average exercise price of $2.78 per share; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">5,052,120 shares of common stock reserved for future issuance under our
<FONT STYLE="white-space:nowrap">non-qualified</FONT> stock option plans. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Except as otherwise noted, all information in
this prospectus supplement assumes no exercise of the underwriters&#146; option to purchase additional shares. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-11 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom579833_3"></A>R<A NAME="psuppcov579833_1"></A>ISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>An investment in our common stock involves a high degree of risk. Before deciding whether to invest in our common stock, you should
carefully consider the risks described below and the risks described under &#147;Risk Factors&#148; in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2017, as well as the other risks and
uncertainties described in the other documents incorporated by reference in this prospectus supplement and the accompanying prospectus and the information contained in our other filings with the SEC, which are incorporated by reference in this
prospectus supplement and the accompanying prospectus in their entirety, and in any free writing prospectus that we have authorized for use in connection with this offering. If any of these risks actually occurs, our business, financial condition,
results of operations or cash flow could be seriously harmed. This could cause the trading price of our common stock to decline, resulting in a loss of all or part of your investment. </I></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Additional Risks Related to this Offering and our Common Stock </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>You will experience immediate and substantial dilution in the book value per share of the common stock you purchase and may experience further dilution
in the future as a result of equity offerings and other issuances of our common stock or other securities. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The offering price of
our common stock being offered in this offering and the concurrent underwritten offering is substantially higher than the net tangible book value per share of our common stock outstanding prior to this offering. Therefore, if you purchase our common
stock in this offering at the assumed public offering price of $5.52&nbsp;per share, which was the last reported sale price of our common stock on the Nasdaq Global Select Market on July&nbsp;30, 2018, you will incur an immediate substantial
dilution of $4.85&nbsp;in net tangible book value per share from the price you paid based on our net tangible book value and outstanding shares as of June&nbsp;30, 2018. For a further description of the dilution that you will experience immediately
after this offering, see the section titled &#147;Dilution.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">To raise additional capital, we may in the future offer additional
shares of our common stock or other securities convertible into or exchangeable for our common stock at prices that may not be the same as the price per share in this offering. We cannot assure you that we will be able to sell shares or other
securities in any other offering at a price per share that is equal to or greater than the price per share paid by investors in this offering, and investors purchasing shares or other securities in the future could have rights superior to existing
stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As of June 30, 2018, there were outstanding options representing the right to purchase a total of&nbsp;25,210,899 shares of
our common stock at a weighted average exercise price of $3.92 per share, outstanding warrants representing the right to purchase a total of 3,007,571 shares of our common stock at a weighted-average exercise price of $2.78 per share and 5,052,120
shares of our common stock reserved for future issuance under our <FONT STYLE="white-space:nowrap">non-qualified</FONT> stock option plans. You will incur dilution upon exercise of any outstanding stock options or warrants or upon the issuance of
shares of common stock under our stock incentive programs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, the sale of shares in this offering and the concurrent
underwritten offering and any future sales of a substantial number of shares of our common stock in the public market, or the perception that such sales may occur, could adversely affect the price of our common stock. We cannot predict the effect,
if any, that market sales of those shares of common stock or the availability of those shares of common stock for sale will have on the market price of our common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have broad discretion to determine how to use the proceeds raised in this offering and the concurrent underwritten offering, and we may not use the
proceeds effectively. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our management will have broad discretion over the use of proceeds from this offering and the concurrent
underwritten offering, and we could spend the proceeds from this offering in ways with which you may not agree or that do not yield a favorable return. We intend to use the net proceeds from this </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-12 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
offering and the concurrent underwritten offering to fund a portion of the costs for the commercial launch of our recently approved product, IMVEXXY&#153; (estradiol vaginal inserts) for the
treatment of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">moderate-to-severe</FONT></FONT> dyspareunia (vaginal pain associated with sexual activity), a symptom of VVA, due to menopause, and to fund a portion of the costs for <FONT
STYLE="white-space:nowrap">pre-commercialization</FONT> and commercialization activities for <FONT STYLE="white-space:nowrap">TX-001HR,</FONT> our <FONT STYLE="white-space:nowrap">bio-identical</FONT> hormone therapy combination of
17&szlig;-estradiol and progesterone in a single, oral softgel drug candidate, for the treatment of moderate to severe VMS due to menopause in menopausal women with an intact uterus, and our <FONT STYLE="white-space:nowrap">one-year</FONT> vaginal
contraceptive system candidate. We additionally intend to use a portion of the net proceeds from this offering and the concurrent underwritten offering for working capital and general corporate purposes. We may also use a portion of the net proceeds
from this offering and the concurrent underwritten offering to acquire or invest in businesses and products that we believe would complement our women&#146;s health products and drug candidates. If we do not invest or apply the proceeds of this
offering and the concurrent underwritten offering in ways that improve our operating results, we may fail to achieve expected financial results, which could cause our stock price to decline. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Sales of a substantial number of shares of our common stock, or the perception that such sales might occur, could adversely affect the trading price of
our common stock. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As of June&nbsp;30, 2018, we had 216,834,059 shares of our common stock outstanding. Also, we had, as of
June&nbsp;30, 2018, 28,218,470 shares of our common stock issuable upon the exercise of outstanding options and warrants. If this offering and the concurrent underwritten offering are completed, the number of shares of common stock that we have
outstanding will increase. Sales of a substantial number of shares of our common stock, or the perception that such sales might occur, could adversely affect the trading price of our common stock. Further, sales of shares underlying stock options
and warrants, or the perception in the market that the holders of a large number of shares intend to sell shares, could reduce the market price of our common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Because the closing of this offering is contingent upon the closing of the concurrent underwritten offering, there can be no assurance that this
offering will ultimately be completed. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of the Subscription Agreement, closing of this offering is
contingent upon the closing of the concurrent underwritten offering. In the event we do not close the concurrent underwritten offering, we cannot close this offering. There can be no assurance that we will close the concurrent underwritten offering,
and, if we do not consummate the concurrent underwritten offering, then this offering will not be completed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may not be able to complete the
development and commercialization of our hormone therapy drug candidates if we fail to obtain additional financing. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We need
substantial amounts of cash to complete the commercialization of IMVEXXY&#153; and the clinical development and commercialization of our hormone therapy drug candidates and our <FONT STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive
system candidate. Our existing cash may not be sufficient to fund these requirements. In addition, changing circumstances may cause us to consume funds significantly faster than we currently anticipate, and we may need to spend more money than
currently expected on these programs. We may attempt to raise additional capital from the issuance of equity securities, collaborations with third parties, licensing of rights to our products, the issuance of debt securities and the incurrence of
debt, to the extent permitted under our $200&nbsp;million term loan facility with MidCap Financial Trust, as agent and as lender, and the additional lenders party thereto from time to time, or the Credit Agreement, or other means, or a combination
of any of the foregoing. Securing additional financing will require a substantial amount of time and attention from our management and may divert a disproportionate amount of management&#146;s attention away from our
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> activities, which may adversely affect our ability to conduct our <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT>
operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-13 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We cannot guarantee that future debt or equity financing will be available in sufficient
amounts or on terms acceptable to us, if at all. If we are unable to raise additional capital when required or on acceptable terms, we may be required to take one or more of the following actions: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">significantly delay, scale back, or discontinue our product development and commercialization efforts;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">seek collaborators for our hormone therapy drug products and candidates at an earlier stage than otherwise would
be desirable or on terms that are less favorable than might otherwise be the case; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">license, potentially on unfavorable terms, our rights to our hormone therapy drug products and candidates that we
otherwise would seek to develop or commercialize ourselves. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Credit Agreement does, and any agreements governing
future debt financing, if available, may, include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures, or declaring dividends. To the extent that we raise additional
capital through the sale of equity or convertible debt securities, the ownership interest of our existing stockholders will be diluted, and the terms of these new securities may include liquidation or other preferences that adversely affect the
rights of our existing stockholders. If we raise additional funds through collaborations, strategic alliances, or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams,
research programs, or proposed products or grant licenses on terms that may not be favorable to us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If we are unable to raise additional
capital in sufficient amounts or on terms acceptable to us, we will be prevented from pursuing discovery, development and commercialization efforts, and our ability to generate revenue and achieve or sustain profitability will be substantially
harmed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are subject to extensive and costly government regulation. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The products we currently market, including IMVEXXY<SUP STYLE="font-size:85%; vertical-align:top">TM</SUP> and our prenatal vitamins, and the
pharmaceutical products we are developing and planning to develop in the future, are subject to extensive and rigorous domestic government regulation, including regulation by the FDA, the Centers for Medicare&nbsp;&amp; Medicaid Services, or CMS,
other divisions of the U.S. Department of Health and Human Services, including its Office of Inspector General, the U.S. Department of Justice, the Departments of Defense and Veterans Affairs, to the extent our products are paid for directly or
indirectly by those departments, state and local governments, and their respective foreign equivalents. The FDA regulates dietary supplements, cosmetics, and drugs under different regulatory schemes. For example, the FDA regulates the processing,
formulation, safety, manufacturing, packaging, labeling, and distribution of dietary supplements and cosmetics under its dietary supplement and cosmetic authority, respectively. The FDA also regulates the research, development, <FONT
STYLE="white-space:nowrap">pre-clinical</FONT> and clinical testing, manufacture, safety, effectiveness, record keeping, reporting, labeling, storage, approval, advertising, promotion, sale, distribution, import, and export of pharmaceutical
products under various regulatory provisions. If any drug products we develop are tested or marketed abroad, they will also be subject to extensive regulation by foreign governments, whether or not we have obtained FDA approval for a given product
and its uses. Such foreign regulation may be equally or more demanding than corresponding U.S. regulation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are also subject to
additional health care regulation and enforcement by the federal government and the states in which we conduct our business. Applicable federal and state health care laws and regulations include the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The federal health care Anti-Kickback Statute, or AKS, prohibits, among other things, persons from knowingly and
willfully soliciting, offering, receiving, or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, order, or recommendation of, any good or service, for
which payment may be </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-14 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
made under federal health care programs, such as Medicare, Medicaid, TriCare, and Children&#146;s Health Insurance Program. Liability may be established without proving actual knowledge of the
statute or specific intent to violate it. In addition, federal law provides that the government may assert that a claim including items or services resulting from a violation of the AKS constitutes a false or fraudulent claim for purposes of the
FCA, described below. Violations of the AKS carry potentially significant civil and criminal penalties, including imprisonment, fines, administrative civil monetary penalties, and exclusion from participation in government health care
programs.</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Ethics in Patient Referrals Act of 1989, commonly referred to as the Stark Law, and its corresponding
regulations, prohibit physicians from referring patients for designated health services, including outpatient drugs, reimbursed under the Medicare or Medicaid programs to entities with which the physicians or their immediate family members have a
financial relationship or an ownership interest, subject to narrow regulatory exceptions, and prohibits those entities from submitting claims to Medicare or Medicaid for payment of items or services provided to a referred beneficiary.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The federal False Claims Act, or FCA, imposes criminal and civil penalties, and authorizes civil whistleblower or
qui tam actions, against individuals or entities for knowingly presenting, or causing to be presented, claims for payment involving federally funded programs that are false or fraudulent or making a false statement to avoid, decrease, or conceal an
obligation to pay money with respect to a federal program. The FCA prohibits knowingly and willfully falsifying, concealing, or covering up a material fact or making any materially false statement in connection with the delivery of or payment for
health care benefits, items, or services. Government enforcement agencies and private whistleblowers have asserted liability under the FCA for, among other things, claims for items or services not provided as claimed, with inaccurate coding or for
medically unnecessary items or services, kickbacks, promotion of <FONT STYLE="white-space:nowrap">off-label</FONT> uses, and misreporting of drug prices to federal agencies. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology for
Economic and Clinical Health Act of 2009, and their respective implementing regulations, or collectively, HIPAA, imposes criminal and civil liability for executing a scheme to defraud any health care benefit program, including private payors, or
falsifying, concealing, or covering up a material fact, or making any materially false statements in connection with the delivery of or payment for health care benefits, items, or services. HIPAA also imposes obligations, including mandatory
contractual terms, with respect to safeguarding the privacy, security, and transmission of individually identifiable health information. State laws may also govern the privacy and security of health information or other personal information in
certain circumstances. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Federal laws require pharmaceutical manufacturers to report certain calculated product prices to the government
or provide certain discounts or rebates to government authorities or private entities, often as a condition of reimbursement under government health care programs. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Physician Payments Sunshine Act, enacted as part of the Patient Protection and Affordable Care Act, as
amended by the Health Care and Education Reconciliation Act of 2010, or the ACA, imposes annual reporting requirements for certain manufacturers of drugs, devices, biologics, and medical supplies for which payment is available under certain
government health care programs for certain payments and &#147;transfers of value&#148; provided to physicians and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members. Numerous
state laws may also require disclosure of transfers of value to health care providers, pharmaceutical pricing information and marketing expenditures. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-15 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Analogous state laws and regulations, such as state anti-kickback and false claims laws, may apply to
interactions between pharmaceutical manufacturers and health care providers, sales or marketing arrangements, and claims involving health care items or services reimbursed by commercial third-party payors, including private health care insurers and
health maintenance organizations; further, some state laws require pharmaceutical companies to comply with the pharmaceutical industry&#146;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Many aspects of these laws have not been definitively interpreted by the regulatory authorities or the courts, and
their provisions are open to a variety of subjective interpretations that increases the risk of potential violations. In addition, these laws and their interpretations are subject to change. Many state laws differ from each other in significant ways
and often are not preempted by federal laws, thus complicating compliance efforts. Moreover, the number and complexity of both federal and state laws continues to increase, and additional governmental resources are being used to enforce these laws
and to prosecute companies and individuals who are believed to be violating them. In particular, the ACA includes a number of provisions aimed at strengthening the government&#146;s ability to pursue AKS and FCA cases against pharmaceutical
manufacturers and other health care entities, including substantially increased funding for health care fraud enforcement activities, enhanced investigative powers, and amendments to the FCA that make it easier for the government and whistleblowers
to pursue cases for alleged kickback and false claim violations. We anticipate that government scrutiny of pharmaceutical sales and marketing practices will continue for the foreseeable future and subject us to the risk of government investigations
and enforcement actions. For example, federal enforcement agencies recently have shown interest in pharmaceutical companies&#146; product and patient assistance programs, including manufacturer reimbursement support services and relationships with
specialty pharmacies. Some of these investigations have resulted in significant civil and criminal settlements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Efforts to ensure that
our operations, including our business arrangements with third parties, comply with applicable health care laws and regulations could be costly. In connection with the commercial launch of
IMVEXXY<SUP STYLE="font-size:85%; vertical-align:top">TM</SUP>, we have grown our compliance program and are in the process of expanding our compliance team to focus on developing a program based on industry best practices. As this program has not
yet been tested and the requirements in this area are constantly evolving, our program may not eliminate all areas of potential exposure. Although effective compliance programs can help mitigate the risk of investigation, regulatory and enforcement
actions, and prosecution for violations of these laws, the risks cannot be entirely eliminated. Moreover, achieving and sustaining compliance with applicable federal and state fraud, privacy, security, and reporting laws may prove costly. Although
we believe that our business practices are structured to be compliant with applicable laws, it is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations, or case
law involving applicable fraud and abuse or other health care laws and regulations. If our past or present operations, including activities conducted by our sales team or agents, are found to be in violation of any of these laws or any other
governmental regulations that may apply to us, we may be subject to significant civil, criminal, and administrative penalties, damages, fines, exclusion from government health care programs, and the curtailment or restructuring of our operations. If
any of the physicians, providers, or entities with whom we do business are found to be not in compliance with applicable laws, they may be subject to criminal, civil, or administrative sanctions, including exclusion from government health care
programs. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses, divert our management&#146;s attention from the operation of our business, and damage our
reputation. In addition, even if we are not determined to have violated these laws, government investigations into these issues typically require the expenditure of significant resources and generate negative publicity, and could result in related
shareholder suits, any of which could also have an adverse effect on our business, financial condition and results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In
addition, from time to time in the future, we may become subject to additional laws or regulations administered by the FDA, the FTC, or by other federal, state, local, or foreign regulatory authorities, to the repeal of laws or regulations that we
generally consider favorable, such as the Dietary Supplement Health and Education Act of 1994, or to more stringent interpretations of current laws or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-16 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
regulations. We are not able to predict the nature of such future laws, regulations, repeals, or interpretations, and we cannot predict what effect additional governmental regulation, if it
occurs, would have on our business in the future. Such developments could, however, require reformulation of certain products to meet new standards, recalls or discontinuance of certain products not able to be reformulated, additional record-keeping
requirements, increased documentation of the properties of certain products, additional or different labeling, additional scientific substantiation, additional personnel, or other new requirements. Any such developments could have a material adverse
effect on our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Coverage and reimbursement may not be available for our products, which could make it difficult for us to sell our products
profitably, or if available, government mandated rebates may be too high and may adversely affect our profitability. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Market
acceptance and sales of our products, including IMVEXXY<SUP STYLE="font-size:85%; vertical-align:top">TM</SUP>, our <FONT STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive system candidate and our hormone therapy drug candidates or
prescription vitamins, will depend on coverage and reimbursement policies and may be affected by health care reform measures. Government health care programs and third-party payors decide which prescription drug products they will pay for and
establish reimbursement levels. Payors generally do not cover OTC products, and coverage for prescription vitamins and dietary supplements varies. Many private third-party payors, such as managed care plans, manage access to drug products&#146;
coverage partly to control costs to their plans, and may use drug formularies and medical policies to limit their exposure. Factors considered by these payors include product efficacy, cost effectiveness, and safety, as well as the availability of
other treatments including generic prescription drugs. Our ability to commercialize IMVEXXY<SUP STYLE="font-size:85%; vertical-align:top">TM</SUP> successfully depends on coverage and reimbursement levels set by government health care programs and
third-party private payors. Obtaining and maintaining favorable reimbursement can be a time-consuming and expensive process, and we may not be able to negotiate or continue to negotiate reimbursement or pricing terms for our products, including
IMVEXXY<SUP STYLE="font-size:85%; vertical-align:top">TM</SUP>, our <FONT STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive system candidate and our hormone therapy drug candidates with payors at levels that are profitable to us, or
at all.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In both the United States and some foreign jurisdictions, there have been a number of legislative and regulatory proposals to
change the health care system in ways that could affect our ability to sell our products profitably. In the United States, the Medicare Prescription Drug, Improvement, and Modernization Act of 2003, also called the Medicare Modernization Act, or
MMA, changed the way Medicare covers and pays for pharmaceutical products. The legislation expanded Medicare coverage for drug purchases by the elderly and certain others by establishing a new Part D to the Medicare program. However, unlike Medicare
Part A and Part B&#151;through which Medicare provides coverage for certain drugs in certain circumstances&#151;coverage under Part D is provided by private insurers operating under contract with CMS. In addition, this legislation provided authority
for limiting the number of certain outpatient drugs that will be covered in any therapeutic class. As a result of this legislation and the expansion of federal coverage of drug products, we expect that there will be additional pressure to contain
and reduce costs. These and future cost-reduction initiatives could decrease the coverage and price that we receive for our products from Medicare, if any, including IMVEXXY<SUP STYLE="font-size:85%; vertical-align:top">TM</SUP> and our other
hormone therapy drug candidates, if approved, and could significantly harm our business. It was historically unclear whether products approved to treat&nbsp;moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy due to menopause,
such as IMVEXXY<SUP STYLE="font-size:85%; vertical-align:top">TM</SUP>, were excluded under Medicare Part D, which resulted in limited Medicare coverage for such products. Recent clarification issued by CMS in May 2018 indicated that drugs, such as
IMVEXXY<SUP STYLE="font-size:85%; vertical-align:top">TM</SUP>, that are approved for the treatment of moderate to severe dyspareunia (as well as drugs approved for the treatment of moderate to severe symptoms of vulvar and vaginal atrophy
associated with menopause) are not excluded from Medicare Part D coverage. CMS&#146;s clarification, however, is no guarantee that such coverage will be obtained for IMVEXXY<SUP STYLE="font-size:85%; vertical-align:top">TM</SUP>, and obtaining
Medicare or other government health care program reimbursement for any new drug products may take up to several years following FDA approval. While the MMA applies only to drug benefits for Medicare beneficiaries, third-party payors often follow
Medicare coverage policies and payment limitations in setting their own reimbursement rates, and any reduction in reimbursement under Medicare may result in a similar reduction in payments from third-party payors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-17 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our ability to commercialize successfully the
<FONT STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive system, if approved, depends on coverage and reimbursement levels set by government health care programs and third-party private payors. The ACA mandates that private health
plans provide coverage for women&#146;s preventative services, without imposing patient cost-sharing requirements, as recommended by HRSA. HRSA Guidelines require private health plans to cover, with no patient <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs, at least one form of treatment (e.g., one product) in each of the methods (e.g., classes of contraception) identified by the FDA for women in its Birth Control Guide. If the <FONT
STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive system is deemed a new class of contraception by the FDA, this designation could allow for coverage by private health plans with no patient <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs. However, there is no guarantee that the FDA will designate the <FONT STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive system as a new class of contraception, or that such
coverage will be obtained. Even if the FDA does designate it as a new class of contraception, it is possible that other <FONT STYLE="white-space:nowrap">FDA-approved</FONT> products could also be included in this new class. Pursuant to HRSA
Guidelines, private payors need only provide <FONT STYLE="white-space:nowrap">no-cost</FONT> coverage for one product in each class, and may use reasonable medical management to determine whether and to what extent to cover other products in the
class. To the extent the <FONT STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive system is not the only <FONT STYLE="white-space:nowrap">FDA-approved</FONT> product in a designated class of contraception, private payors may choose not
to cover our <FONT STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive system, or may require patient cost-sharing obligations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">To the extent we obtain coverage for our products by state Medicaid programs, we may be required to pay a rebate to each state Medicaid
program for any covered outpatient drugs that are dispensed to Medicaid beneficiaries and paid for by a state Medicaid program, and to comply with all Medicaid rebate requirements of the Omnibus Budget Reconciliation Act of 1990 and the Veterans
Healthcare Act of 1992. Moreover, federal law requires that any company participating in the Medicaid Drug Rebate program also participate in the Public Health Service&#146;s 340B Program, which impose additional requirements. In addition, if our
products are made available to authorized users of the Federal Supply Schedule of the General Services Administration or to low income patients of certain hospitals, additional laws and requirements may apply. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We expect to experience pricing pressures in connection with the sale of our products generally due to the trend toward managed health care,
the increasing influence of health maintenance organizations, the scrutiny of pharmaceutical pricing, the ongoing debates on reducing government spending and additional legislative proposals. As discussed more below, the goal of the ACA, as enacted
in 2010, was to reduce the cost of health care and substantially change the way health care is financed by both government health care programs and third-party payors. Among other measures, the ACA increased rebates on manufacturers for certain
covered drug products reimbursed by state Medicaid programs. While we cannot predict the full effect that the ACA will have on government health care programs&#146; reimbursement policies in general or on our business specifically, the ACA may
result in downward pressure on drug reimbursement, which could negatively affect market acceptance of our products. In addition, we cannot predict whether new proposals will be made or adopted, when they may be adopted, or what impact they may have
on us if they are adopted. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The availability of generic products at lower prices than branded products may substantially reduce the
likelihood of reimbursement for branded products, such as IMVEXXY<SUP STYLE="font-size:85%; vertical-align:top">TM</SUP>, our <FONT STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive system candidate, or our other hormone therapy drug
candidates, if approved. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If we fail to successfully secure and maintain adequate coverage and reimbursement for our products or are
significantly delayed in doing so, we could have difficulty achieving market acceptance of our products and our business, financial condition, results of operations, and prospects could be harmed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Future legislation or regulations may adversely affect reimbursement from government health care programs and third-party payors. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Legislative changes have been proposed and adopted since the ACA was enacted. In August 2011, President Obama signed into law the Budget
Control Act of 2011, which, among other things, created the Joint Select Committee on Deficit Reduction to recommend to Congress proposals in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-18 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
spending reductions. The Joint Select Committee did not achieve a targeted deficit reduction, triggering the legislation&#146;s automatic reduction of several government programs. This includes
aggregate reductions to Medicare payments to health care providers of up to 2.0% per fiscal year, starting in 2013. In January 2013, President Obama signed into law the American Taxpayer Relief Act of 2012, which, among other things, reduced
Medicare payments to several categories of health care providers and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. Under the Trump administration, there have been
ongoing efforts to modify or repeal all or certain provisions of the ACA. If the ACA or parts of it are repealed, it is unclear what impact that would have on drug reimbursements or coverage and it is also unclear what programs, if any, Congress
might enact to replace the repealed portions of the ACA. The Trump administration may also take executive action in the absence of legislative action.&nbsp;For example, in October 2017, the President announced that the administration will withhold
the cost-sharing subsidies paid to health insurance exchange plans serving <FONT STYLE="white-space:nowrap">low-income</FONT> enrollees.&nbsp;With respect to IMVEXXY<SUP STYLE="font-size:85%; vertical-align:top">TM</SUP>, and to the extent we ever
obtain regulatory approval and commercialization of our other drug candidates, these new laws and policies (as well as proposed legislation, if enacted) may result in additional reductions in Medicare and other health care funding, which could have
a material adverse effect on our customers and accordingly, our financial operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On December&nbsp;13, 2016, President Obama signed
into law the 21st Century Cures Act, which, among other things, may increase the types of clinical trial designs that would be acceptable to support an NDA. It is unclear, at this time, how these provisions will be implemented or whether they would
have any effect on our company. Legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities for pharmaceutical products. We cannot be sure whether additional legislative
changes will be enacted, or whether the FDA regulations, guidance or interpretations will be changed, or what the impact of such changes on our drug product and drug candidates may be. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">There have also been efforts by government officials or legislators to implement measures to regulate prices or payment for pharmaceutical
products, including legislation on drug importation. Recently, there has been considerable public and government scrutiny of pharmaceutical pricing and proposals to address the perceived high cost of pharmaceuticals; proposed and enacted legislation
generally have focused on increasing transparency around drug costs or limiting drug prices. For example, in 2017, California enacted a new law, which went into effect on January&nbsp;1, 2018, to facilitate greater transparency in brand-name and
generic drug pricing through the implementation of specific price reporting requirements for pharmaceutical manufacturers. If adequate reimbursement levels are not maintained by government and third-party payors for our products, our ability to sell
our products may be limited and/or our ability to establish acceptable pricing levels may be impaired, thereby reducing anticipated revenues and profitability.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our dependence upon third parties for the manufacture and supply of our existing women&#146;s health care products and our hormone therapy drug
candidates may cause delays in, or prevent us from, successfully developing, commercializing, and marketing our products. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We do
not currently have, nor do we currently plan to build or accure, the infrastructure or capability to internally manufacture our existing women&#146;s health care products, our <FONT STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive
system candidate, or our hormone therapy drug candidates. We have relied, and will continue to rely, on third parties to manufacture these products in accordance with our specifications and in compliance with applicable regulatory
requirements.&nbsp;We have entered into long-term supply agreements with Catalent for the commercial supply of IMVEXXY<SUP STYLE="font-size:85%; vertical-align:top">TM</SUP> and our <FONT STYLE="white-space:nowrap">TX-001HR</FONT> hormone therapy
drug candidate, if approved. Under the terms of the agreements, we will be obligated to purchase certain minimum annual amounts of each product once we commence commercial sales of such product following regulatory approval of Catalent as a
manufacturer of such product.&nbsp;We depend on Lang, a full-service, private label and corporate brand manufacturer, to supply approximately 100% of our vitaMedMD and BocaGreen products.&nbsp;We do not have long-term contracts for the commercial
supply of our existing women&#146;s health care products, however, in certain circumstances, including our failure to satisfy our production forecasts to Lang, we may be obligated to reimburse Lang for the costs of excess raw materials purchased by
Lang that it cannot use in another product category that it then sells. We intend to enter into agreements with </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-19 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Crystal Pharma SAU and QPharma AB for the commercial supply of one of the active pharmaceutical ingredients for, and the manufacturing of, our <FONT STYLE="white-space:nowrap">one-year</FONT>
vaginal contraceptive system, respectively. However, if we experience delays in finalizing these agreements or are unable to execute these agreements on commercially reasonable terms, we may need to find alternative manufacturing facilities, which
would result in disruption in our commercialization of the <FONT STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive system, if approved. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Regulatory requirements could pose barriers to the manufacture of our existing women&#146;s health care products and our hormone therapy drug
product and drug candidates. Our third-party manufacturers are required to comply with cGMP regulations. As a result, the facilities used by any of our current or future manufacturers may be subject to an NDA
<FONT STYLE="white-space:nowrap">pre-approval</FONT> inspection, or PAI, by the FDA, and any noncompliance could cause the NDA to be disapproved or delayed in approval. Holders of NDAs, or other forms of FDA approvals or clearances, or those
distributing a regulated product under their own name, are ultimately responsible for compliance with manufacturing obligations even if the manufacturing is conducted by a third-party contract manufacturing organization, or CMO. All of our existing
products are, and our hormone therapy drug candidates, if approved, will be manufactured by CMOs. These CMOs are required by the terms of our contracts to manufacture our products in compliance with the applicable regulatory requirements. The CMO
that will manufacture IMVEXXY<SUP STYLE="font-size:85%; vertical-align:top">TM</SUP> and our <FONT STYLE="white-space:nowrap">TX-001HR</FONT> hormone therapy drug candidate, if approved, has previously been inspected by the FDA and received Form 483
observations with respect to its softgel manufacturing plant that will be used for the manufacture of the commercial supply of IMVEXXY<SUP STYLE="font-size:85%; vertical-align:top">TM</SUP> and <FONT STYLE="white-space:nowrap">TX-001HR,</FONT> if
approved.&nbsp;We anticipate that as part of a PAI of our NDA for <FONT STYLE="white-space:nowrap">TX-001HR,</FONT> the FDA may inspect Catalent&#146;s manufacturing facilities that would be used to manufacture that product. If this inspection
results in Form 483 observations, the approval of our NDA could be delayed significantly. The CMO that manufactured the hormone therapy drug candidate used in our phase 3 clinical trial for TX-001HR was previously inspected by the FDA, which issued
it a Form FDA 483 listing various observations, some of which pertained to the clinical supply of TX-001HR. The CMO has submitted its written response to the Form 483 observations to the FDA. We believe the responses satisfactorily address the
FDA&#146;s observations with respect to the clinical supply of TX-001HR and in a subsequent inspection the FDA did not find the CMO out of compliance with the commitments and associated deliverables contained in its response to the Form 483
observations. However, if the FDA were to determine that this CMO did not comply with cGMP regulations, it could cause the NDA for TX-001HR to be disapproved or delayed in approval. As noted above, we have contracted with a different CMO, Catalent,
to provide the commercial supply of IMVEXXY<SUP STYLE="font-size:85%; vertical-align:top">TM</SUP> and our TX-001HR drug candidate, if approved. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">QPharma, the CMO that will manufacture our <FONT STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive system, if approved, has
previously been inspected by the FDA and received Form 483 observations on December&nbsp;15, 2017, with respect to its facility that will be used for the commercial supply of the <FONT STYLE="white-space:nowrap">one-year</FONT> contraceptive system.
The FDA classified the inspection as Voluntary Action Indicated, meaning that the FDA found instances of noncompliance but the problems likely would not result in further regulatory action. QPharma submitted its written response to the Form 483
observations to the FDA on December&nbsp;22, 2017, however neither we nor QPharma has been informed by the FDA as to whether QPharma&#146;s response addresses and remediates these observations in a manner satisfactory to the FDA. If QPharma is
unable to address and remediate the FDA&#146;s observations, it could have a material adverse effect on the manufacture of the commercial supply of our <FONT STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive system, if approved. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If our manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of
the FDA and any applicable foreign regulatory authority, our regulatory submissions may be delayed or disapproved, and our marketed products may be affected. If these facilities are not in compliance for the manufacture of our vitamin products, our
hormone therapy drug product and our drug candidates, we may need to find alternative manufacturing facilities, which would result in disruptions of our sales and significant delays of up to several years in obtaining approval for our hormone
therapy drug candidates. In addition, our manufacturers will be subject to ongoing periodic unannounced inspections by the FDA and corresponding state and foreign agencies for compliance with cGMPs and similar regulatory requirements. Failure by any
of our manufacturers to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-20 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
comply with applicable cGMP regulations or other applicable requirements could result in sanctions being imposed on us, including fines, injunctions, civil penalties, violation letters, delays,
suspensions or withdrawals of approvals, operating restrictions, interruptions in supply, recalls, withdrawals, issuance of safety alerts, and criminal prosecutions, any of which could have a material adverse impact on our business, financial
condition, results of operations, and prospects. We do not currently have alternative manufacturers, and we may not be able to enter into a long-term agreement with alternative manufacturers, or do so on commercially reasonable terms, which could
have a material adverse impact on our business. Finally, we also could experience manufacturing delays if our CMOs give greater priority to the supply of other products over our products and proposed products to the delay or other detriment of our
products and proposed products, or otherwise do not satisfactorily perform according to the terms of their agreements with us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We also do
not have long-term contracts for the supply of the API used in IMVEXXY<SUP STYLE="font-size:85%; vertical-align:top">TM</SUP>, our hormone therapy drug candidates or the <FONT STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive system
candidate.&nbsp;If any supplier of the API or other products used in our hormone therapy drug candidates experiences any significant difficulties in its respective manufacturing processes, does not comply with the terms of an agreement between us,
or does not devote sufficient time, energy, and care to providing our manufacturing needs, we could experience significant interruptions in the supply of our hormone therapy drug candidates, which could impair our ability to supply our hormone
therapy drug candidates at the levels required for commercialization and prevent or delay their successful commercialization. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Even after the
approval of IMVEXXY<SUP STYLE="font-size:85%; vertical-align:top">TM</SUP>, and even if we obtain regulatory approval for our <FONT STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive system candidate and for our other hormone therapy
drug candidates, we will still face extensive, ongoing regulatory requirements and review, and our products may face future development and regulatory difficulties. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Even if we obtain regulatory approval for our <FONT STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive system or for one or more
of our hormone therapy drug candidates in the United States, and with respect to IMVEXXY<SUP STYLE="font-size:85%; vertical-align:top">TM</SUP>, the FDA may still impose significant restrictions on a product&#146;s indicated uses or marketing or to
the conditions for approval, or impose ongoing requirements for potentially costly post-approval studies, including phase 4 clinical trials or post-market surveillance. As a condition to granting marketing approval of a product, the FDA may require
a company to conduct additional clinical trials. The results generated in these post-approval clinical trials could result in loss of marketing approval, changes in product labeling, or new or increased concerns about side effects or efficacy of a
product. For example, the labeling for IMVEXXY<SUP STYLE="font-size:85%; vertical-align:top">TM</SUP> contains restrictions on use and warnings, and the labeling for our hormone therapy drug candidates and our
<FONT STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive system candidate, if approved, may also include restrictions on use or warnings. The Food and Drug Administration Amendments Act of 2007, or FDAAA, gives the FDA enhanced
post-market authority, including the explicit authority to require post-market studies and clinical trials, labeling changes based on new safety information, and compliance with <FONT STYLE="white-space:nowrap">FDA-approved</FONT> REMS programs.
IMVEXXY<SUP STYLE="font-size:85%; vertical-align:top">TM</SUP> and our hormone therapy drug candidates and our <FONT STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive system candidate, if approved, will also be subject to ongoing FDA
requirements governing the manufacturing, labeling, packaging, storage, distribution, safety surveillance, advertising, promotion, record keeping, and reporting of safety and other post-market information. The FDA&#146;s exercise of its authority
could result in delays or increased costs during product development, clinical trials and regulatory review, increased costs to comply with additional post-approval regulatory requirements, and potential restrictions on sales of approved products.
As part of the FDA&#146;s approval of IMVEXXY<SUP STYLE="font-size:85%; vertical-align:top">TM</SUP>, we have committed to conduct a post-approval observational study to evaluate the risk of endometrial cancer in post-menopausal women with a uterus
who use a <FONT STYLE="white-space:nowrap">low-dose</FONT> vaginal estrogen unopposed by a progestogen such as IMVEXXY&#153;. Foreign regulatory agencies often have similar authority and may impose comparable costs. Post-marketing studies, whether
conducted by us or by others and whether mandated by regulatory agencies or voluntary, and other emerging data about marketed products, such as adverse event reports, may also adversely affect sales of our hormone therapy drug candidates once
approved, and potentially our other marketed products. Further, the discovery of significant problems with a product similar to one of our products that implicate (or are perceived to implicate) an entire class of products could have an adverse
effect on sales of our approved products. Accordingly, new data about our products could negatively affect demand because of real or perceived side effects or uncertainty </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-21 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
regarding efficacy and, in some cases, could result in product withdrawal or recall. Furthermore, new data and information, including information about product misuse, may lead government
agencies, professional societies, and practice management groups or organizations involved with various diseases to publish guidelines or recommendations related to the use of our products or the use of related therapies or place restrictions on
sales. Such guidelines or recommendations may lead to lower sales of our products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The holder of an approved NDA also is subject to
obligations to monitor and report adverse events and instances of the failure of a product to meet the specifications in the NDA. Application holders must submit new or supplemental applications and obtain FDA approval for certain changes to the
approved product, product labeling, or manufacturing process. Application holders must also submit advertising and other promotional material to the FDA and report on ongoing clinical trials. Legal requirements have also been enacted to require
disclosure of certain clinical trial results on a publicly available database. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, manufacturers of drug products and their
facilities are subject to continual review and periodic inspections by the FDA and other regulatory authorities for compliance with the FDA&#146;s cGMPs regulations and other regulatory requirements, such as adverse event reporting. If we or a
regulatory agency discovers problems with a product, such as adverse events of unanticipated severity or frequency or problems with the facility where the product is manufactured, a regulatory agency may impose restrictions on that product, the
manufacturing facility, or us, including requiring recall or withdrawal of the product from the market or suspension of manufacturing, requiring new warnings or other labeling changes to limit use of the drug, requiring that we conduct additional
clinical trials, imposing new monitoring requirements, or requiring that we establish a REMS program. Advertising and promotional materials must comply with FDA rules in addition to other potentially applicable federal and state laws, and are
subject to review by FDA. If the FDA raises concerns regarding our&nbsp;promotional materials&nbsp;or messages, we may be required to modify or discontinue using them and may be required to provide corrective information. Should we fail to comply
with these requirements, we may be subject to significant liability including civil and administrative actions as well as criminal sanctions. The distribution of product samples to physicians must comply with the requirements of the Prescription
Drug Marketing Act and its implementing regulations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our activities are also potentially subject to federal and state consumer protection
and unfair competition laws. If we or our third-party collaborators fail to comply with applicable regulatory requirements, a regulatory agency may take any of the following actions: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">conduct an investigation into our practices and any alleged violation of law; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">issue warning letters or untitled letters asserting that we are in violation of the law; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">seek an injunction or impose civil or criminal penalties or monetary fines; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">suspend or withdraw regulatory approval; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">require that we suspend or terminate any ongoing clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">refuse to approve pending applications or supplements to applications filed by us; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">suspend or impose restrictions on operations, including costly new manufacturing requirements;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">seize or detain products, refuse to permit the import or export of products, or require us to initiate a product
recall; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">exclude us from providing our products to those participating in government health care programs, such as
Medicare and Medicaid, and refuse to allow us to enter into supply contracts, including government contracts. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-22 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Recent government enforcement has targeted pharmaceutical companies for violations of fraud and abuse
laws. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The AKS has been interpreted to apply to arrangements between pharmaceutical manufacturers on one hand and prescribers,
purchasers, pharmacies, and formulary managers on the other.&nbsp;Although there are a number of statutory exemptions and regulatory safe harbors protecting certain common activities from prosecution, the exemptions and safe harbors are drawn
narrowly and practices that involve remuneration to those who prescribe, purchase, or recommend pharmaceutical products, including certain discounts, or engagement of speakers or consultants, may be subject to scrutiny if they do not fit squarely
within an exemption or safe harbor.&nbsp;Our practices with respect to interactions with health care professionals, including but not limited to consultant relationships, speaker programs, advisory boards, and scientific/educational grant programs,
as well as our arrangements with pharmacies, may not in all cases meet all of the criteria for safe harbor protection from AKS liability. Moreover, there are no safe harbors for many common practices, such as educational and research grants or
patient assistance programs. In addition, several states have recently enacted legislation requiring pharmaceutical companies to establish marketing and promotional compliance programs or codes of conduct and/or to file periodic reports with the
state or make periodic public disclosures on sales, marketing, pricing, clinical trials, and other activities. Several states have also adopted laws that prohibit certain marketing-related activities, including the provision of gifts, meals or other
items to certain health care providers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Though we are continuing to develop our compliance program, we cannot ensure that our compliance
controls, policies and procedures will be sufficient to protect against acts of our employees, business partners or vendors that may violate federal or state fraud and abuse laws or other applicable requirements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Federal enforcement agencies and private whistleblowers recently have shown interest in pharmaceutical companies&#146; product and patient
assistance programs, including reimbursement support, <FONT STYLE="white-space:nowrap">co-pay</FONT> support, nursing, adherence and educational services, referrals to other providers, donations to independent patient assistance charities, and
relationships with specialty pharmacies. <FONT STYLE="white-space:nowrap">Co-pay</FONT> assistance programs are intended to assist qualified patients with private insurance with any
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> financial obligations, but must exclude any government health care program beneficiaries. A number of investigations into patient assistance practices have
resulted in significant civil and criminal settlements. We offer <FONT STYLE="white-space:nowrap">co-pay</FONT> assistance for our vitamin products, and will offer patient assistance including <FONT STYLE="white-space:nowrap">co-pay</FONT>
assistance and free drug sample starter packs for IMVEXXY<SUP STYLE="font-size:85%; vertical-align:top">TM</SUP>, and potentially for our other drug candidates. If we fail to structure these and other support programs to comply with applicable law,
we risk becoming subject to government investigations, and potentially, facing penalties or consequences for violations under fraud and abuse laws. In addition, to the extent we, our subsidiary, VitaMed Rx, or our other contractors or agents receive
or obtain individually identifiable health information from patients, health care professionals, pharmacies, or other individuals or entities, although we are not directly subject to HIPAA, we could be subject to criminal penalties if we mishandle
individually identifiable health information in a manner that is not authorized or permitted by HIPAA. Claims that we have violated individuals&#146; privacy rights or breached our contractual obligations, even if we are not found liable, could be
expensive and time-consuming to defend and could result in adverse publicity that could harm our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The occurrence of any of the
foregoing events or penalties may force us to expend significant amounts of time and money and may significantly inhibit our ability to bring to market or continue to market our products and generate revenue. Similar regulations apply in foreign
jurisdictions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-23 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Any failure to adequately expand a direct sales force will impede our growth. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We expect to be substantially dependent on a direct sales force to attract new business and to manage customer relationships. We plan to
expand our direct sales force and believe that there is significant competition for qualified, productive direct sales personnel with advanced sales skills and technical knowledge. Our ability to achieve significant growth in revenue in the future
will depend, in large part, on our success in recruiting, training, and retaining sufficient direct sales personnel. New and future hires may not become as productive as expected, and we may be unable to hire sufficient numbers of qualified
individuals in the future in the markets in which we do business. If we are unable to hire and develop sufficient numbers of productive sales personnel or are required to hire more sales personnel than we expect our business prospects could suffer.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Other pharmaceutical companies with which we compete for qualified personnel may have greater financial and other resources, different
risk profiles, and longer histories than we do. They also may provide more diverse opportunities and better chances for career advancement. Some of these characteristics may be more appealing to high-quality candidates than what we offer. If we are
unable to continue to attract and retain high-quality personnel, our ability to commercialize drug candidates may be limited. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Licensing of
intellectual property involves complex legal, business and scientific issues, and disputes could jeopardize our rights under such agreements. Additionally, our current licensing agreements contain limitations and restrictions that could limit or
adversely affect our ability to develop and commercialize other products in the future. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are currently and may in the future be
a party to license agreements of importance to our business and to our current product and product candidates, and we expect to be subject to additional such agreements in the future. Disputes may arise between us and any of these counterparties
regarding intellectual property subject to and each parties&#146; obligations under such agreements, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our diligence obligations with respect to the use of the licensed technology in relation to our development and
commercialization of our product and product candidates, and what activities satisfy those diligence obligations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope of rights granted under the agreement and other interpretation-related issues; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our obligations to make milestone, royalty or other payments under those agreements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether and the extent to which our technology and processes infringe on intellectual property of the licensor
that is not subject to the agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our right to sublicense patent and other rights to third parties; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ownership of inventions and <FONT STYLE="white-space:nowrap">know-how</FONT> arising under the agreement or
resulting from the joint creation or use of intellectual property by our licensors and us and our partners; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our right to transfer or assign the license; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the effects of termination. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">These or other disputes over our obligations or intellectual property that we have licensed may prevent or impair our ability to maintain our
current arrangements on acceptable terms, or may impair the value of the arrangement to us. Any such dispute could have an adverse effect on our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If we fail to meet our obligations under a license agreement in a material respect, the respective licensor could have the right to terminate
the respective agreement and upon the effective date of such termination, have the right to <FONT STYLE="white-space:nowrap">re-obtain</FONT> the related technology as well as, potentially, aspects of any intellectual property controlled by us and
developed during the period the agreement was in force that relate to the applicable technology. This means that the licensor to each of these agreements could effectively take control of the development and commercialization of the applicable
product or product candidate after an uncured, material breach of the agreement by us. This may also be the case if we voluntarily terminate the relevant agreement.&nbsp;Any uncured, material breach under a license agreement could result in our loss
of exclusive rights and may lead to a complete termination of our product development and any commercialization efforts for the applicable product or product candidates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-24 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In July 2018, we entered into a license agreement with the Population Council to obtain
exclusive U.S. rights to commercialize the Population Council&#146;s investigational segesterone acetate/ethinyl estradiol <FONT STYLE="white-space:nowrap">one-year</FONT> vaginal system for human contraceptive indications. The agreement requires us
to use commercially reasonable efforts to commercialize, if approved, this product candidate and enter into certain manufacturing agreements, make timely milestone and other payments, provide certain information regarding our activities under the
agreement, and indemnify the other party with respect to our development and commercialization activities under the terms of the agreements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, our current licensing agreement with the Population Council contains limitations and restrictions, including limitations that
could limit or adversely affect our ability to develop and commercialize this or other product candidates including the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we cannot sublicense the rights licensed to us&nbsp;without the consent of the Population Council;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">neither we nor the Population Council may develop a competitive product (as defined with respect to each party in
the agreement) for six years from the date of the agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">currently there are no Orange Book listable patents or patent applications covering this system; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Population Council owns any program improvements, as defined in the agreement. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our level of indebtedness and the terms of the Credit Agreement could adversely affect our operations and limit our ability to plan for or respond to
changes in our business. If we are unable to satisfy certain conditions in our Credit Agreement, we will be unable to draw down the remaining the facility and if we are unable to comply with restrictions in the Credit Agreement, the repayment of our
existing indebtedness could be accelerated. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Under the Credit Agreement, we have incurred a substantial amount of debt, which
could adversely affect our business. In June 2018, we drew down the first tranche of $75.0&nbsp;million under the Credit Agreement and we currently intend to draw down up to an additional $125.0&nbsp;million in the aggregate in two additional
tranches under the terms of the Credit Agreement, when and if the conditions precedent to such tranches have been met. Our high level of indebtedness could affect our business in the following ways, among other things: make it more difficult for us
to satisfy our contractual and commercial commitments; require us to use a substantial portion of our cash flow from operations to pay interest and principal, which would reduce funds available for working capital, capital expenditures and other
general corporate purposes; limit our ability to obtain additional financing for working capital, capital expenditures, acquisitions and other investments or general corporate purposes; heighten our vulnerability to downturns in our business, our
industry or in the general economy; place us at a disadvantage compared to those of our competitors that may have proportionately less debt; limit management&#146;s discretion in operating our business; and limit our flexibility in planning for, or
reacting to, changes in our business, the industry in which we operate or the general economy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We must satisfy certain conditions to be
eligible to draw down the second tranche of $75.0&nbsp;million and the third tranche of $50.0&nbsp;million. The second tranche may be drawn by us on or before May&nbsp;31, 2019, provided that we satisfy certain conditions described in the Credit
Agreement, including (i)&nbsp;the approval by the FDA of the NDA for our <FONT STYLE="white-space:nowrap">TX-001HR</FONT> drug candidate and (ii)&nbsp;that we have consummated our first commercial sale in the United States of <FONT
STYLE="white-space:nowrap">TX-001HR.</FONT> The third tranche of $50.0&nbsp;million may be drawn by us on or before December&nbsp;31, 2019, provided that we satisfy certain conditions described in the Credit Agreement, including that
(i)&nbsp;tranche 2 has been drawn and (ii)&nbsp;we and our subsidiaries party to the Credit Agreement have generated at least $75.0&nbsp;million of consolidated net revenue attributable to commercial sales of
<FONT STYLE="white-space:nowrap">TX-001HR</FONT> and IMVEXXY&#153; during the twelve-month period ending immediately prior to the funding of tranche 3. If we are unable to satisfy those conditions, we would not be able to draw down the respective
tranche of financing and may not be able to obtain alternative financing on commercially reasonable terms or at all. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-25 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Credit Agreement requires us to make certain payments of principal and interest over
time and contains a number of other restrictive covenants. Among other requirements of the Credit Agreement, we and our subsidiaries party to the Credit Agreement must (i)&nbsp;maintain a minimum cash balance of $50.0&nbsp;million and
(ii)&nbsp;achieve certain minimum consolidated net revenue amounts attributable to commercial sales of our products. The Credit Agreement also contains covenants that limit, among other things, the ability of us and our subsidiaries party to the
Credit Agreement to (i)&nbsp;incur indebtedness, (ii)&nbsp;incur liens on our property, (iii)&nbsp;pay dividends or make other distributions, (iv)&nbsp;sell our assets, (v)&nbsp;make certain loans or investments, (vi)&nbsp;merge or consolidate,
(vii)&nbsp;voluntarily repay or prepay certain permitted indebtedness and (viii)&nbsp;enter into transactions with affiliates, in each case subject to certain exceptions. These and other terms in the Credit Agreement have to be monitored closely for
compliance and could restrict our ability to grow our business or enter into transactions that we believe would be beneficial to our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As part of an amendment to the Credit Agreement entered in connection with entering into the Council License Agreement, we are required to
receive aggregate net cash proceeds of at least $75&nbsp;million from the issuance of our equity securities within thirty days of entering into the Council License Agreement. Failure to complete this obligation will constitute an automatic event of
default under the Credit Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our business may not generate cash flow from operations in the future sufficient to service our debt
and support our growth strategies. If we are unable to generate such cash flow, we may be required to adopt one or more alternatives, such as selling assets, restructuring debt or obtaining additional equity capital on terms that may be onerous or
highly dilutive. Our ability to refinance our indebtedness will depend on the capital markets and our financial condition at such time. We may not be able to engage in any of these activities or engage in these activities on desirable terms, which
could result in a default on our debt obligations, including under our current debt obligations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-26 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom579833_4"></A>CAUTIONARY STATEMENT ABOUT FORWARD-LOOKING INFORMATION
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">This prospectus supplement, the accompanying prospectus and the documents and information incorporated by reference herein and
therein may contain &#147;forward-looking statements&#148; within the meaning of Section&nbsp;27A of the Securities Act of 1933, as amended, or the Securities Act, and Section&nbsp;21E of the Exchange Act. Forward-looking statements may include, but
are not limited to, statements relating to our objectives, plans and strategies as well as statements, other than historical facts, that address activities, events, or developments that we intend, expect, project, believe or anticipate will or may
occur in the future. These statements are often characterized by terminology such as &#147;may,&#148; &#147;will,&#148; &#147;should,&#148; &#147;expects,&#148; &#147;plans,&#148; &#147;anticipates,&#148; &#147;could,&#148; &#147;intends,&#148;
&#147;target,&#148; &#147;projects,&#148; &#147;contemplates,&#148; &#147;believes,&#148; &#147;estimates,&#148; &#147;predicts,&#148; &#147;potential,&#148; or &#147;continue&#148; or the negative of these terms or other similar expressions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Forward-looking statements are based on assumptions and assessments made in light of our experience and perception of historical trends,
current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties, many of which are outside of our control.
You should not place undue reliance on these forward-looking statements, which reflect our view only as of the date of this prospectus supplement, and we undertake no obligation to update these forward-looking statements in the future, except as
required by applicable law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">A number of important factors could cause actual results to differ materially from those indicated by the
forward-looking statements, including, without limitation, those factors described under the caption &#147;Risk Factors&#148; in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended December&nbsp;31, 2017,
which is incorporated by reference in this prospectus supplement and the accompanying prospectus, and under similar headings in our subsequently filed quarterly reports on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> as well as the other risks
and uncertainties described herein and in the other documents incorporated by reference in this prospectus supplement. Some of the key factors that could cause actual results to differ from our expectations include the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our operating losses incurred since inception and anticipated for the foreseeable future; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to maintain or increase sales of our products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability of our products to produce the intended effects; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to develop and commercialize our hormone therapy drug product and drug candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to obtain additional financing necessary to complete the development and commercialization of our
hormone therapy drug product and drug candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the FDA will approve our NDAs for our <FONT STYLE="white-space:nowrap">TX-001HR</FONT> drug candidate and
our <FONT STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive system candidate and whether such approvals will occur by their respective PDUFA target action dates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our lack of experience in bringing a drug to regulatory approval or marketing and selling a drug after regulatory
approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the length, cost and uncertain results of our clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays, suspensions, or discontinuation of our clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the potential of adverse side effects or other safety risks that could preclude the approval of our drug
candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our reliance on third parties to conduct our clinical trials, research and development and manufacturing;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the effects of laws, regulations and enforcement; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-27 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to gain and retain market acceptance for our hormone therapy drug product or drug candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the competitive nature of the industries in which we conduct our business; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the availability of reimbursement from government authorities and health insurance companies for our products;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the impact of product liability lawsuits; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the influence of extensive and costly government regulation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the effect of governmental regulations on our business; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether we will be able to comply with the covenants and conditions under our credit agreement;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability of our partners and third-party manufacturers to manufacture and distribute sufficient amounts of our
hormone therapy drug product; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability of our licensees to commercialize and distribute our hormone therapy drug product and drug
candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the volatility of the trading price of our common stock; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the concentration of power in our stock ownership. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-28 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom579833_5"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We estimate that the net proceeds from the sale of the shares of common stock in this offering and the concurrent underwritten offering will
be approximately $&nbsp;&nbsp;&nbsp;&nbsp;million, or approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million if the underwriters in the concurrent underwritten offering exercise in full
their option to purchase additional shares, based on the public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, after deducting underwriting discounts and commissions
(payable only in the concurrent underwritten offering) and estimated offering and concurrent underwritten offering expenses payable by us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We intend to use the net proceeds from this offering and the concurrent underwritten offering to fund a portion of the costs for the
commercial launch of our recently approved product, IMVEXXY&#153; (estradiol vaginal inserts) for the treatment of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">moderate-to-severe</FONT></FONT> dyspareunia (vaginal pain
associated with sexual activity), a symptom of VVA, due to menopause, and to fund a portion of the costs for <FONT STYLE="white-space:nowrap">pre-commercialization</FONT> and commercialization activities for
<FONT STYLE="white-space:nowrap">TX-001HR,</FONT> our <FONT STYLE="white-space:nowrap">bio-identical</FONT> hormone therapy combination of 17&szlig;- estradiol and progesterone in a single, oral softgel drug candidate, for the treatment of moderate
to severe VMS due to menopause in menopausal women with an intact uterus. and our <FONT STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive system candidate. We additionally intend to use a portion of the net proceeds from this offering
and the concurrent underwritten offering for working capital and general corporate purposes. We may also use a portion of the net proceeds from this offering and the concurrent underwritten offering to acquire or invest in businesses and products
that we believe would complement our women&#146;s health products and drug candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As of the date of this prospectus supplement, we
cannot specify with certainty all of the particular uses of the proceeds from this offering and the concurrent underwritten offering. The amounts and timing of our actual expenditures will depend on numerous factors, including the progress of
regulatory approvals, commercialization activities, the timing of our revenue and the amount of cash used by our operations. Accordingly, we will retain broad discretion over the use of such proceeds. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The closing of this offering is contingent upon the closing of the concurrent underwritten offering, and we can offer no assurance that the
concurrent underwritten offering will close. If the concurrent underwritten offering does not close, then this offering will not be completed. See &#147;Risk Factors&#151;Because the closing of this offering is contingent upon the closing of the
concurrent underwritten offering, there can be no assurance that this offering will ultimately be completed.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Pending use of the
proceeds as described above or otherwise, we intend to invest the net proceeds in short-term interest-bearing, investment-grade securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-29 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom579833_6"></A>DILUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our net tangible book value as of June&nbsp;30, 2018 was approximately $74.1&nbsp;million, or $0.34 per share. Net tangible book value per
share is determined by dividing our total tangible assets, less total liabilities, by the number of shares of our common stock outstanding as of June&nbsp;30, 2018. Dilution in net tangible book value per share represents the difference between the
amount per share paid by purchasers of shares of common stock in this offering and the net tangible book value per share of our common stock immediately after this offering and the concurrent underwritten offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">After giving effect to the sale of $85&nbsp;million of shares of our common stock in this offering and the concurrent underwritten offering at
an assumed public offering price of $5.52 per share, which was the last reported sale price of our common stock on the Nasdaq Global Select Market on July&nbsp;30, 2018, and after deducting the underwriting discounts and commissions (payable only in
the concurrent underwritten offering) and estimated offering and concurrent underwritten offering expenses we must pay, our as adjusted net tangible book value as of June&nbsp;30, 2018 would have been approximately $154.9&nbsp;million, or $0.67 per
share. This would represent an immediate increase in net tangible book value of $0.33 per share to existing stockholders and immediate dilution in net tangible book value of $4.85 per share to new investors purchasing our common stock in this
offering and the concurrent underwritten offering. The following table illustrates this dilution on a per share basis. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="84%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assumed public offering price per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5.52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net tangible book value per share as of June&nbsp;30, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase per share attributable to new investors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">As adjusted net tangible book value per share after this offering and the concurrent underwritten
offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dilution per share to new investors in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If the underwriters in the concurrent underwritten offering exercise in full their option to purchase
1,766,304 additional shares of common stock in the concurrent underwritten offering at the public offering price of $5.52 per share, the as adjusted net tangible book value after this offering and the concurrent underwritten offering would be $0.70
per share, representing an increase in net tangible book value of $0.36 per share to existing stockholders and immediate dilution in net tangible book value of $4.82 per share to new investors purchasing our common stock in this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The above discussion and table are based on 216,834,059 shares outstanding on June&nbsp;30, 2018 and exclude the following as of that date:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">outstanding options representing the right to purchase a total of 25,210,899 shares of common stock at a weighted average exercise price of $3.92 per share; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">outstanding warrants representing the right to purchase a total of&nbsp;&nbsp;&nbsp;&nbsp;3,007,571 shares of common stock at a weighted-average exercise price of $2.78 per share; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">5,052,120 shares of common stock reserved for future issuance under our <FONT STYLE="white-space:nowrap">non-qualified</FONT> stock option plans. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">To the extent that outstanding options or warrants are exercised or we issue shares of common stock under our stock incentive plans, investors
purchasing our common stock in this offering will experience further dilution. In addition, we may choose to raise additional capital due to market conditions or strategic considerations even if we believe we have sufficient funds for our current or
future operating plans. To the extent that additional capital is raised through the sale of equity or convertible debt securities, the issuance of these securities could result in further dilution to our stockholders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-30 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom579833_7"></A>PLAN OF DISTRIBUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are offering &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock under
this prospectus supplement directly to Knight in a privately negotiated transaction in which no party is acting as an underwriter or placement agent. Similarly, no broker or dealer has been retained by us in connection with this offering. Subject to
the terms of the Subscription Agreement, Knight has agreed to purchase from us and we have agreed to sell to Knight, an aggregate of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common
stock at the public offering price per share for our common stock in the concurrent underwritten offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We expect to deliver the
shares of common stock against payment of the aggregate purchase price therefor on or about August&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018. The closing of this offering is contingent upon
the closing of the concurrent underwritten offering, but the closing of the underwritten offering is not contingent upon the closing of this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Goldman Sachs &amp; Co. LLC is acting as underwriter in the concurrent underwritten offering.&nbsp;In connection with this offering, Knight
has agreed that, without our prior written consent, which cannot be given without Goldman Sachs &amp; Co. LLC&#146;s prior written consent, Knight will not offer or contract to sell any shares of our common stock until the date that is 90 days after
the date of this prospectus supplement, after which date, the agreement will terminate and Knight will be released from its related obligations. Knight&#146;s agreement is subject to certain customary exceptions, including in respect of bona fide
gifts of shares.&nbsp;Additionally, provided that no public disclosure is required pursuant to the Exchange Act, Knight may, immediately and without restriction, sell or contract to sell up to 50% of the shares of common stock acquired by Knight in
this offering, as well as up to an additional 16.67% of such shares on or after each of the 30<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> day and the 60<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> day following the date of
this prospectus supplement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-31 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom579833_8"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The validity of the shares of common stock offered hereby will be passed upon for us by Greenberg Traurig, LLP, Las Vegas, Nevada. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom579833_9"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The audited financial statements and management&#146;s assessment of the effectiveness of internal control over financial reporting
incorporated by reference in this prospectus supplement and elsewhere in the registration statement have been incorporated by reference in reliance upon the reports of Grant Thornton LLP, independent registered public accountants, upon the authority
of said firm as experts in accounting and auditing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom579833_10"></A>WHERE YOU CAN FIND MORE INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We file annual, quarterly and current reports, proxy statements and other information with the SEC. Through our website at
<I>www.therapeuticsmd.com</I>, you may access, free of charge, our filings, as soon as reasonably practical after we electronically file them with or furnish them to the SEC. The information contained in, or available through, our website is not
incorporated by reference in, and should not be considered a part of, this prospectus supplement or the accompanying prospectus. You also may read and copy any document we file with the SEC at the SEC&#146;s Public Reference Room at 100 F Street,
N.E., Washington, D.C. 20549. Please call the SEC at <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-800-SEC-0330</FONT></FONT></FONT> for further information. Our SEC filings are also available
to the public at the SEC&#146;s website at <I>www.sec.gov</I>. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The
accompanying prospectus is part of a registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> that we filed with the SEC to register the securities offered hereby under the Securities Act. The accompanying prospectus does not
contain all of the information included in the registration statement, including certain exhibits and schedules. You may obtain the registration statement and exhibits to the registration statement from the SEC at the address listed above or from
the SEC&#146;s website listed above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom579833_11"></A>INCORPORATION OF CERTAIN INFORMATION BY REFERENCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The SEC allows us to incorporate by reference the information we file with the SEC, which means that we can disclose important information to
you by referring you to those documents. The information that we incorporate by reference is considered to be part of this prospectus supplement and the accompanying prospectus. Information that we file with the SEC in the future and incorporate by
reference in this prospectus supplement and the accompanying prospectus automatically updates and supersedes previously filed information as applicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We incorporate by reference into this prospectus supplement and the accompanying prospectus the following documents filed by us with the SEC,
other than any portion of any such documents that is not deemed &#147;filed&#148; under the Exchange Act in accordance with the Exchange Act and applicable SEC rules: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended
December&nbsp;31, 2017, filed with the SEC on February&nbsp;23, 2018; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarters ended March&nbsp;31,
2018 and June&nbsp;30, 2018, filed with the SEC on May&nbsp;7, 2018 and July&nbsp;30, 2018; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Definitive Proxy Statement on Schedule 14A, filed with the SEC on April&nbsp;27, 2018; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Current Reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed with the SEC on April&nbsp;2, 2018,
May&nbsp;3, 2018, June&nbsp;7, 2018 and June&nbsp;26, 2018; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-32 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the description of our common stock included under the heading &#147;Description of Common Stock&#148; in the
prospectus forming a part of the Registration Statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-207837),</FONT> as filed with the SEC on November&nbsp;5, 2015, which description has
been incorporated by reference in Item 1 of our Form <FONT STYLE="white-space:nowrap">8-A</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;001-00100),</FONT> as filed with the SEC on October&nbsp;6, 2017, including any amendment or report
filed with the SEC for the purpose of updating such description. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, all documents subsequently filed by us
pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act (not including any information furnished under Item 2.02, 7.01 or 9.01 of Form <FONT STYLE="white-space:nowrap">8-K</FONT> and any other information that is identified as
&#147;furnished&#148; rather than filed, which information is not incorporated by reference herein) prior to the termination of this offering, will be deemed to be incorporated herein by reference and to be a part of this prospectus supplement and
the accompanying prospectus from the date of filing of such documents. Any statement contained in a document incorporated herein by reference will be deemed to be modified or superseded for purposes of this prospectus supplement and the accompanying
prospectus to the extent that a statement contained herein, or in a subsequently filed document incorporated herein by reference, modifies or supersedes the statement. Any statement modified or superseded will not be deemed, except as modified or
superseded, to constitute a part of this prospectus supplement and the accompanying prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We will provide without charge to each
person, including any beneficial owner, to whom a prospectus supplement is delivered, upon written or oral request of that person, a copy of any and all of the information that has been incorporated by reference in this prospectus supplement and the
accompanying prospectus but not delivered with this prospectus supplement (excluding exhibits unless specifically incorporated by reference into those documents). Please direct requests to us at the following address: </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TherapeuticsMD, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Attention: Corporate Secretary </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>6800 Broken Sound Parkway NW, Third Floor </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Boca Raton, Florida 33487 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(561) <FONT STYLE="white-space:nowrap">961-1900</FONT> </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-33 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>PROSPECTUS </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g579833g96q94.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>$250,000,000 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="4"><B>Common Stock </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="4"><B>Preferred Stock </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="4"><B>Debt Securities </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="4"><B>Depositary Shares </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="4"><B>Warrants </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="4"><B>Purchase Contracts </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="4"><B>Units </B></FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We may offer
and sell from time to time, in one or more series or issuances and on terms that we will determine at the time of the offering, any combination of the securities described in this prospectus, up to an aggregate amount of $250,000,000. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This prospectus provides you with a general description of the securities we may offer and sell. We will provide specific terms of any
offering in a supplement to this prospectus. Any prospectus supplement may also add, update, or change information contained in this prospectus. You should carefully read this prospectus and the applicable prospectus supplement as well as the
documents incorporated or deemed to be incorporated by reference in this prospectus before you invest in any of our securities. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">These securities may be offered and sold in the same offering or in separate offerings; to or through underwriters, dealers and agents;
or directly to purchasers. The names of any underwriters, dealers, or agents involved in the sale of our securities and any applicable fees, commissions, or discounts will be described in the applicable prospectus supplement. Our net proceeds from
the sale of securities will also be set forth in the applicable prospectus supplement. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This prospectus may not be used to
consummate a sale of our securities unless accompanied by the applicable prospectus supplement. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Investing in our
securities involves a high degree of risk. See &#147;<A HREF="#cov579833_rf">Risk Factors</A>&#148; beginning on page 1 of this prospectus for a discussion of information that should be considered in connection with an investment in our securities.
</B></FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or
passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense. </B></FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>The
date of this prospectus is November 17, 2015. </B></FONT></P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>TABLE OF CONTENTS </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="97%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#rom579833_1">ABOUT THIS PROSPECTUS</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">ii</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#rom579833_2">RISK FACTORS</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#rom579833_3">FORWARD-LOOKING STATEMENTS</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#rom579833_3a">OUR COMPANY</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#rom579833_4">RATIO OF EARNINGS TO FIXED CHARGES</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#rom579833_5">DILUTION</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#rom579833_6">USE OF PROCEEDS</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#rom579833_7">DESCRIPTION OF COMMON STOCK</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#rom579833_8">DESCRIPTION OF PREFERRED STOCK</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#rom579833_9">DESCRIPTION OF DEBT SECURITIES</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">13</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#rom579833_10">DESCRIPTION OF DEPOSITARY SHARES</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">25</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#rom579833_11">DESCRIPTION OF WARRANTS</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">28</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#rom579833_12">DESCRIPTION OF PURCHASE CONTRACTS</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">31</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#rom579833_13">DESCRIPTION OF UNITS</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">32</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#rom579833_14">CERTAIN PROVISIONS OF NEVADA LAW AND OUR CHARTER AND BYLAWS</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">34</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#rom579833_15">LEGAL OWNERSHIP OF SECURITIES</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">37</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#rom579833_16">PLAN OF DISTRIBUTION</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">41</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#rom579833_17">LEGAL MATTERS</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">44</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#rom579833_18">EXPERTS</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">44</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#rom579833_19">WHERE YOU CAN FIND MORE INFORMATION</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">44</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#rom579833_20">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">45</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">i </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="rom579833_1"></A><A NAME="supprom579833_12"></A>ABOUT THIS PROSPECTUS
</B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This prospectus is part of a registration statement that we filed with the Securities and Exchange Commission, or the
SEC, utilizing a &#147;shelf&#148; registration process. Under this shelf registration process, we may sell any combination of the securities described in this prospectus in one or more offerings, up to a total dollar amount of $250,000,000. This
prospectus provides you with general information regarding the securities we may offer. We will provide a prospectus supplement that contains specific information about any offering by us. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The prospectus supplement also may add, update, or change information contained in the prospectus. You should read both this prospectus
and the prospectus supplement related to any offering as well as additional information described under the headings &#147;Where You Can Find More Information&#148; and &#147;Incorporation of Certain Information by Reference.&#148; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have not authorized anyone to provide you with information different from that contained or incorporated by reference in this
prospectus or any accompanying prospectus supplement or any &#147;free writing prospectus.&#148; We are offering to sell, and seeking offers to buy, securities only in jurisdictions where offers and sales are permitted. The information contained in
this prospectus and in any accompanying prospectus supplement is accurate only as of the dates of their covers, regardless of the time of delivery of this prospectus or any prospectus supplement or of any sale of our securities. Our business,
financial condition, results of operations, and prospects may have changed since those dates. You should rely only on the information contained or incorporated by reference in this prospectus or any accompanying prospectus supplement. To the extent
there is a conflict between the information contained in this prospectus and the prospectus supplement, you should rely on the information in the prospectus supplement, provided that if any statement in one of these documents is inconsistent with a
statement in another document having a later date &#151; for example, a document incorporated by reference into this prospectus or any prospectus supplement &#151; the statement in the document having the later date modifies or supersedes the
earlier statement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Unless the context otherwise requires, the terms &#147;Therapeutics,&#148; &#147;TXMD,&#148;
&#147;Company,&#148; &#147;we,&#148; &#147;us,&#148; or &#147;our&#148; refer to TherapeuticsMD, Inc., a Nevada corporation, and its subsidiaries, vitaMedMD, LLC, a Delaware limited liability company, or VitaMed, BocagreenMD, Inc., a Nevada
corporation, or BocaGreen, and VitaCare Prescription Services, Inc., a Florida corporation, or VitaCare. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">ii </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="rom579833_2"></A><A NAME="cov579833_rf"></A><A NAME="supprom579833_13"></A>RISK FACTORS </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Investing in our securities involves a high degree of risk. Before making an investment decision, you should carefully consider the
discussion of risks and uncertainties under the heading &#147;Risk Factors&#148; contained in our Annual Report on Form 10-K for the fiscal year ended December 31, 2014, which is incorporated by reference in this prospectus, and under similar
headings in our subsequently filed quarterly reports on Form 10-Q and annual reports on Form 10-K, as well as the other risks and uncertainties described in any applicable prospectus supplement or free writing prospectus and in the other documents
incorporated by reference in this prospectus. See the sections entitled &#147;Where You Can Find More Information&#148; and &#147;Incorporation of Certain Information by Reference&#148; in this prospectus. The risks and uncertainties we discuss in
this prospectus, in any applicable prospectus supplement or free writing prospectus and in the other documents incorporated by reference in this prospectus are not the only ones facing our company. Additional risks and uncertainties not presently
known to us or that we currently believe are immaterial also may materially and adversely affect our business, financial condition and results of operations. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">1 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="rom579833_3"></A><A NAME="supprom579833_14"></A>FORWARD-LOOKING STATEMENTS
</B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This prospectus, any applicable prospectus supplement and the documents and information incorporated by reference herein
and therein may contain &#147;forward-looking statements.&#148; Forward-looking statements may include, but are not limited to, statements relating to our objectives, plans and strategies as well as statements, other than historical facts, that
address activities, events, or developments that we intend, expect, project, believe or anticipate will or may occur in the future. These statements are often characterized by terminology such as &#147;may,&#148; &#147;will,&#148;
&#147;should,&#148; &#147;expects,&#148; &#147;plans,&#148; &#147;anticipates,&#148; &#147;could,&#148; &#147;intends,&#148; &#147;target,&#148; &#147;projects,&#148; &#147;contemplates,&#148; &#147;believes,&#148; &#147;estimates,&#148;
&#147;predicts,&#148; &#147;potential,&#148; or &#147;continue&#148; or the negative of these terms or other similar expressions. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Forward-looking statements are based on assumptions and assessments made in light of our experience and perception of historical trends, current conditions, expected future developments and other factors
believed to be appropriate. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties, many of which are outside of our control. You should not place undue reliance on
these&nbsp;forward-looking&nbsp;statements, which reflect our view only as of the date of this prospectus, and we undertake no obligation to update these forward-looking statements in the future, except as required by applicable law. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">A number of important factors could cause actual results to differ materially from those indicated by the forward-looking statements,
including, without limitation, those factors described under the caption &#147;Risk Factors&#148; in our Annual Report on Form 10-K for the fiscal year ended December&nbsp;31, 2014, which is incorporated by reference in this prospectus, and under
similar headings in our subsequently filed quarterly reports on Form 10-Q and annual reports on Form 10-K, as well as the other risks and uncertainties described in any applicable prospectus supplement or free writing prospectus and in the other
documents incorporated by reference in this prospectus. Some of the key factors that could cause actual results to differ from our expectations include the following: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our operating losses incurred since inception and anticipated for the foreseeable future; </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our ability to maintain or increase sales of our products; </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the ability of our products to produce the intended effects; </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our ability to develop and commercialize our hormone therapy drug candidates; </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our ability to obtain additional financing necessary to complete the development and commercialization of our hormone therapy drug candidates;
</FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our lack of experience in bringing a drug to regulatory approval; </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the length, cost and uncertain results of our clinical trials; </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">delays, suspensions, or discontinuation of our clinical trials; </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the potential of adverse side effects or other safety risks that could preclude the approval of our hormone therapy drug candidates;
</FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our reliance on third parties to conduct our clinical trials and research and development; </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the effects of laws, regulations and enforcement; </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our dependence on third-party manufacturers; </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our ability to gain and retain market acceptance for our hormone therapy drug candidates; </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the competitive nature of the industries in which we conduct our business; </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the availability of reimbursement from government authorities and health insurance companies for our products; </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the impact of product liability lawsuits; </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the influence of extensive and costly government regulation; </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the effect of governmental regulations on our business; </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the volatility of the trading price of our common stock; and </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the concentration of power in our stock ownership. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">2 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="rom579833_3a"></A><A NAME="supprom579833_15"></A>OUR COMPANY </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are a women&#146;s health care product company focused on creating and commercializing products targeted exclusively for women.
Currently, we are focused on conducting the clinical trials necessary for regulatory approval and commercialization of advanced hormone therapy pharmaceutical products. The current drug candidates used in our clinical trials are designed to
alleviate the symptoms of and reduce the health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort. We are developing these hormone therapy drug candidates, which contain estradiol
and progesterone alone or in combination, with the aim of demonstrating equivalent clinical efficacy at lower doses, thereby enabling an enhanced side effect profile compared with competing products. Our drug candidates are created from a platform
of hormone technology that enables the administration of hormones with high bioavailability alone or in combination. In addition, we manufacture and distribute branded and generic prescription prenatal vitamins, as well as over-the-counter, or OTC,
vitamins and cosmetics. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are a Nevada corporation. We maintain our principal executive offices at 6800 Broken Sound Parkway
NW, Third Floor, Boca Raton, Florida 33487. Our telephone number is (561) 961-1900. We maintain websites at <I>www.therapeuticsmd.com</I>, <I>www.vitamedmd.com</I>, <I>www.vitamedmdrx.com</I> and <I>www.bocagreenmd.com</I>. The information contained
on our websites or that can be accessed through our websites does not constitute part of this prospectus or any prospectus supplement. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">3 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="rom579833_4"></A><A NAME="supprom579833_16"></A>RATIO OF EARNINGS TO FIXED
CHARGES </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our ratio of earnings to fixed charges for each of the five most recently completed fiscal years and any required
interim periods will each be specified in a prospectus supplement or in a document that we file with the SEC and incorporate by reference pertaining to the issuance, if any, by us of debt securities in the future. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">4 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="rom579833_5"></A><A NAME="supprom579833_17"></A>DILUTION </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We will set forth in a prospectus supplement the following information regarding any material dilution of the equity interests of
investors purchasing securities in an offering under this prospectus: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the net tangible book value per share of our equity securities before and after the offering; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the amount of the increase in such net tangible book value per share attributable to the cash payments made by purchasers in the offering; and
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the amount of the immediate dilution from the public offering price which will be absorbed by such purchasers.
</FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">5 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="rom579833_6"></A><A NAME="supprom579833_18"></A>USE OF PROCEEDS
</B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Except as may be otherwise set forth in any prospectus supplement accompanying this prospectus, we will use the net
proceeds we receive from sales of securities offered hereby for general corporate purposes, which may include the repayment of indebtedness outstanding from time to time and for working capital, capital expenditures, acquisitions and repurchases of
our common stock or other securities. Pending these uses, the net proceeds may also be temporarily invested in cash equivalents or short-term securities. When specific securities are offered, the prospectus supplement relating thereto will set forth
our intended use of the net proceeds that we receive from the sale of such securities. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">6 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="rom579833_7"></A><A NAME="supprom579833_19"></A>DESCRIPTION OF COMMON STOCK
</B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This section describes the general terms of our common stock. A prospectus supplement may provide information that is
different from this prospectus. If the information in the prospectus supplement with respect to our common stock being offered differs from this prospectus, you should rely on the information in the prospectus supplement. A copy of our amended and
restated articles of incorporation, as amended, has been incorporated by reference from our filings with the SEC as an exhibit to the registration statement of which this prospectus forms a part. Our common stock and the rights of the holders of our
common stock are subject to the applicable provisions of the Nevada Private Corporation Code, which we refer to as &#147;Nevada law,&#148; our amended and restated articles of incorporation, our bylaws, the rights of the holders of our preferred
stock, if any, as well as some of the terms of our outstanding indebtedness. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under our amended and restated articles of
incorporation, as amended, we have the authority to issue 350,000,000 shares of common stock, par value $0.001 per share. As of November&nbsp;2, 2015, there were 177,848,041 shares of our common stock outstanding. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following description of our common stock, and any description of our common stock in a prospectus supplement, may not be complete
and is subject to, and qualified in its entirety by reference to, Nevada law and the actual terms and provisions contained in our amended and restated articles of incorporation and our bylaws, each as amended from time to time. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Voting Rights </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Each
outstanding share of our common stock is entitled to one vote per share of record on all matters submitted to a vote of stockholders and to vote together as a single class for the election of directors and in respect of other corporate matters. At a
meeting of stockholders at which a quorum is present, for all matters other than the election of directors, an affirmative vote of the majority of shares entitled to vote on a matter and that are represented either in person or by proxy at a meeting
of stockholders decides all questions, unless the matter is one upon which a different vote is required by express provision of law or our amended and restated articles incorporation or our bylaws. Directors will be elected by a plurality of the
votes of the shares present at a meeting. Holders of shares of common stock do not have cumulative voting rights with respect to the election of directors or any other matter. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Dividends </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Holders of our common stock are entitled to receive dividends or
other distributions when, as and if declared by our board of directors. The right of our board of directors to declare dividends, however, is subject to any rights of the holders of other classes of our capital stock, any indebtedness outstanding
from time to time and the availability of sufficient funds, as determined under Nevada law, to pay dividends. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Preemptive Rights
</B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The holders of our common stock do not have preemptive rights to purchase or subscribe for any of our capital stock or
other securities. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Redemption </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Shares of our common stock are not subject to redemption by operation of a sinking fund or otherwise. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Liquidation Rights </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In the event of any liquidation, dissolution, or
winding up of our company, subject to the rights, if any, of the holders of other classes of our capital stock, the holders of shares of our common stock are entitled to receive any of our assets available for distribution to our stockholders
ratably in proportion to the number of shares held by them. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">7 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Options and Other Stock-Based Rights </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">From time to time, we have issued and expect to continue to issue options and other stock-based rights to various lenders, investors,
consultants, employees, officers and directors of our company. As of November&nbsp;2, 2015, we had outstanding (i)&nbsp;stock options to purchase 17,479,325 shares of our common stock, of which 13,898,297 shares of common stock were issuable upon
exercise of vested stock options as of that date, and (ii)&nbsp;warrants for the purchase of 12,722,431 shares of our common stock. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Listing </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our common
stock is listed on the NYSE MKT under the symbol &#147;TXMD.&#148; </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Transfer Agent and Registrar </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The transfer agent and registrar for our common stock is Computershare Trust Company, N.A., 350 Indiana Street, Suite 800, Golden,
Colorado 80401. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">8 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="rom579833_8"></A><A NAME="supprom579833_20"></A>DESCRIPTION OF PREFERRED
STOCK </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This section describes the general terms of our preferred stock to which any prospectus supplement may relate. A
prospectus supplement will describe the terms relating to any preferred stock to be offered by us in greater detail and may provide information that is different from terms described in this prospectus. If the information in the prospectus
supplement with respect to the particular preferred stock being offered differs from this prospectus, you should rely on the information in the prospectus supplement. A copy of our amended and restated articles of incorporation, as amended, has been
incorporated by reference from our filings with the SEC as an exhibit to the registration statement of which this prospectus forms a part. A certificate of designation or amendment to the amended and restated articles of incorporation, as amended,
will specify the terms of the preferred stock being offered, and will be filed or incorporated by reference as an exhibit to the registration statement before the preferred stock is issued. The following description of our preferred stock, and any
description of the preferred stock in a prospectus supplement may not be complete and is subject to, and qualified in its entirety by reference to, Nevada law and the actual terms and provisions contained in our amended and restated articles of
incorporation, as amended, and bylaws, each as amended from time to time. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under our amended and restated articles of
incorporation, as amended, we have the authority to issue 10,000,000 shares of preferred stock, par value $0.001 per share, which are issuable in series on terms to be determined by our board of directors. Accordingly, our board of directors is
authorized, without action by the stockholders, to issue preferred stock from time to time with such dividend, liquidation, conversion, voting, redemption, sinking fund and other rights and restrictions as it may determine. All shares of any one
series of our preferred stock will be identical, except that shares of any one series issued at different times may differ as to the dates from which dividends may be cumulative. All series will rank equally and will provide for other terms as
described in the applicable prospectus supplement. As of the date of this prospectus, there were no outstanding shares of our preferred stock. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Terms of Preferred Stock </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Unless provided in a prospectus supplement, the shares of our preferred stock to be issued will have no preemptive rights. Any prospectus
supplement offering our preferred stock will furnish the following information with respect to the preferred stock offered by that prospectus supplement: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the title and stated value of the preferred stock; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the number of shares of preferred stock to be issued and the offering price of the preferred stock; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">any dividend rights; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">any dividend rates, periods, or payment dates, or methods of calculating dividends applicable to the preferred stock; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the date from which distributions on the preferred stock will accumulate, if applicable; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the terms and conditions, if applicable, upon which the preferred stock will be convertible into our common stock, including the conversion price (or
manner of calculation thereof); </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">any right to convert the preferred stock into a different type of security; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">any voting rights attributable to the preferred stock; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">any rights and preferences upon our liquidation, dissolution, or winding up of our affairs; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">any terms of redemption; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">any procedures for any auction and remarketing for the preferred stock; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">any provisions for a sinking fund for the preferred stock; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">any listing of the preferred stock on any securities exchange; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">9 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a discussion of material U.S. federal income tax considerations applicable to the preferred stock; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the relative ranking and preferences of the preferred stock as to distribution rights (including whether any liquidation preference as to the preferred
stock will be treated as a liability for purposes of determining the availability of assets for distributions to holders of stock ranking junior to the shares of preferred stock as to distribution rights); </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">any limitations on issuance of any series of preferred stock ranking senior to or on a parity with the series of preferred stock being offered as to
distribution rights and rights upon the liquidation, dissolution, or winding up or our affairs; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">any other specific terms, preferences, rights, limitations, or restrictions of the preferred stock. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Rank </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Unless otherwise
indicated in the applicable prospectus supplement, shares of our preferred stock will rank, with respect to payment of distributions and rights upon our liquidation, dissolution, or winding up, and allocation of our earnings and losses as follows:
</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">senior to all classes or series of our common stock and to all of our equity securities ranking junior to the preferred stock;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">on a parity with all equity securities issued by us, the terms of which specifically provide that such equity securities rank on a parity with the
preferred stock; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">junior to all equity securities issued by us, the terms of which specifically provide that such equity securities rank senior to the preferred stock.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Distributions </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Subject to any preferential rights of any outstanding stock or series of stock, our preferred stockholders will be entitled to receive distributions, in accordance with the applicable terms of each series
of preferred stock, when, as, and if declared by our board of directors, out of legally available funds, and to share pro rata based on the number of preferred shares, common stock, and other parity equity securities outstanding. The rates and dates
of payment of dividends, if any, will be set forth in the prospectus supplement relating to the applicable series of preferred stock. Dividends, if any, will be payable to holders of record of preferred stock as they appear on our books or, if
applicable, the records of the depositary, if any, referred to below on the record dates fixed by our board of directors. Dividends on a series of preferred stock may be cumulative or noncumulative. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We may not declare, pay, or set apart for payment dividends on the preferred stock unless full dividends on other series of preferred
stock that rank on an equal or senior basis have been paid or sufficient funds have been set apart for payment for: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">all prior dividend periods of other series of preferred stock that pay dividends on a cumulative basis; or </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the immediately preceding dividend period of other series of preferred stock that pay dividends on a noncumulative basis. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Partial dividends declared on shares of preferred stock and each other series of preferred stock ranking on an equal basis as to
dividends will be declared pro rata. A pro rata declaration means that the ratio of dividends declared per share to accrued dividends per share will be the same for each series of preferred stock. Similarly, we may not declare, pay, or set apart for
payment non-stock dividends or make other payments on the common stock or any other of our stock ranking junior to the preferred stock until full dividends on the preferred stock have been paid or set apart for payment for: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">all prior dividend periods if the preferred stock pays dividends on a cumulative basis; or </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the immediately preceding dividend period if the preferred stock pays dividends on a noncumulative basis. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Voting Rights </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Unless otherwise indicated in the applicable prospectus supplement, or as required by Nevada law, holders of our preferred stock will not have any voting rights. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Liquidation Preference </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Upon the voluntary or involuntary liquidation, dissolution, or winding up of our affairs, then, before any distribution or payment will be
made to the holders of any common stock or any other class or series of stock ranking junior to the preferred stock in our distribution of assets upon any liquidation, dissolution, or winding up, the holders of each series of our preferred stock
will be entitled to receive, after payment or provision for payment of our debts and other liabilities, out of our assets legally available for distribution to stockholders, liquidating distributions in the amount of the liquidation preference per
share (set forth in the applicable prospectus supplement), plus an amount, if applicable, equal to all distributions accrued and unpaid thereon (which will not include any accumulation in respect of unpaid distributions for prior distribution
periods if the preferred stock is not entitled to a cumulative distribution). Unless otherwise specified in the applicable prospectus supplement, after payment of the full amount of the liquidating distributions to which they are entitled, the
holders of preferred stock will have no right or claim to any of our remaining assets. In the event that, upon our voluntary or involuntary liquidation, dissolution, or winding up, the legally available assets are insufficient to pay the amount of
the liquidating distributions on all of our outstanding preferred stock and the corresponding amounts payable on all of our other classes or series of equity securities ranking on a parity with the preferred stock in the distribution of assets upon
liquidation, dissolution, or winding up, then the holders of our preferred stock and all other such classes or series of equity securities will share ratably in the distribution of assets in proportion to the full liquidating distributions to which
they would otherwise be respectively entitled. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If the liquidating distributions are made in full to all holders of preferred
stock, our remaining assets will be distributed among the holders of any other classes or series of equity securities ranking junior to the preferred stock upon our liquidation, dissolution, or winding up, according to their respective rights and
preferences and in each case according to their respective number of shares of stock. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Conversion Rights </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The terms and conditions, if any, upon which shares of any series of preferred stock are to be convertible into other securities will be
set forth in the applicable prospectus supplement. These terms will include the amount and type of security into which the shares of preferred stock are convertible, the conversion price (or manner of calculation thereof), the conversion period,
provisions as to whether conversion will be at the option of the holders of the preferred stock or us, the events requiring an adjustment of the conversion price, and provisions affecting conversion in the event of the redemption of that preferred
stock. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Redemption </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">If so provided in the applicable prospectus supplement, our preferred stock will be subject to mandatory redemption or redemption at our option, in whole or in part, in each case upon the terms, at the
times and at the redemption prices set forth in such prospectus supplement. Unless we default in the payment of the redemption price, dividends will cease to accrue after the redemption date on shares of preferred stock called for redemption and all
rights of holders of such shares will terminate, except for the right to receive the redemption price. No series of preferred stock will receive the benefit of a sinking fund except as set forth in the applicable prospectus supplement. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Registrar and Transfer Agent </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The registrar and transfer agent for our preferred stock will be set forth in the applicable prospectus supplement. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">11 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If our board of directors decides to issue any shares of preferred stock, it may
discourage or make more difficult a merger, tender offer, business combination or proxy contest, assumption of control by a holder of a large block of our securities, or the removal of incumbent management, even if these events were favorable to the
interests of stockholders. Our board of directors, without stockholder approval, may issue preferred stock with voting and conversion rights and dividend and liquidation preferences that may adversely affect the holders of our other equity or debt
securities. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">12 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="rom579833_9"></A><A NAME="supprom579833_21"></A>DESCRIPTION OF DEBT
SECURITIES </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This prospectus describes certain general terms and provisions of the debt securities that we may offer under
this prospectus and one or more prospectus supplements. When we offer to sell a particular series of debt securities, we will describe the specific terms of the series in a prospectus supplement. The following description of debt securities will
apply to the debt securities offered by this prospectus unless we provide otherwise in the applicable prospectus supplement. The applicable prospectus supplement for a particular series of debt securities may specify different or additional terms.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We may issue &#147;senior,&#148; &#147;senior subordinated,&#148; or &#147;subordinated&#148; debt securities. &#147;Senior
securities&#148; will be direct obligations of ours and will rank equally and ratably in right of payment with other indebtedness of ours that is not subordinated. &#147;Senior subordinated securities&#148; will be subordinated in right of payment
to the prior payment in full of senior indebtedness, as defined in the applicable prospectus supplement, and may rank equally and ratably with any other senior subordinated indebtedness. &#147;Subordinated securities&#148; will be subordinated in
right of payment to senior subordinated securities. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We need not issue all debt securities of one series at the same time.
Unless we provide otherwise, we may reopen a series, without the consent of the holders of such series, for issuances of additional securities of that series. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We will issue the senior debt securities and senior subordinated debt securities under a senior indenture, which we will enter into with a trustee to be named in the senior indenture, and we will issue
the subordinated debt securities under a subordinated indenture, which we will enter into with a trustee to be named in the subordinated indenture. We use the term &#147;indenture&#148; or &#147;indentures&#148; to refer to both the senior indenture
and the subordinated indenture. Each indenture will be subject to and governed by the Trust Indenture Act of 1939, as amended, or the Trust Indenture Act, and we may supplement the indenture from time to time. Any trustee under any indenture may
resign or be removed with respect to one or more series of debt securities, and we may appoint a successor trustee to act with respect to that series. We have filed a form of indenture as an exhibit to this registration statement, of which this
prospectus forms a part. The terms of the senior indenture and subordinated indenture will be substantially similar, except that the subordinated indenture will include provisions pertaining to the subordination of the subordinated debt securities
and senior subordinated debt securities to the senior debt securities and any other of our senior securities. The following statements relating to the debt securities and the indenture are summaries only, are subject to change, and are qualified in
their entirety to the detailed provisions of the indenture, any supplemental indenture, and the discussion contained in any prospectus supplements. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>General </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The debt securities will be our direct obligations. We may issue
debt securities from time to time and in one or more series as our board of directors may establish by resolution or as we may establish in one or more supplemental indentures. The particular terms of each series of debt securities will be described
in a prospectus supplement relating to the series. We may issue debt securities with terms different from those of debt securities that we previously issued. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We may issue debt securities from time to time and in one or more series with the same or various maturities, at par, at a premium, or at a discount. We will set forth in a prospectus supplement, relating
to any series of debt securities being offered, the initial offering price, and the following terms of the debt securities: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the title of the debt securities; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the series designation and whether they are senior securities, senior subordinated securities, or subordinated securities;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the aggregate principal amount of the debt securities and any limit on the aggregate amount of the series of debt securities;
</FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">13 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the price or prices (expressed as a percentage of the aggregate principal amount) at which we will issue the debt securities and, if other than the
principal amount of the debt securities, the portion of the principal amount of the debt securities payable upon the maturity of the debt securities; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the date or dates on which we will pay the principal on the debt securities; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the rate or rates (which may be fixed or variable) per annum or the method used to determine the rate or rates (including any commodity, commodity
index, stock exchange index, or financial index) at which the debt securities will bear interest, the date or dates from which interest will accrue, the date or dates on which interest will commence and be payable, and any regular record date for
the interest payable on any interest payment date; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the place or places where principal, interest, and any additional amounts will be payable and where the debt securities can be surrendered for
transfer, exchange, or conversion; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the terms, if any, by which holders of the debt securities may convert or exchange the debt securities for our common stock, preferred stock, or any
other security or property; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">if convertible, the initial conversion price, the conversion period, and any other terms governing such conversion; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">any subordination provisions or limitations relating to the debt securities; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">any sinking fund requirements; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">any obligation we have to redeem, purchase or repay the debt securities pursuant to any sinking fund or analogous provisions or at the option of a
holder of debt securities and the price or prices at which and the period and periods within which and the terms and conditions upon which debt securities of the series shall be redeemed, purchased, or repaid pursuant to such obligation;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the dates on which and the price or prices at which we will repurchase the debt securities at the option of the holders of debt securities and other
detailed terms and provisions of these repurchase obligations; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the denominations in which the debt securities will be issued, if other than denominations of $1,000 and any integral multiple thereof;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the portion of principal amount of the debt securities payable upon declaration of acceleration of the maturity date, if other than the principal
amount; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">whether we will issue the debt securities in certificated or book-entry form; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the price or prices at which (if any), the period or periods within which (if any), and the terms and conditions upon which (if other than as provided
herein) the debt securities may be redeemed, in whole or in part, at the option, or as an obligation, of the Company; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">whether the debt securities shall be issued in whole or in part in the form of a global security or securities; the terms and conditions, if any, upon
which such global security or securities may be exchanged in whole or in part for other individual debt securities, and the depositary for such global security and securities; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">whether the debt securities will be in registered or bearer form and, if in registered form, the denominations if other than in even multiples of
$1,000 and, if in bearer form, the denominations and terms and conditions relating thereto; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the currency of denomination of the debt securities; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the designation of the currency, currencies, or currency units in which payment of principal of, premium, and interest on the debt securities will be
made; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">if payments of principal of, and interest and any additional amounts on the debt securities will be made in one or more currencies or currency units
other than that or those in which the debt securities are </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">14 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P><FONT STYLE="font-family:Times New Roman" SIZE="2">
denominated, the manner in which the exchange rate with respect to these payments will be determined; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the manner in which the amounts of payment of principal of, and interest and any additional amounts on the debt securities will be determined, if these
amounts may be determined by reference to an index based on a currency or currencies other than that in which the debt securities are denominated or designated to be payable or by reference to a commodity, commodity index, stock exchange index, or
financial index; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">any applicability of the defeasance provisions described in this prospectus or any prospectus supplement; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the trustee for the debt securities; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">whether and under what circumstances, if any, we will pay additional amounts on any debt securities in respect of any tax, assessment, or governmental
charge and, if so, whether we will have the option to redeem the debt securities instead of making this payment; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">any addition to or change in the events of default described in this prospectus or in the indenture with respect to the debt securities and any change
in the acceleration provisions described in this prospectus or in the indenture with respect to the debt securities; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">any addition to or change in the covenants described in this prospectus or in the indenture with respect to the debt securities;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">if the debt securities are to be issued upon the exercise of debt warrants, the time, manner, and place for them to be authenticated and delivered;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">any securities exchange on which we will list the debt securities; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">any restrictions on transfer, sale, or other assignment; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">any provisions relating to any security provided for the debt securities; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">any provisions relating to any guarantee of the debt securities; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">any other terms of the debt securities, which may modify or delete any provision of the indenture as it applies to that series; and
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">any depositaries, interest rate calculation agents, exchange rate calculation agents, or other agents with respect to the debt securities.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We may issue debt securities that are exchangeable for or convertible into shares of our common stock or
other securities or property. The terms, if any, on which the debt securities may be exchanged for or converted into shares of our common stock or other securities or property will be set forth in the applicable prospectus supplement. Such terms may
include provisions for conversion, either mandatory, at the option of the holder or at our option, in which case the number of shares of common stock or other securities or property to be received by the holders of debt securities would be
calculated as of a time and in the manner stated in the prospectus supplement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We may issue debt securities at less than the
principal amount payable upon maturity. We refer to these securities as &#147;original issue discount securities.&#148; If material or applicable, we will describe in the applicable prospectus supplement special U.S. federal income tax, accounting,
and other considerations applicable to original issue discount securities. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If we denominate the purchase price of any of the
debt securities in a foreign currency or currencies or a foreign currency unit or units, or if the principal of and interest and any additional amounts on any series of debt securities is payable in a foreign currency or currencies or a foreign
currency unit or units, we will describe the restrictions, elections, general tax considerations, specific terms, and provide other information with respect to that issue of debt securities and such foreign currency or currencies or foreign currency
unit or units in the applicable prospectus supplement. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">15 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Except as may be set forth in any prospectus supplement relating to the debt
securities, no indenture will contain any other provisions that would limit our ability to incur indebtedness or that would afford holders of the debt securities protection in the event of a highly leveraged or similar transaction involving us or in
the event of a change in control. You should review carefully the applicable prospectus supplement for information with respect to events of default and any covenants applicable to the debt securities being offered. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Payments and Paying Agents </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Unless we otherwise indicate in the applicable prospectus supplement, we will make payment of the interest on any debt securities on any interest payment date to the person in whose name the debt
securities, or one or more predecessor securities, are registered at the close of business on the regular record date for the interest. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We will pay principal of, and interest and any additional amounts on, the debt securities of a particular series at the office of the paying agents designated by us, except that, unless we otherwise
indicate in the applicable prospectus supplement, we may make interest payments by check, which we will mail to the holder, or by wire transfer to certain holders. Unless we otherwise indicate in a prospectus supplement, we will designate the
corporate trust office of the trustee as our sole paying agent for payments with respect to debt securities of each series. We will name in the applicable prospectus supplement any other paying agents that we initially designate for the debt
securities of a particular series.</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Form, Transfer, and Exchange </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Each debt security will be represented by either one or more global securities registered in the name of The Depository Trust Company, as
depositary, or a nominee of the depositary (as a &#147;book-entry debt security&#148;), or a certificate issued in definitive registered form (as a &#147;certificated debt security&#148;), as described in the applicable prospectus supplement. Except
as described under &#147;Global Debt Securities and Book-Entry System&#148; below, book-entry debt securities will not be issuable in certificated form. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Certificated Debt Securities </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">A holder of our debt securities may transfer
or exchange certificated debt securities at the trustee&#146;s office or paying agencies in accordance with the terms of the indenture. No service charge will be made for any transfer or exchange of certificated debt securities, but we may require
payment of a sum sufficient to cover any tax or other governmental charge payable in connection with a transfer or exchange. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">A holder of our debt securities may transfer certificated debt securities and the right to receive the principal of, and interest and any
additional amounts on, certificated debt securities only by surrendering the old certificate representing those certificated debt securities and either we or the trustee will reissue the old certificate to the new holder, or we or the trustee will
issue a new certificate to the new holder. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Global Debt Securities and Book-Entry System </I></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Each global debt security representing book-entry debt securities will be deposited with, or on behalf of, the depositary, and registered
in the name of the depositary or a nominee of the depositary. Ownership of beneficial interests in book-entry debt securities will be limited to persons that have accounts with the depositary for the related global debt security, whom we refer to as
participants, or persons that may hold interests through participants. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Except as described in this prospectus or any
applicable prospectus supplement, beneficial owners of <FONT STYLE="white-space:nowrap">book-entry</FONT> debt securities will not be entitled to have securities registered in their names, will not receive or be entitled to receive physical delivery
of a certificate in definitive form representing securities, and will not be considered the owners or holders of those securities under the indenture. Accordingly, to exercise any rights of a holder under the indenture, each person beneficially
owning book-entry debt securities must rely on the procedures of the depositary for the related global debt security and, if that person is not a participant, on the procedures of the participant through which that person owns its interest.
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">16 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We understand, however, that under existing industry practice, the depositary will
authorize the persons on whose behalf it holds a global debt security to exercise certain rights of holders of debt securities, and the indenture provides that we, the trustee, and our respective agents will treat as the holder of a debt security
the persons specified in a written statement of the depositary with respect to that global debt security for purposes of obtaining any consents or directions required to be given by holders of the debt securities pursuant to the indenture.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We will make payments of principal of, and interest and any additional amounts on, book-entry debt securities to the
depositary or its nominee, as the case may be, as the registered holder of the related global debt security. We, the trustee, and any other agent of ours or agent of the trustee will not have any responsibility or liability for any aspect of the
records relating to or payments made on account of beneficial ownership interests in a global debt security or for maintaining, supervising, or reviewing any records relating to such beneficial ownership interests. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Any certificated debt securities issued in exchange for a global debt security will be registered in such name or names as the depositary
shall instruct the trustee. We expect that such instructions will be based upon directions received by the depositary from participants with respect to ownership of book-entry debt securities relating to such global debt security. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">For additional discussion of book entry and certificated securities, see the section entitled &#147;Legal Ownership of Securities&#148;
included in this prospectus. We have obtained the foregoing information in this section and the &#147;Legal Ownership of Securities&#148; section concerning the depositary and the depositary&#146;s book-entry system from sources we believe to be
reliable. We take no responsibility for the depositary&#146;s performance of its obligations under the rules and regulations governing its operations. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>No Protection in the Event of a Change in Control </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Unless we provide
otherwise in the applicable prospectus supplement, the debt securities will not contain any provisions that may afford holders of the debt securities protection in the event we have a change in control or in the event of a highly leveraged
transaction (whether or not such transaction results in a change in control). </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Covenants </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Unless we provide otherwise in the applicable prospectus supplement, the debt securities will not contain any restrictive covenants,
including covenants restricting us or any of our subsidiaries from incurring, issuing, assuming, or guaranteeing any indebtedness secured by a lien on any of our or our subsidiaries&#146; property or capital stock or restricting us or any of our
subsidiaries from entering into any sale and leaseback transactions. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Merger, Consolidation, and Sale of Assets </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Unless we provide otherwise in the applicable prospectus supplement, we may not merge with or into or consolidate with, or convey,
transfer, or lease all or substantially all of our properties and assets to, any person (a &#147;successor person&#148;), unless the following applies: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">either (a)&nbsp;the company is the surviving entity or (b)&nbsp;the successor person is a corporation, partnership, trust, or other entity organized
and validly existing under the laws of any U.S. domestic jurisdiction and expressly assumes our obligations on the debt securities and under the indenture; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">immediately after giving effect to the transaction, no event of default, and no event that, after notice or lapse of time, or both, would become an
event of default, will have occurred and be continuing under the indenture; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">certain other conditions that may be set forth in the applicable prospectus supplement are met. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">17 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This covenant would not apply to any recapitalization transaction, a change in control
of us, or a transaction in which we incur a large amount of additional debt unless the transactions or change in control included a merger, consolidation, or transfer or lease of substantially all of our assets. Except as may be described in the
applicable prospectus supplement, there are no covenants or other provisions in the indenture providing for a &#147;put&#148; right or increased interest or that would otherwise afford holders of debt securities additional protection in the event of
a recapitalization transaction, a change in control of us, or a transaction in which we incur a large amount of additional debt. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Events of
Default Under the Indenture </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Unless we provide otherwise in the applicable prospectus supplement, an &#147;event of
default&#148; will mean, with respect to any series of debt securities, any of the following: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">default in the payment of any interest upon any debt security of that series when it becomes due and payable and continuance of that default for a
period of 30 days (unless the entire amount of such payment is deposited by us with the trustee or with a paying agent before the expiration of the 30-day period); </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">default in the payment of principal of, and any other amounts due on, any debt security of that series when due and payable either at maturity,
redemption, or otherwise; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">default in the deposit of any sinking fund payment, when and as due in respect of any debt security of that series; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">default in the performance or breach of any other covenant or warranty by us in the indenture (other than a covenant or warranty that has been included
in the indenture solely for the benefit of a series of debt securities other than that series) or in the debt security, which default continues uncured for a period of 60 days after we receive written notice from the trustee or we and the trustee
receive written notice from the holders of not less than a majority in principal amount of the outstanding debt securities of that series as provided in the indenture; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">we, pursuant to or within the meaning of any applicable bankruptcy law, commence a voluntary case, consent to the entry of an order for relief against
us in an involuntary case, consent to the appointment of a custodian for all or substantially all of our property, make a general assignment for the benefit of our creditors, or admit in writing our inability generally to pay our debts as they
become due; or, similarly, a court enters an order or decree under any applicable bankruptcy law that provides for relief against us in an involuntary case, appoints a custodian for all or substantially all of our properties, or orders our
liquidation (and the order remains in effect for 60 days); and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">any other event of default provided with respect to debt securities of that series that is included in any supplemental indenture or is described in
the applicable prospectus supplement accompanying this prospectus. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">No event of default with respect to a
particular series of debt securities (except as to certain events of bankruptcy, insolvency, or reorganization) necessarily will constitute an event of default with respect to any other series of debt securities. An event of default may also be an
event of default under our bank credit agreements or other debt securities in existence from time to time and under certain guaranties by us of any subsidiary indebtedness. In addition, certain events of default or an acceleration under the
indenture may also be an event of default under some of our other indebtedness outstanding from time to time. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Unless we
provide otherwise in the applicable prospectus supplement, if an event of default with respect to debt securities of any series at the time outstanding occurs and is continuing (other than certain events of our bankruptcy, insolvency, or
reorganization), then the trustee or the holders of not less than a majority in principal amount of the outstanding debt securities of that series may, by written notice to us (and to the trustee if given by the holders), declare to be due and
payable immediately the principal (or, if the debt securities of that series are </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">18 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
discount securities, that portion of the principal amount as may be specified in the terms of that series) of and accrued and unpaid interest, if any, of all debt securities of that series. In
the case of an event of default resulting from certain events of bankruptcy, insolvency, or reorganization, the principal (or such specified amount) of and accrued and unpaid interest, if any, of all outstanding debt securities will become and be
immediately due and payable without any declaration or other act by the trustee or any holder of outstanding debt securities. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">At any time after an acceleration with respect to debt securities of a series has been made, but before a judgment or decree for payment
of the money due has been obtained by the trustee, the holders of not less than a majority in principal amount of the outstanding debt securities of that series may cancel the acceleration and annul its consequences if the rescission would not
conflict with any judgment or decree and if all existing events of default with respect to that series have been cured or waived except nonpayment of principal (or such lesser amount) or interest that has become due solely because of the
acceleration. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The indenture also provides that the holders of not less than a majority in principal amount of the outstanding
debt securities of any series may waive any past default with respect to that series and its consequences, except a default involving the following: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our failure to pay the principal of, and interest and any additional amounts on, any debt security; or </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a covenant or provision contained in the indenture that cannot be modified or amended without the consent of the holders of each outstanding debt
security affected by the default. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The trustee is generally required to give notice to the holders of debt
securities of each affected series within 90 days of a default actually known to a responsible officer of the trustee unless the default has been cured or waived. The indenture provides that the trustee may withhold notice to the holders of debt
securities of any series of any default or event of default (except in payment on any debt securities of that series) with respect to debt securities of that series if it in good faith determines that withholding notice is in the interest of the
holders of those debt securities. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Unless we provide otherwise in the applicable prospectus supplement, the indenture will
provide that the trustee will be under no obligation to exercise any of its rights or powers under the indenture at the request or discretion of any holder of any such outstanding debt securities unless the trustee receives indemnity satisfactory to
it against any loss, liability, or expense. Subject to certain rights of the trustee, the holders of a majority in principal amount of the outstanding debt securities of any series will have the right to direct the time, method, and place of
conducting any proceeding for any remedy available to the trustee or exercising any trust or power conferred on the trustee with respect to the debt securities of that series. The trustee may, however, refuse to follow any discretion that conflicts
with the indenture or any law or which may be unduly prejudicial to the holders of the debt securities of the applicable series not joining in the discretion. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Unless we provide otherwise in the applicable prospectus supplement, no holder of any debt security of any series will have any right to institute any proceeding, judicial or otherwise, with respect to
the indenture or for the appointment of a receiver or trustee, or for any remedy under the indenture, unless: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">that holder has previously given to the trustee written notice of a continuing event of default with respect to debt securities of that series; and
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the holders of at least 25% in principal amount of the outstanding debt securities of that series have made written request, and offered reasonable
indemnity, to the trustee to institute such proceeding as trustee, and the trustee will not have received from the holders of a majority in principal amount of the outstanding debt securities of that series a direction inconsistent with that request
and has failed to institute the proceeding within 60 days. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Notwithstanding the foregoing, except as
provided in the subordination provisions, if any, the holder of any debt security will have an absolute and unconditional right to receive payment of the principal of, and any interest or additional amounts on, that debt security on or after the due
dates expressed in that debt security and to institute suit for the enforcement of payment. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">19 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The indenture requires us, within 120 days after the end of our fiscal year, to furnish
to the trustee a certificate as to compliance with the indenture, or, in the event of noncompliance, specify the noncompliance and the nature and status of the noncompliance. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Modification of Indenture and Waiver </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Except as specified below,
modifications and amendments to the indenture require the approval of not less than a majority in principal amount of our outstanding debt securities. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Changes Requiring the Unanimous Approval </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We and the trustee may not make
any modification or amendment to the indenture without the consent of the holder of each affected debt security then outstanding if that amendment will have any of the following results: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">reduce the rate of or extend the time for payment of interest, including default interest, on any debt security; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">reduce the principal of or any additional amounts on or change the fixed maturity of any debt security or reduce the amount of, or postpone the date
fixed for, the payment of any sinking fund or analogous obligation with respect to any series of debt securities; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">reduce the principal amount of discount securities payable upon acceleration of maturity; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">waive a default in the payment of the principal, interest, or any additional amounts on any debt security, except a rescission of acceleration of the
debt securities of any series by the holders of at least a majority in aggregate principal amount of the then outstanding debt securities of that series and a waiver of the payment default that resulted from that acceleration;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">make the principal of, or interest or any additional amounts on, any debt security payable in currency other than that stated in the debt security;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">change the place of payment on a debt security; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">change the currency or currencies of payment of the principal of, and any premium, make-whole payment, interest, or additional amounts on, any debt
security; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">impair the right to initiate suit for the enforcement of any payment on or with respect to any debt security; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">reduce the percentage of holders of debt securities whose consent is needed to modify or amend an indenture, to waive compliance with certain
provisions of an indenture, or to waive certain defaults; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">reduce the percentage of the holders of outstanding debt securities of any series necessary to modify or amend the indenture, to waive compliance with
provisions of the indenture or defaults and their consequences under the indenture, or to reduce the quorum or voting requirements contained in the indenture; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">make any change that adversely affects the right to convert or exchange any debt security other than as permitted by the indenture or decrease the
conversion or exchange rate or increase the conversion or exchange price of any such debt security; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">waive a redemption payment with respect to any debt security; or </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">make any change to certain provisions of the indenture relating to, among other things, the right of holders of debt securities to receive payment of
the principal of, and interest and any additional amount on, those debt securities, the right of holders to institute suit for the enforcement of any payment or the right of holders to waive past defaults. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">20 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Changes Not Requiring Approval of Debt Holders </I></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We and the trustee may modify or amend an indenture, without the consent of any holder of debt securities, for any of the following
purposes: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">to evidence the succession of another person to us as obligor under the indenture; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">to add to our existing covenants additional covenants for the benefit of the holders of all or any series of debt securities, or to surrender any right
or power conferred upon us in the indenture; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">to add events of default for the benefit of the holders of all or any series of debt securities; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">to add or change any provisions of the indenture to facilitate the issuance of, or to liberalize the terms of, debt securities in bearer form, or to
permit or facilitate the issuance of debt securities in uncertificated form, provided that this action will not adversely affect the interests of the holders of the debt securities of any series in any material respect; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">to add, change, or eliminate any provisions of the indenture, provided that any addition, change, or elimination (a)&nbsp;shall neither (i)&nbsp;apply
to any debt security of any series created prior to the execution of such supplemental indenture and entitled to the benefit of such provision nor (ii)&nbsp;modify the rights of the holder of any debt security with respect to such provision, or (b)
shall become effective only when there are no outstanding debt securities; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">to establish additional series of debt securities; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">to secure previously unsecured debt securities; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">to establish the form or terms of debt securities of any series, including the provisions and procedures, if applicable, for the conversion or exchange
of the debt securities into our common stock, preferred stock, or other securities or property; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">to evidence and provide for the acceptance or appointment of a successor trustee or facilitate the administration of the trusts under the indenture by
more than one trustee; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">to make any provision with respect to the conversion or exchange of rights of holders pursuant to the requirements of the indenture;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">to cure any ambiguity, defect, or inconsistency in the indenture, provided that the action does not adversely affect the interests of holders of debt
securities of any series issued under the indenture; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">to close the indenture with respect to the authentication and delivery of additional series of debt securities or to qualify, or maintain qualification
of, the indenture under the Trust Indenture Act; or </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">to supplement any of the provisions of the indenture to the extent necessary to permit or facilitate defeasance and discharge of any series of debt
securities, provided that the action shall not adversely affect the interests of the holders of the debt securities of any series in any material respect. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">A vote by holders of debt securities will not be required for clarifications and certain other changes that would not adversely affect holders of the debt securities. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Defeasance of Debt Securities and Certain Covenants in Certain Circumstances </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Legal Defeasance </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Unless the terms of the applicable series of debt securities provide otherwise, we may be discharged from any and all obligations in respect of the debt securities of any series (except for certain
obligations to register the transfer or exchange of debt securities of the series; to replace stolen, lost, or mutilated debt securities of the series; and to maintain paying agencies and certain provisions relating to the treatment of funds held by
paying agents). We will be so discharged upon the deposit with the trustee, in trust, of money and/or U.S. government obligations or, in the case of debt securities denominated in a single currency other than U.S. dollars, foreign
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">21 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
government obligations (as described at the end of this section), that, through the payment of interest and principal in accordance with their terms, will provide money in an amount sufficient to
pay and discharge each installment of principal, interest, and any additional amounts on and any mandatory sinking fund payments in respect of the debt securities of that series on the stated maturity of such payments in accordance with the terms of
the indenture and those debt securities. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This discharge may occur only if, among other things, we have delivered to the
trustee an officers&#146; certificate and an opinion of counsel stating that we have received from, or there has been published by, the U.S.&nbsp;Internal Revenue Service a ruling or, since the date of execution of the indenture, there has been a
change in the applicable U.S. federal income tax law, in either case to the effect that holders of the debt securities of such series will not recognize income, gain, or loss for U.S. federal income tax purposes as a result of the deposit,
defeasance, and discharge and will be subject to U.S. federal income tax on the same amount and in the same manner and at the same times as would have been the case if the deposit, defeasance, and discharge had not occurred. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Defeasance of Certain Covenants </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Unless the terms of the applicable series of debt securities provide otherwise, upon compliance with certain conditions, we may omit to comply with the restrictive covenants contained in the indenture
(except for certain obligations to maintain paying agencies and certain provisions relating to the treatment of funds held by paying agents), as well as any additional covenants contained in the applicable prospectus supplement. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The conditions include, among others, the following: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">depositing with the trustee money and/or U.S. government obligations or, in the case of debt securities denominated in a single currency other than
U.S. dollars, foreign government obligations, that, through the payment of interest and principal in accordance with their terms, will provide money in an amount sufficient, in the opinion of a nationally recognized firm of independent public
accountants, to pay principal, interest, and any additional amounts on and any mandatory sinking fund payments in respect of the debt securities of that series on the stated maturity of those payments in accordance with the terms of the indenture
and those debt securities; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">delivering to the trustee an opinion of counsel to the effect that the holders of the debt securities of that series will not recognize income, gain,
or loss for U.S. federal income tax purposes as a result of the deposit and related covenant defeasance and will be subject to U.S. federal income tax in the same amount and in the same manner and at the same times as would have been the case if the
deposit and related covenant defeasance had not occurred. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Covenant Defeasance and Events of Default
</I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If we exercise our option, as described above, not to comply with certain covenants of the indenture with respect to any
series of debt securities, and the debt securities of that series are declared due and payable because of the occurrence of any event of default, the amount of money and/or U.S. government obligations or foreign government obligations on deposit
with the trustee will be sufficient to pay amounts due on the debt securities of that series at the time of their stated maturity but may not be sufficient to pay amounts due on the debt securities of that series at the time of the acceleration
resulting from the event of default. However, we will remain liable for those payments. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;Foreign government
obligations&#148; means, with respect to debt securities of any series that are denominated in a currency other than U.S. dollars: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">direct obligations of the government that issued or caused to be issued such currency for the payment of which obligations its full faith and credit is
pledged, which are not callable or redeemable at the option of the issuer thereof; or </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">22 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">obligations of a person controlled or supervised by or acting as an agency or instrumentality of that government, the timely payment of which is
unconditionally guaranteed as a full faith and credit obligation by that government, which are not callable or redeemable at the option of the issuer thereof. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Guarantees </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our payment obligations under any series of debt securities may
be guaranteed by us or one or more of our subsidiaries. The terms of any such guarantee will be set forth in the applicable prospectus supplement. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Subordination </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We will set forth in the applicable prospectus supplement
the terms and conditions, if any, upon which any series of senior subordinated securities or subordinated securities is subordinated to debt securities of another series or to other indebtedness of ours. The terms will include a description of the
following: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the indebtedness ranking senior to the debt securities being offered; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">any restrictions on payments to the holders of the debt securities being offered while a default with respect to the senior indebtedness is continuing;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">any restrictions on payments to the holders of the debt securities being offered following an event of default; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">provisions requiring holders of the debt securities being offered to remit some payments to holders of senior indebtedness.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Conversion and Exchange Rights </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The terms on which debt securities of any series may be convertible into or exchangeable for our common stock, preferred stock, or other securities or property of our company will be described in the
applicable prospectus supplement. These terms will include the following: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the conversion or exchange price, or the manner of calculating the price; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the exchange or conversion period; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">whether the conversion or exchange is mandatory, or voluntary at the option of the holder, or at our option; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">any restrictions on conversion or exchange in the event of redemption of the debt securities and any restrictions on conversion or exchange; and
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the means of calculating the number of shares of our common stock, preferred stock, or other securities or property of our company to be received by
the holders of debt securities. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The conversion or exchange price of any debt securities of any series that
are convertible into our common stock or preferred stock may be adjusted for any stock dividends, stock splits, reclassification, combinations, or similar transactions, as set forth in the applicable prospectus supplement. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Redemption of Debt Securities </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The debt securities may be subject to optional or mandatory redemption on terms and conditions described in the applicable prospectus supplement. Subject to such terms, we may opt at any time to redeem
the debt securities in whole or in part. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If less than all the debt securities of any series are to be redeemed or purchased
in an offer to purchase at any time, the trustee will select the debt securities of that series to be redeemed or purchased as follows: (1)&nbsp;if the securities of such series are listed on any national securities exchange, in compliance with the
requirements of the </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">23 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
principal national securities exchange on which the debt securities of that series are listed, or, (2)&nbsp;if the debt securities of that series are not listed on a national securities exchange,
on a pro rata basis, by lot, or by such other method as the trustee deems fair and appropriate. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Except as otherwise provided
as to any particular series of debt securities, at least 30&nbsp;days but not more than 60 days before a redemption date, we or the trustee will mail a notice of redemption to each holder whose debt securities are to be redeemed. From and after
notice has been given as provided in the applicable indenture, if funds for the redemption of any debt securities called for redemption shall have been made available on the redemption date, the debt securities will cease to bear interest on the
date fixed for the redemption specified in the notice, and the only right of the holders of the debt securities will be to receive payment of the redemption price. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Governing Law </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The indentures and the debt securities will be governed by
and construed in accordance with the laws of the state of New York, except to the extent that the Trust Indenture Act is applicable. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">24 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="rom579833_10"></A><A NAME="supprom579833_22"></A>DESCRIPTION OF DEPOSITARY
SHARES </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We may issue receipts for depositary shares representing fractional shares of preferred stock. The fractional
share of the applicable series of preferred stock represented by each depositary share will be set forth in the applicable prospectus supplement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The shares of any series of preferred stock underlying any depositary shares that we may sell under this prospectus will be deposited under a deposit agreement between us and a depositary selected by us.
Subject to the terms of the deposit agreement, each holder of a depositary share will be entitled, in proportion to the applicable fraction of a share of the preferred stock underlying the depositary share, to all of the rights, preferences, and
privileges, and will be subject to the qualifications and restrictions, of the preferred stock underlying that depositary share. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The depositary shares will be evidenced by depositary receipts issued under the deposit agreement. Depositary receipts will be distributed to the holders of the depositary shares that are sold in the
applicable offering. We will incorporate by reference into the registration statement of which this prospectus forms a part the form of any deposit agreement, including a form of depositary receipt, that describes the terms of any depositary shares
we are offering before the issuance of the related depositary shares. The following summaries of material provisions of the deposit agreement, the depositary shares and the depositary receipts are subject to, and qualified in their entirety by
reference to, all of the provisions of the deposit agreement applicable to a particular offering of depositary shares. We urge you to read the prospectus supplements relating to any depositary shares that are sold under this prospectus, as well as
the complete deposit agreement and depositary receipt. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Form </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Pending the preparation of definitive depositary receipts, the depositary may, upon our written order, issue temporary depositary receipts substantially identical to the definitive depositary receipts but
not in definitive form. These temporary depositary receipts will entitle their holders to all of the rights of definitive depositary receipts. Temporary depositary receipts will then be exchangeable for definitive depositary receipts at our expense.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Dividends and Other Distributions </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The depositary will distribute all cash dividends or other cash distributions received with respect to the underlying preferred stock to the record holders of depositary shares in proportion to the number
of depositary shares owned by those holders. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If there is a distribution other than in cash, the depositary will distribute
property received by it to the record holders of depositary shares in proportion to the number of depositary shares owned by those holders, unless the depositary determines that it is not feasible to do so. If this occurs, the depositary may, with
our approval, sell the property and distribute the net proceeds from the sale to those holders in proportion to the number of depositary shares owned by them. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The amount distributed to holders of depositary shares will be reduced by any amounts required to be withheld by us or the preferred stock depositary on account of taxes or other governmental charges.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Liquidation Preference </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">If a series of preferred stock underlying the depositary shares has a liquidation preference, in the event of our voluntary or involuntary liquidation, dissolution, or winding up, holders of depositary
shares will be entitled to receive the fraction of the liquidation preference accorded each share of the applicable series of preferred stock, as set forth in the applicable prospectus supplement. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">25 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Withdrawal of Underlying Preferred Stock </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Except as otherwise provided in a prospectus supplement, holders may surrender depositary receipts at the principal office of the
depositary and, upon payment of any unpaid amount due to the depositary, be entitled to receive the number of whole shares of underlying preferred stock and all money and other property represented by the related depositary shares. We will not issue
any partial shares of preferred stock. If the holder delivers depositary receipts evidencing a number of depositary shares that represent more than a whole number of shares of preferred stock, the depositary will issue a new depositary receipt
evidencing the excess number of depositary shares to the holder. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Redemption of Depositary Shares </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If the preferred stock underlying any depositary shares we may sell under this prospectus is subject to redemption, the depositary shares
will be redeemed from the proceeds received by the depositary resulting from any such redemption, in whole or in part, of that underlying preferred stock. The redemption price per depositary share will be equal to the applicable fraction of the
redemption price per share payable with respect to the underlying preferred stock. Whenever we redeem shares of underlying preferred stock that are held by the depositary, the depositary will redeem, as of the same redemption date, the number of
depositary shares representing the shares of underlying preferred stock so redeemed. If fewer than all of the depositary shares are to be redeemed, the depositary shares to be redeemed will be selected by lot or proportionately, as may be determined
by the depositary. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">After the date fixed for redemption, the depositary shares called for redemption will no longer be deemed
to be outstanding, and all rights of the holders of the depositary shares will cease, except the right to receive the monies payable and any other property to which the holders were entitled upon the redemption upon surrender to the preferred stock
depositary of the depositary receipts evidencing the depositary shares. Any funds deposited by us with the preferred stock depositary for any depositary shares that the holders fail to redeem will be returned to us after a period of two years from
the date the funds are deposited. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Voting </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Upon receipt of notice of any meeting at which holders of the preferred stock underlying any depositary shares that we may sell under this prospectus are entitled to vote, the depositary will mail the
information contained in the notice to the record holders of the depositary shares. Each record holder of the depositary shares on the record date, which will be the same date as the record date for the underlying preferred stock, will be entitled
to instruct the depositary as to the exercise of the voting rights pertaining to the amount of the underlying preferred stock represented by the holder&#146;s depositary shares. The depositary will then try, as far as practicable, to vote the number
of shares of preferred stock underlying those depositary shares in accordance with those instructions, and we will agree to take all reasonable actions which may be deemed necessary by the depositary to enable the depositary to do so. The depositary
will not vote the underlying preferred stock to the extent it does not receive specific instructions with respect to the depositary shares representing such preferred stock. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Conversion of Preferred Stock </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If the prospectus supplement relating to any
depositary shares that we may sell under this prospectus states that the underlying preferred stock is convertible into our common stock or other securities, the following will apply. The depositary shares, as such, will not be convertible into any
of our securities. Rather, any holder of the depositary shares may surrender the related depositary receipts to the depositary with written instructions that direct us to cause conversion of the preferred stock represented by the depositary shares
into or for whole shares of our common stock or other securities, as applicable. Upon receipt of those instructions and any amounts payable by the holder in connection with the conversion, we will cause the conversion using the same procedures as
those provided for conversion of the underlying preferred stock. If only some of a holder&#146;s depositary shares are converted, a new depositary receipt or receipts will be issued to the holder for any depositary shares not converted. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">26 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Amendment and Termination of the Deposit Agreement </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The form of depositary receipt evidencing the depositary shares and any provision of the deposit agreement may at any time be amended by
agreement between us and the depositary. However, any amendment which materially and adversely alters the rights of the holders of depositary shares will not be effective until 90 days after notice of that amendment has been given to the holders.
Each holder of depositary shares at the time any amendment becomes effective shall be deemed to consent and agree to that amendment and to be bound by the deposit agreement as so amended. The deposit agreement may be terminated by us or by the
depositary only if all outstanding depositary shares have been redeemed or converted into any other securities into which the underlying preferred stock is convertible or there has been a final distribution, including to holders of depositary
receipts, of the underlying preferred stock in connection with our liquidation, dissolution, or winding up. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Charges of Depositary
</B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We will pay all transfer and other taxes and governmental charges arising solely from the existence of the depositary
arrangement. We will also pay charges of the depositary in connection with the initial deposit of the preferred stock, the initial issuance of the depositary shares, any redemption of the preferred stock, and all withdrawals of preferred stock by
owners of depositary shares. Holders of depositary receipts will pay transfer, income, and other taxes and governmental charges and other specified charges as provided in the deposit arrangement for their accounts. If these charges have not been
paid, the depositary may refuse to transfer depositary shares, withhold dividends and distributions, and sell the depositary shares evidenced by the depositary receipt. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Limitation on Liability </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Neither we nor the depositary will be liable if
either of us is prevented or delayed by law or any circumstance beyond our control in performing our respective obligations under the deposit agreement. Our obligations and those of the depositary will be limited to performance of our respective
duties under the deposit agreement without, in our case, negligence or bad faith or, in the case of the depositary, negligence or willful misconduct. We and the depositary may rely upon advice of counsel or accountants, or upon information provided
by persons presenting the underlying preferred stock for deposit, holders of depositary receipts, or other persons believed by us in good faith to be competent and on documents believed to be genuine. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Corporate Trust Office of Preferred Stock Depositary </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The preferred stock depositary&#146;s corporate trust office will be set forth in the applicable prospectus supplement relating to a series of depositary shares. The preferred stock depositary will act as
transfer agent and registrar for depositary receipts, and, if shares of a series of preferred stock are redeemable, the preferred stock depositary will act as redemption agent for the corresponding depositary receipts. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Resignation and Removal of Depositary </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The depositary may resign at any time by delivering notice to us of its election to resign. We may remove the depositary at any time. Any resignation or removal will take effect upon the appointment of a
successor depositary and its acceptance of the appointment. The successor depositary must be appointed within 60 days after delivery of the notice of resignation or removal and must be a bank or trust company having its principal office in the
United States and having a combined capital and surplus of at least $50,000,000. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Reports to Holders </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We will deliver all required reports and communications to holders of the preferred stock to the preferred stock depositary, and it will
forward those reports and communications to the holders of depositary shares. Upon request, the preferred stock depositary will provide for inspection to the holders of depositary shares the transfer books of the depositary and the list of holders
of receipts; provided that any requesting holder certifies to the preferred stock depositary that such inspection is for a proper purpose reasonably related to such person&#146;s interest as an owner of depositary shares evidenced by the receipts.
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">27 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="rom579833_11"></A><A NAME="supprom579833_23"></A>DESCRIPTION OF WARRANTS
</B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>General </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We may issue warrants to purchase common stock, which we refer to as common stock warrants, preferred stock, which we refer to as
preferred stock warrants, debt securities, which we refer to as debt security warrants, or depositary shares, which we refer to as depositary share warrants. Any of these warrants may be issued independently or together with any other securities
offered by this prospectus and may be attached to or separate from those securities. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">While the terms we have summarized below
will generally apply to any future warrants we may offer under this prospectus, we will describe the particular terms of any warrants that we may offer in more detail in the applicable prospectus supplement. The terms of any warrants we offer under
a prospectus supplement may differ from the terms we describe below. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We may issue the warrants under a warrant agreement,
which we will enter into with a warrant agent to be selected by us. Each warrant agent will act solely as our agent under the applicable warrant agreement and will not assume any obligation or relationship of agency or trust with any holder of any
warrant. A single bank or trust company may act as warrant agent for more than one issue of warrants. A warrant agent will have no duty or responsibility in case of any default by us under the applicable warrant agreement or warrant, including any
duty or responsibility to initiate any proceedings at law or otherwise, or to make any demand upon us. Any holder of a warrant may, without the consent of the related warrant agent or the holder of any other warrant, enforce by appropriate legal
action its right to exercise, and receive the securities purchasable upon exercise of, its warrants. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We will incorporate by
reference into the registration statement of which this prospectus forms a part the form of warrant agreement, including a form of warrant certificate, that describes the terms of the series of warrants we are offering before the issuance of the
related series of warrants. The following summaries of material provisions of the warrants and the warrant agreements are subject to, and qualified in their entirety by reference to, all the provisions of the warrant agreement applicable to a
particular series of warrants. We urge you to read the applicable prospectus supplements related to the warrants that we sell under this prospectus, as well as the complete warrant agreements that contain the terms of the warrants. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We will set forth in the applicable prospectus supplement the terms of the warrants in respect of which this prospectus is being
delivered, including, when applicable, the following: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the title of the warrants; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the aggregate number of the warrants; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the price or prices at which the warrants will be issued; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the designation, number, and terms of the securities purchasable upon exercise of the warrants; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the designation and terms of the other securities, if any, with which the warrants are issued and the number of warrants issued with each such
security; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the date, if any, on and after which the warrants and the related underlying securities will be separately transferable; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the price at which each underlying security purchasable upon exercise of the warrants may be purchased; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the date on which the right to exercise the warrants will commence and the date on which such right will expire; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the minimum amount of the warrants that may be exercised at any one time; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">any information with respect to book-entry procedures; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">28 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the effect of any merger, consolidation, sale, or other disposition of our business on the warrant agreement and the warrants;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">any other terms of the warrants, including terms, procedures, and limitations relating to the transferability, exchange, and exercise of such warrants;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the terms of any rights to redeem or call, or accelerate the expiration of, the warrants; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the date on which the right to exercise the warrants begins and the date on which that right expires; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the U.S. federal income tax consequences of holding or exercising the warrants; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">any other specific terms, preferences, rights, or limitations of, or restrictions on, the warrants. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Unless specified in an applicable prospectus supplement, common stock warrants, preferred stock warrants, debt security warrants, or
depositary shares warrants will be in registered form only. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">A holder of warrant certificates may exchange them for new
certificates of different denominations, present them for registration of transfer, and exercise them at the corporate trust office of the warrant agent or any other office indicated in the applicable prospectus supplement. Until any common stock
warrants, preferred stock warrants, debt security warrants, or depositary shares warrants are exercised, holders of the warrants will not have any rights of holders of the underlying common stock, preferred stock, debt securities, or depositary
shares, including any rights to receive dividends or to exercise any voting rights, except to the extent set forth under the heading &#147;Warrant Adjustments&#148; below. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Exercise of Warrants </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Each warrant will entitle the holder to purchase for
cash shares of common stock, preferred stock, debt securities, or depositary shares at the applicable exercise price set forth in, or determined as described in, the applicable prospectus supplement. Warrants may be exercised at any time up to the
close of business on the expiration date set forth in the applicable prospectus supplement. After the close of business on the expiration date, unexercised warrants will become void. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Warrants may be exercised by delivering to the corporation trust office of the warrant agent or any other officer indicated in the
applicable prospectus supplement (a)&nbsp;the warrant certificate properly completed and duly executed and (b)&nbsp;payment of the amount due upon exercise. As soon as practicable following exercise, we will forward the shares of common stock,
preferred stock, debt securities, or depositary shares. If less than all of the warrants represented by a warrant certificate are exercised, a new warrant certificate will be issued for the remaining warrants. If we so indicate in the applicable
prospectus supplement, holders of the warrants may surrender securities as all or a part of the exercise price for the warrants. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Amendments and Supplements to the Warrant Agreements </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We may amend or supplement a warrant agreement without the consent of the holders of the applicable warrants to cure ambiguities in the warrant agreement, to cure or correct a defective provision in the
warrant agreement, or to provide for other matters under the warrant agreement that we and the warrant agent deem necessary or desirable, so long as, in each case, such amendments or supplements do not materially and adversely affect the interests
of the holders of the warrants. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Warrant Adjustments </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Unless the applicable prospectus supplement states otherwise, the exercise price of, and the number of securities covered by, a common stock warrant, preferred stock warrant, debt security warrant, or
depositary </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">29 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
share warrant will be adjusted proportionately if we subdivide or combine our common stock, preferred stock, debt securities, or depositary shares, as applicable. In addition, unless the
prospectus supplement states otherwise, if we, without payment: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">issue capital stock or other securities convertible into or exchangeable for common stock or preferred stock, or any rights to subscribe for, purchase,
or otherwise acquire any of the foregoing, as a dividend or distribution to holders of our common stock or preferred stock; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">pay any cash to holders of our common stock or preferred stock other than a cash dividend paid out of our current or retained earnings or other than in
accordance with the terms of the preferred stock; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">issue any evidence of our indebtedness or rights to subscribe for or purchase our indebtedness to holders of our common stock or preferred stock; or
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">issue common stock or preferred stock or additional stock or other securities or property to holders of our common stock or preferred stock by way of
spinoff, split-up, reclassification, combination of shares, or similar corporate rearrangement, </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">then the holders of common
stock warrants, preferred stock warrants, debt security warrants, and depositary share warrants, as applicable, will be entitled to receive upon exercise of the warrants, in addition to the securities otherwise receivable upon exercise of the
warrants and without paying any additional consideration, the amount of stock and other securities and property such holders would have been entitled to receive had they held the common stock, preferred stock, debt securities, or depositary shares,
as applicable, issuable under the warrants on the dates on which holders of those securities received or became entitled to receive such additional stock and other securities and property. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Except as stated above, the exercise price and number of securities covered by a common stock warrant, preferred stock warrant, debt
security warrant, and depositary share warrant, and the amounts of other securities or property to be received, if any, upon exercise of those warrants, will not be adjusted or provided for if we issue those securities or any securities convertible
into or exchangeable for those securities, or securities carrying the right to purchase those securities or securities convertible into or exchangeable for those securities. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Holders of common stock warrants, preferred stock warrants, debt security warrants, and depositary share warrants may have additional rights under the following circumstances: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">certain reclassifications, capital reorganizations, or changes of the common stock, preferred stock, or depositary shares, as applicable;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">certain share exchanges, mergers, or similar transactions involving us and which result in changes of the common stock, preferred stock, or depositary
shares, as applicable; or </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">certain sales or dispositions to another entity of all or substantially all of our property and assets. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If one of the above transactions occurs and holders of our common stock, preferred stock, debt securities, or depositary shares are
entitled to receive stock, securities, or other property with respect to or in exchange for their securities, the holders of the common stock warrants, preferred stock warrants, debt security warrants, and depositary share warrants then outstanding,
as applicable, will be entitled to receive upon exercise of their warrants the kind and amount of shares of stock and other securities or property that they would have received upon the applicable transaction if they had exercised their warrants
immediately before the transaction. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">30 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="rom579833_12"></A><A NAME="supprom579833_24"></A>DESCRIPTION OF PURCHASE
CONTRACTS </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We may issue purchase contracts, including contracts obligating holders to purchase from us, and for us to sell
to holders, a specific or varying number of debt securities, shares of common stock or preferred stock, depositary shares, warrants, or any combination of the above, at a future date or dates. Alternatively, the purchase contracts may obligate us to
purchase from holders, and obligate holders to sell to us, a specific or varying number of debt securities, shares of common stock or preferred stock, depositary shares, warrants, or any combination of the above. The price of the securities subject
to the purchase contracts may be fixed at the time the purchase contracts are issued or may be determined by reference to a specific formula described in the purchase contracts. We may issue purchase contracts separately or as a part of units each
consisting of a purchase contract and one or more of the other securities described in this prospectus or securities of third parties, including U.S.&nbsp;Treasury securities, securing the holder&#146;s obligations under the purchase contract. If we
issue a purchase contract as part of a unit, the applicable prospectus supplement will state whether the purchase contract will be separable from the other securities in the unit before the purchase contract settlement date. The purchase contracts
may require us to make periodic payments to holders or vice versa and the payments may be unsecured or pre-funded on some basis. The purchase contracts may require holders to secure the holder&#146;s obligations in a manner specified in the
applicable prospectus supplement, and in certain circumstances, we may deliver newly issued prepaid purchase contracts, often known as prepaid securities, upon release to a holder of any collateral securing such holder&#146;s obligations under the
original purchase contract. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We will incorporate by reference into the registration statement of which this prospectus forms a
part the form of purchase contract we are offering before the issuance of the purchase contract. The following summaries of material provisions of the purchase contract are subject to, and qualified in their entirety by reference to, all the
provisions of the purchase contract. We urge you to read the applicable prospectus supplements related to the purchase contracts that we sell under this prospectus, as well as the complete purchase contract. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The applicable prospectus supplement will describe the terms of any purchase contracts in respect of which this prospectus is being
delivered, including, to the extent applicable, the following: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">whether the purchase contracts obligate the holder or us to purchase or sell, or both purchase and sell, the securities subject to purchase under the
purchase contract, and the nature and amount of each of those securities, or the method of determining those amounts; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">whether the purchase contracts are to be prepaid or not; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">whether the purchase contracts will be issued as part of a unit and, if so, the other securities comprising the unit; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">whether the purchase contracts are to be settled by delivery, or by reference or linkage to the value, performance, or level of the securities subject
to purchase under the purchase contract; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">any acceleration, cancellation, termination, or other provisions relating to the settlement of the purchase contracts; and
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">whether the purchase contracts will be issued in fully registered or global form. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Material U.S. federal income tax consideration applicable to the purchase contracts and the purchase units will also be discussed in the
applicable prospectus supplement. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">31 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="rom579833_13"></A><A NAME="supprom579833_25"></A>DESCRIPTION OF UNITS
</B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following description, together with the additional information we include in any applicable prospectus supplement,
summarizes the material terms and provisions of the units that we may offer under this prospectus. Units may be offered independently or together with common stock, preferred stock, debt securities, depositary shares, and warrants offered by any
prospectus supplement, and may be attached to or separate from those securities. While the terms we have summarized below will generally apply to any future units that we may offer under this prospectus, we will describe the particular terms of any
series of units that we may offer in more detail in the applicable prospectus supplement. The terms of any units offered under a prospectus supplement may differ from the terms described below. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We will incorporate by reference into the registration statement of which this prospectus forms a part the form of unit agreement,
including a form of unit certificate, if any, that describes the terms of the series of units we are offering before the issuance of the related series of units. The following summaries of material provisions of the units and the unit agreements are
subject to, and qualified in their entirety by reference to, all the provisions of the unit agreement applicable to a particular series of units. We urge you to read the applicable prospectus supplements related to the units that we sell under this
prospectus, as well as the complete unit agreements that contain the terms of the units. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>General </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We may issue units consisting of common stock, preferred stock, debt securities, depositary shares, and warrants in any combination. Each
unit will be issued so that the holder of the unit is also the holder of each security included in the unit. Thus, the holder of a unit will have the rights and obligations of a holder of each included security. The unit agreement under which a unit
is issued may provide that the securities included in the unit may not be held or transferred separately, at any time, or at any time before a specified date. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We will describe in the applicable prospectus supplement the terms of the series of units, including the following: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the designation and terms of the units and of the securities comprising the units, including whether and under what circumstances those securities may
be held or transferred separately; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">any provisions of the governing unit agreement that differ from those described below; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">any provisions for the issuance, payment, settlement, transfer, or exchange of the units or of the securities comprising the units.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The provisions described in this section, as well as those described under &#147;Description of Common
Stock,&#148; &#147;Description of Preferred Stock,&#148; &#147;Description of Debt Securities,&#148; &#147;Description of Depositary Shares,&#148; and &#147;Description of Warrants,&#148; will apply to each unit and to any common stock, preferred
stock, debt security, depositary share, or warrant included in each unit, respectively. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Issuance in Series </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We may issue units in such amounts and in such numerous distinct series as we determine. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Enforceability of Rights by Holders of Units </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Each unit agent will act solely as our agent under the applicable unit agreement and will not assume any obligation or relationship of agency or trust with any holder of any unit. A single bank or trust
company may act as unit agent for more than one series of units. A unit agent will have no duty or responsibility in case of any default by us under the applicable unit agreement or unit, including any duty or responsibility to initiate any
proceedings at law or otherwise, or to make any demand upon us. Any holder of a unit, without the consent of the related unit agent or the holder of any other unit, may enforce by appropriate legal action its rights as holder under any security
included in the unit. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">32 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Title </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We, the unit agent, and any of their agents may treat the registered holder of any unit certificate as an absolute owner of the units evidenced by that certificate for any purposes and as the person
entitled to exercise the rights attaching to the units so requested, despite any notice to the contrary. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">33 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="rom579833_14"></A><A NAME="supprom579833_26"></A>CERTAIN PROVISIONS OF
NEVADA LAW AND </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>OUR CHARTER AND BYLAWS </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The following paragraphs summarize certain provisions of Nevada law and our amended and restated articles of incorporation, as amended, and bylaws. The summary does not purport to be complete and is
subject to and qualified in its entirety by reference to Nevada law and to our amended and restated articles of incorporation, as amended, and bylaws, copies of which are on file with the SEC as exhibits to reports previously filed by us. See
&#147;Where You Can Find More Information.&#148; </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>General </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Certain provisions of our amended and restated articles of incorporation, as amended, and bylaws and Nevada law could make our acquisition by a third party, a change in our incumbent management, or a
similar change in control more difficult, including: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">an acquisition of us by means of a tender or exchange offer; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">an acquisition of us by means of a proxy contest or otherwise; or </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the removal of a majority or all of our incumbent officers and directors. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">These provisions, which are summarized below, are likely to discourage certain types of coercive takeover practices and inadequate takeover bids. These provisions are also designed to encourage persons
seeking to acquire control of us to first negotiate with our board of directors. We believe that these provisions help to protect our potential ability to negotiate with the proponent of an unfriendly or unsolicited proposal to acquire or
restructure us, and that this benefit outweighs the potential disadvantages of discouraging such a proposal because our ability to negotiate with the proponent could result in an improvement of the terms of the proposal. The existence of these
provisions which are described below could limit the price that investors might otherwise pay in the future for our securities. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Articles
of Incorporation and Bylaws </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Authorized But Unissued Capital Stock. </I>We have shares of common stock and preferred
stock available for future issuance without stockholder approval, subject to any limitations imposed by the listing standards of any securities exchange on which our stock may be listed. We may utilize these additional shares for a variety of
corporate purposes, including for future public offerings to raise additional capital or facilitate corporate acquisitions or for payment as a dividend on our capital stock. The existence of unissued and unreserved common stock and preferred stock
may enable our board of directors to issue shares to persons friendly to current management or to issue preferred stock with terms that could have the effect of making it more difficult for a third party to acquire, or could discourage a third party
from seeking to acquire, a controlling interest in our company by means of a merger, tender offer, proxy contest, or otherwise. In addition, if we issue preferred stock, the issuance could adversely affect the voting power of holders of common stock
and the likelihood that such holders will receive dividend payments and payments upon liquidation. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Blank Check Preferred
Stock</I>. Our board of directors, without stockholder approval, has the authority under our amended and restated articles of incorporation, as amended, to issue preferred stock with rights superior to the rights of the holders of common stock. As a
result, preferred stock could be issued quickly and easily, could impair the rights of holders of common stock, and could be issued with terms calculated to delay or prevent a change in control or make removal of management more difficult.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Election of Directors</I>. Our bylaws provide that a majority of directors then in office may fill any vacancy occurring
on our board of directors, even though less than a quorum may then be in office. These provisions may discourage a third party from voting to remove incumbent directors and simultaneously gaining control of our board of directors by filling the
vacancies created by that removal with its own nominees. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">34 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Removal of Directors</I>. Except in certain cases for directors elected by the
holders of any series of preferred stock, a director may be removed from office only with cause and only by the affirmative vote of two-thirds or more of the combined voting power of the then issued and outstanding shares of our capital stock
entitled to vote in the election of directors, voting together as a single class. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Stockholder Meetings</I>. Our bylaws do
not permit stockholders to call a special meeting of stockholders. Rather, only our board of directors or such person or persons authorized by our board of directors will be able to call special meetings of stockholders. This provision may
discourage another person or entity from making a tender offer, even if it acquired a majority of our outstanding voting stock, because the person or entity could only take action at a duly called stockholders&#146; meeting. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Anti-takeover Effects of Nevada Law </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Business Combinations with Interested Stockholders </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The &#147;business combination with interested stockholders&#148; provisions of Sections 78.411 to 78.444, inclusive, of the Nevada Revised Statutes, or NRS, generally prohibit a Nevada corporation with
at least 200 stockholders of record from engaging in various &#147;combination&#148; transactions with any interested stockholder for a period of two years after the date of the transaction in which the person became an interested stockholder,
unless the combination is approved by our board of directors prior to the date the interested stockholder obtained such status or the combination is approved by our board of directors and at such time or thereafter is approved at a meeting of the
stockholders by the affirmative vote of stockholders representing at least 60% of the outstanding voting power held by disinterested stockholders, and extends beyond the expiration of the two-year period, unless: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the combination was approved by our board of directors prior to the person becoming an interested stockholder or the transaction by which the person
first became an interested stockholder was approved by our board of directors before the person became an interested stockholder or the combination is later approved by a majority of the voting power held by disinterested stockholders; or
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">if the consideration to be paid by the interested stockholder is at least equal to the highest of: (a)&nbsp;the highest price per share paid by the
interested stockholder within the two years immediately preceding the date of the announcement of the combination or in the transaction in which it became an interested stockholder, whichever is higher; (b)&nbsp;the market value per share of common
stock on the date of announcement of the combination and the date the interested stockholder acquired the shares, whichever is higher; or (c)&nbsp;for holders of preferred stock, the highest liquidation value of the preferred stock, if it is higher.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Notwithstanding the foregoing, NRS 78.411 to 78.444, inclusive, do not apply to any combination of a
resident domestic corporation with an interested stockholder after the expiration of four years after the person first became an interested stockholder. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">A &#147;combination&#148; is generally defined to include mergers or consolidations or any sale, lease exchange, mortgage, pledge, transfer, or other disposition, in one transaction or a series of
transactions, with an &#147;interested stockholder&#148; having: (a)&nbsp;an aggregate market value equal to more than 5% of the aggregate market value of the assets of the corporation, (b)&nbsp;an aggregate market value equal to more than 5% of the
aggregate market value of all outstanding voting shares of the corporation, (c)&nbsp;more than 10% of the earning power or net income of the corporation, and (d)&nbsp;certain other transactions with an interested stockholder or an affiliate or
associate of an interested stockholder. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In general, an &#147;interested stockholder&#148; is a person who, together with
affiliates and associates, owns (or within two years, did own) 10% or more of a corporation&#146;s voting stock. The statute could prohibit or delay mergers or other takeover or change in control attempts and, accordingly, may discourage attempts to
acquire our company even though such a transaction may offer our stockholders the opportunity to sell their stock at a price above the prevailing market price. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">35 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Control Share Acquisitions </I></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The &#147;control share&#148; provisions of Sections 78.378 to 78.3793, inclusive, of the NRS apply to &#147;issuing corporations&#148;
that are Nevada corporations with at least 200 stockholders of record, including at least 100 stockholders of record who are Nevada residents, and that conduct business directly or indirectly in Nevada. The control share statute prohibits an
acquirer, under certain circumstances, from voting its shares of a target corporation&#146;s stock after crossing certain ownership threshold percentages, unless the acquirer obtains approval of the target corporation&#146;s disinterested
stockholders. The statute specifies three thresholds: one-fifth or more but less than one-third, one-third but less than a majority, and a majority or more, of the outstanding voting power. Generally, once an acquirer crosses one of the above
thresholds, those shares in an offer or acquisition and acquired within 90 days thereof become &#147;control shares&#148; and such control shares are deprived of the right to vote until disinterested stockholders restore the right. These provisions
also provide that if control shares are accorded full voting rights and the acquiring person has acquired a majority or more of all voting power, all other stockholders who do not vote in favor of authorizing voting rights to the control shares are
entitled to demand payment for the fair value of their shares in accordance with statutory procedures established for dissenters&#146; rights. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">A corporation may elect to not be governed by, or &#147;opt out&#148; of, the control share provisions by making an election in its articles of incorporation or bylaws, provided that the opt-out election
must be in place on the 10th&nbsp;day following the date an acquiring person has acquired a controlling interest, that is, crossing any of the three thresholds described above. We have not opted out of the control share statutes, and will be subject
to these statutes if we are an &#147;issuing corporation&#148; as defined in such statutes. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The effect of the Nevada control
share statutes is that the acquiring person, and those acting in association with the acquiring person, will obtain only such voting rights in the control shares as are conferred by a resolution of the stockholders at an annual or special meeting.
The Nevada control share law, if applicable, could have the effect of discouraging takeovers of our company. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Limitations of Liability and
Indemnification of Officers and Directors </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our amended and restated articles of incorporation, as amended, limit the
liability of directors to the fullest extent permitted by Nevada law and provides that no director or officer of ours will be personally liable to us or any of our stockholders for damages for breach of fiduciary duty as a director or officer
involving any act or omission of any act by such director or officer, other than (i)&nbsp;for acts or omissions which involve intentional misconduct, fraud, or a known violation of the law, or (ii)&nbsp;the payment of dividends in violation of
Section&nbsp;78.300 of the NRS. In addition, our amended and restated articles of incorporation, as amended, provide that we will indemnify our directors and officers to the fullest extent permitted by law. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Indemnification for Securities Act Liabilities </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Insofar as indemnification for liabilities arising under the Securities Act of 1933, as amended, or the Securities Act, may be permitted for directors, officers, or controlling persons pursuant to the
provisions described in the preceding paragraph, we have been informed that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">36 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="rom579833_15"></A><A NAME="supprom579833_27"></A>LEGAL OWNERSHIP OF
SECURITIES </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We can issue securities in registered form or in the form of one or more global securities. We refer to those
persons who have securities registered in their own names on the books that we or any applicable trustee, depositary or warrant agent maintain for this purpose as the &#147;holders&#148; of those securities. These persons are the legal holders of
the securities. We refer to those persons who, indirectly through others, own beneficial interests in securities that are not registered in their own names, as &#147;indirect holders&#148; of those securities. As we discuss below, indirect holders
are not legal holders, and investors in securities issued in book-entry form or in street name will be indirect holders. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">See
also the section entitled &#147;Description of Debt Securities &#151; Form, Transfer, and Exchange&#148; above for additional discussion of book entry and certificated form of ownership as such forms of ownership impact the rights and obligations of
purchasers of debt securities to be issued under this prospectus. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Book-Entry Holders </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We may issue securities in book-entry form only, as we will specify in the applicable prospectus supplement. This means securities may be
represented by one or more global securities registered in the name of a financial institution that holds them as depositary on behalf of other financial institutions that participate in the depositary&#146;s book-entry system. These participating
institutions, which are referred to as participants, in turn, hold beneficial interests in the securities on behalf of themselves or their customers. Upon the issuance of a global security, the depositary will credit, on its book-entry registration
and transfer system, the participants&#146; accounts with the respective principal amounts of the book-entry securities represented by the global security beneficially owned by such participants. The accounts to be credited will be designated by any
dealers, underwriters, or agents participating in the distribution of the book-entry securities. Ownership of book-entry securities will be shown on, and the transfer of the ownership interests will be effected only through, records maintained by
the depositary for the related global security (with respect to interests of participants) and on the records of participants (with respect to interests of persons holding through participants). The laws of some states may require that certain
purchasers of securities take physical delivery of such securities in definitive form. These laws may impair the ability to own, transfer, or pledge beneficial interests in book-entry securities. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Only the person in whose name a security is registered is recognized as the holder of that security. Securities issued in global form
will be registered in the name of the depositary or its participants. Consequently, for securities issued in global form, we will recognize only the depositary as the holder of the securities, and we will make all payments on the securities to the
depositary. The depositary passes along the payments it receives to its participants, which in turn pass the payments along to their customers who are the beneficial owners. The depositary and its participants do so under agreements they have made
with one another or with their customers; they are not obligated to do so under the terms of the securities. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As a result,
investors in a book-entry security will not own securities directly. Instead, they will own beneficial interests in a global security, through a bank, broker, or other financial institution that participates in the depositary&#146;s book-entry
system or holds an interest through a participant. As long as the securities are issued in global form, investors will be indirect holders, and not holders, of the securities. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Street Name Holders </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We may terminate a global security or issue securities
in non-global form. In these cases, investors may choose to hold their securities in their own names or in &#147;street name.&#148; Securities held by an investor in street name would be registered in the name of a bank, broker, or other financial
institution that the investor chooses, and the investor would hold only a beneficial interest in those securities through an account he, she, or it maintains at that institution. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">37 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">For securities held in street name, we will recognize only the intermediary banks,
brokers, and other financial institutions in whose names the securities are registered as the holders of those securities, and we will make all payments on those securities to them. These institutions pass along the payments they receive to their
customers who are the beneficial owners, but only because they agree to do so in their customer agreements or because they are legally required to do so. Investors who hold securities in street name will be indirect holders, not holders, of those
securities. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Legal Holders </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Our obligations, as well as the obligations of any applicable trustee and of any third parties employed by us or a trustee, run only to the legal holders of the securities. We do not have obligations to
investors who hold beneficial interests in global securities, in street name, or by any other indirect means. This will be the case whether an investor chooses to be an indirect holder of a security or has no choice because we are issuing the
securities only in global form. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">For example, once we make a payment or give a notice to the holder, we have no further
responsibility for the payment or notice even if that holder is required, under agreements with depositary participants or customers or by law, to pass it along to the indirect holders but does not do so. Whether and how the holders contact the
indirect holders is up to the holders. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Special Considerations For Indirect Holders </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If you hold securities through a bank, broker, or other financial institution, either in book-entry form or in street name, you should
check with your own institution to determine the following: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">how it handles securities payments and notices; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">whether it imposes fees or charges; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">how it would handle a request for the holders&#146; consent, if ever required; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">whether and how you can instruct it to send you securities registered in your own name so you can be a holder, if that is permitted in the future;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">how it would exercise rights under the securities if there were a default or other event triggering the need for holders to act to protect their
interests; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">if the securities are in book-entry form, how the depositary&#146;s rules and procedures will affect these matters. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Global Securities </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">A
global security is a security that represents one or any other number of individual securities held by a depositary. Generally, all securities represented by the same global securities will have the same terms. Each security issued in book-entry
form will be represented by a global security that we deposit with and register in the name of a financial institution or its nominee that we select. The financial institution that we select for this purpose is called the depositary. Unless we
specify otherwise in the applicable prospectus supplement, The Depository Trust Company, New York, New York, known as DTC, will be the depositary for all securities issued in book-entry form. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">A global security may not be transferred to or registered in the name of anyone other than the depositary, its nominee, or a successor
depositary, unless special termination situations arise. We describe those situations below under &#147;Special Situations When a Global Security Will Be Terminated.&#148; As a result of these arrangements, the depositary, or its nominee, will be
the sole registered owner and holder of all securities represented by a global security, and investors will be permitted to own only beneficial interests in a global security. Beneficial interests must be held by means of an account with a broker,
bank, or other financial institution that in turn has an account with the depositary or with another institution that does. Thus, an investor whose security is represented by a global security will not be a holder of the security, but only an
indirect holder of a beneficial interest in the global security. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">38 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If the prospectus supplement for a particular security indicates that the security will
be issued in global form only, then the security will be represented by a global security at all times unless and until the global security is terminated. If termination occurs, we may issue the securities through another book-entry clearing system
or decide that the securities may no longer be held through any book-entry clearing system. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We may at any time and in our
sole discretion determine not to have any of the book-entry securities of any series represented by one or more global securities and, in that event, we will issue certificated securities in exchange for the global securities of that series.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B><B>Special Considerations For Global Securities </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The rights of an indirect holder relating to a global security will be governed by the account rules of the investor&#146;s financial institution and of the depositary, as well as general laws relating to
securities transfers. We do not recognize an indirect holder as a holder of securities and instead deal only with the depositary that holds the global security. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">If securities are issued only in the form of a global security, an investor should be aware of the following: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">an investor cannot cause the securities to be registered in his, her, or its name, and cannot obtain <FONT STYLE="white-space:nowrap">non-global</FONT>
certificates for his, her, or its interest in the securities, except in the special situations we describe below; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">an investor will be an indirect holder and must look to his, her, or its own bank or broker for payments on the securities and protection of his, her,
or its legal rights relating to the securities, as we describe above; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">an investor may not be able to sell interests in the securities to some insurance companies and to other institutions that are required by law to own
their securities in non-book-entry form; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">an investor may not be able to pledge his, her, or its interest in a global security in circumstances where certificates representing the securities
must be delivered to the lender or other beneficiary of the pledge in order for the pledge to be effective; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the depositary&#146;s policies, which may change from time to time, will govern payments, transfers, exchanges, and other matters relating to an
investor&#146;s interest in a global security; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">we and any applicable trustee have no responsibility for any aspect of the depositary&#146;s actions or for its records of ownership interests in a
global security, nor do we or any applicable trustee supervise the depositary in any way; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the depositary may, and we understand that DTC will, require that those who purchase and sell interests in a global security within its book-entry
system use immediately available funds, and your broker or bank may require you to do so as well; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">financial institutions that participate in the depositary&#146;s book-entry system, and through which an investor holds its interest in a global
security, may also have their own policies affecting payments, notices, and other matters relating to the securities. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">There
may be more than one financial intermediary in the chain of ownership for an investor. We do not monitor and are not responsible for the actions of any of those intermediaries. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Special Situations When a Global Security Will Be Terminated </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In a few
special situations described below, the global security will terminate and interests in it will be exchanged for physical certificates representing those interests. After that exchange, the choice of whether to hold securities directly or in street
name will be up to the investor. Investors must consult their own banks or brokers to find out how to have their interests in securities transferred to their own name, so that they will be direct holders. We have described the rights of holders and
street name investors above. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">39 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Unless we provide otherwise in the applicable prospectus supplement, the global
security will terminate when the following special situations occur: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">if the depositary notifies us that it is unwilling, unable, or no longer qualified under the Securities Exchange Act of 1934, as amended, or the
Exchange Act, to continue as depositary for that global security and we do not appoint another institution to act as depositary within 90 days; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">if we notify any applicable trustee that we wish to terminate that global security; or </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">if an event of default has occurred with regard to securities represented by that global security and has not been cured or waived.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The prospectus supplement may also list additional situations for terminating a global security that would apply only to
the particular types and series of securities covered by the applicable prospectus supplement. When a global security terminates, the depositary, and not we or any applicable trustee, is responsible for deciding the names of the institutions that
will be the initial direct holders. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">40 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="rom579833_16"></A><A NAME="supprom579833_28"></A>PLAN OF DISTRIBUTION
</B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We may sell the securities described in this prospectus from time to time in one or more of the following ways:
</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">to or through underwriters or dealers; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">directly to one or more purchasers; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">through agents; or </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">through a combination of any of those methods of sale. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The prospectus supplement with respect to the offered securities will describe the terms of the offering, including the following: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the name or names of any underwriters or agents; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">any public offering price; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the proceeds from such sale; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">any underwriting discounts or agency fees and other items constituting underwriters&#146; or agents&#146; compensation; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">any over-allotment options under which underwriters may purchase additional securities from us; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">any discounts or concessions allowed or reallowed or paid to dealers; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">any securities exchanges on which the securities may be listed. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We may distribute the securities from time to time in one or more of the following ways: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">at a fixed public offering price or prices, which may be changed; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">at prices relating to prevailing market prices at the time of sale; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">at varying prices determined at the time of sale; or </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">at negotiated prices. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Unless otherwise indicated in the applicable prospectus supplement, if we use underwriters for a sale of securities, the underwriters will acquire the securities for their own account. The underwriters
may resell the securities in one or more transactions, including negotiated transactions, at a fixed public offering price, or at varying prices determined at the time of sale. The obligations of the underwriters to purchase the securities will be
subject to the conditions set forth in the applicable underwriting agreement. Unless otherwise indicated in a prospectus supplement, the underwriters will be obligated to purchase all the securities of the series offered if they purchase any of the
securities of that series. We may change from time to time any initial public offering price and any discounts or concessions the underwriters allow or reallow or pay to dealers. We may use underwriters with whom we have a material relationship. We
will describe in the prospectus supplement naming the underwriter the nature of any such relationship. We may designate agents who agree to use their reasonable efforts to solicit purchases for the period of their appointment or to sell securities
on a continuing basis. We may also sell securities directly to one or more purchasers without using underwriters or agents. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Underwriters, dealers, or agents may receive compensation in the form of discounts, concessions, or commissions from us or from
purchasers of the securities as their agents in connection with the sale of the securities. These underwriters, dealers, or agents may be considered to be underwriters under the Securities Act. As a result, discounts, commissions, or profits on
resale received by underwriters, dealers, or agents may be treated as underwriting discounts and commissions. Each prospectus supplement will identify any underwriter, dealer, or agent and describe any compensation received by them from us. Any
initial public offering price and any discounts or concessions allowed or reallowed or paid to dealers may be changed from time to time. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">41 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Unless otherwise specified in the applicable prospectus supplement, each class or
series of securities will be a new issue with no established trading market, other than our common stock, which is listed on the NYSE MKT. We may elect to apply for listing of our common stock on another securities exchange or to list any other
class or series of securities on any exchange, but we are not obligated to do so. It is possible that one or more underwriters may make a market in a class or series of securities, but the underwriters will not be obligated to do so and may
discontinue any market making at any time without notice. We cannot give any assurance as to the liquidity of the trading market for any of the securities. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In connection with any offering, the underwriters may engage in stabilizing transactions, over-allotment transactions, syndicate covering transactions, and penalty bids in accordance with Regulation M
under the Exchange Act. </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stabilizing transactions permit bids to purchase the underlying security so long as the stabilizing bids do not exceed a specified maximum.
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Over-allotment involves sales by the underwriters of shares of our common stock in excess of the number of shares the underwriters are obligated to
purchase, which creates a syndicate short position. The short position may be either a covered short position or a naked short position. In a covered short position, the number of shares of our common stock over-allotted by the underwriters is not
greater than the number of shares that they may purchase in the over-allotment option. In a naked short position, the number of shares of our common stock involved is greater than the number of shares in the over-allotment option. The underwriters
may close out any covered short position by either exercising their over-allotment option or purchasing shares of our common stock in the open market. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Syndicate covering transactions involve purchases of our common stock in the open market after the distribution has been completed in order to cover
syndicate short positions. In determining the source of shares to close out the short position, the underwriters will consider, among other things, the price of shares of our common stock available for purchase in the open market as compared to the
price at which they may purchase shares through the over-allotment option so that if there is a naked short position, the position can only be closed out by buying shares in the open market. A naked short position is more likely to be created if the
underwriters are concerned that there could be downward pressure on the price of the shares of our common stock in the open market after the pricing of any offering that could adversely affect investors who purchase in that offering.
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Penalty bids permit the representatives of the underwriters to reclaim a selling concession from a syndicate member when the common stock originally
sold by the syndicate member is purchased in a stabilizing or syndicate covering transaction to cover syndicate short positions. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">These stabilizing transactions, over-allotments, syndicate covering transactions, and penalty bids may have the effect of raising or maintaining the market price of our common stock or preventing or
retarding a decline in the market price of our common stock. As a result, the price of our common stock may be higher than the price that might otherwise exist in the open market. These transactions may be effected on the NYSE MKT or otherwise and,
if commenced, may be discontinued at any time. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We may engage in at the market offerings into an existing trading market in
accordance with Rule 415(a)(4) under the Securities Act. In addition, we may enter into derivative transactions with third parties, or sell securities not covered by this prospectus to third parties in privately negotiated transactions. If the
applicable prospectus supplement so indicates, in connection with those derivatives, the third parties may sell securities covered by this prospectus and the applicable prospectus supplement, including in short sale transactions. If so, the third
party may use securities pledged by us or borrowed from us or others to settle those sales or to close out any related open borrowings of stock, and may use securities received from us in settlement of those derivatives to close out any related open
borrowings of stock. The third party in such sale transactions will be an underwriter and, if not identified in this prospectus, will be named in the applicable prospectus supplement. In addition, we may otherwise loan or pledge securities to a
financial institution or other third party that in turn may sell the securities short using this prospectus and an applicable prospectus supplement. Such financial institution or other third party may transfer its economic short position to
investors in our securities or in connection with a concurrent offering of other securities. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">42 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The specific terms of any lock-up provisions in respect of any given offering will be
described in the applicable prospectus supplement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Underwriters, dealers, and agents may be entitled under agreements entered
into with us to indemnification against certain civil liabilities, including liabilities under the Securities Act, or to contribution with respect to payments they may be required to make in respect of these liabilities thereof. Underwriters,
dealers, and agents and their affiliates may be customers of, may engage in transactions with, or perform services for us in the ordinary course of business for which they receive compensation. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">43 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="rom579833_17"></A><A NAME="supprom579833_29"></A>LEGAL MATTERS
</B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The validity of the securities offered hereby will be passed upon by Greenberg Traurig, LLP, Las Vegas, Nevada.
</FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="rom579833_18"></A><A NAME="supprom579833_30"></A>EXPERTS </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The consolidated financial statements of TherapeuticsMD, Inc. as of December 31, 2014, 2013 and 2012 appearing in our Annual Report on
Form 10-K for the fiscal year ended December 31, 2014 incorporated into this prospectus by reference, and the effectiveness of our internal control over financial reporting as of December 31, 2014, have been audited by Rosenberg Rich Baker Berman
&amp; Company, independent registered public accounting firm, as set forth in their report thereon, included therein, and incorporated herein by reference. Such consolidated financial statements are incorporated herein by reference in reliance upon
such report given on the authority of such firm as experts in accounting and auditing. </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="rom579833_19"></A><A NAME="supprom579833_31">
</A>WHERE YOU CAN FIND MORE INFORMATION </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We file annual, quarterly and current reports, proxy statements and other
information with the SEC. Through our website at <I>www.therapeuticsmd.com</I>, you may access, free of charge, our filings, as soon as reasonably practical after we electronically file them with or furnish them to the SEC. The information contained
in our website is not incorporated by reference in, and should not be considered a part of, this prospectus or any accompanying prospectus supplement. You also may read and copy any document we file with the SEC at the SEC&#146;s public reference
room at 100 F Street, N.E., Washington, D.C. 20549. Please call the SEC at 1-800-SEC-0330 for further information on the public reference room. Our SEC filings are also available to the public from the SEC&#146;s website at <I>www.sec.gov</I>.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This prospectus is part of a registration statement on Form S-3 that we filed with the SEC to register the securities to be
offered hereby. This prospectus does not contain all of the information included in the registration statement, including certain exhibits and schedules. You may obtain the registration statement and exhibits to the registration statement from the
SEC at the address listed above or from the SEC&#146;s website listed above. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">44 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="rom579833_20"></A><A NAME="supprom579833_32"></A>INCORPORATION OF CERTAIN
INFORMATION BY REFERENCE </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The SEC allows us to incorporate by reference the information we file with the SEC, which means
that we can disclose important information to you by referring you to those documents. The information that we incorporate by reference is considered to be part of this prospectus. Information that we file with the SEC in the future and incorporate
by reference in this prospectus automatically updates and supersedes previously filed information as applicable. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I></I>We
incorporate by reference into this prospectus the following documents filed by us with the SEC, other than any portion of any such documents that is not deemed &#147;filed&#148; under the Exchange Act in accordance with the Exchange Act and
applicable SEC rules: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our Annual Report on Form 10-K for the fiscal year ended December&nbsp;31, 2014, filed with the SEC on March&nbsp;12, 2015;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our Quarterly Reports on Form 10-Q for the quarters ended March&nbsp;31, 2015, June 30, 2015 and September 30, 2015, filed with the SEC on May&nbsp;7,
2015, August&nbsp;7, 2015 and November 5, 2015, respectively; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our Definitive Proxy Statement on Schedule 14A, as filed with the SEC on April&nbsp;30, 2015; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our Current Reports on Form 8-K filed with the SEC on February&nbsp;17, 2015, March&nbsp;18, 2015, March&nbsp;31, 2015, June&nbsp;15, 2015 and
July&nbsp;15, 2015; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the description of our common stock included under the heading &#147;Description of Common Stock&#148; in the prospectus forming a part of the
Registration Statement on Form S-3 (File No. 333-186189), as filed with the SEC on January 25, 2013, which description has been incorporated by reference in Item 1 of the Registrant&#146;s Form 8-A (File No. 001-00100), as filed with the SEC on
April 22, 2013, including any amendment or report filed with the SEC for the purpose of updating such description. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In addition, all documents subsequently filed by us pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act (not including any information furnished under Item 2.02, 7.01 or 9.01 of Form 8-K
and any other information that is identified as &#147;furnished&#148; rather than filed, which information is not incorporated by reference herein), including those filings made after the date of the initial filing of the registration statement of
which this prospectus forms a part, prior to the termination of the offering, will be deemed to be incorporated herein by reference and to be a part of this prospectus from the date of filing of such documents. Any statement contained in a document
incorporated herein by reference will be deemed to be modified or superseded for purposes of this prospectus to the extent that a statement contained herein, or in a subsequently filed document incorporated herein by reference, modifies or
supersedes the statement. Any statement modified or superseded will not be deemed, except as modified or superseded, to constitute a part of this prospectus. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We will provide without charge to each person, including any beneficial owner, to whom a prospectus is delivered, upon written or oral request of that person, a copy of any and all of the information that
has been incorporated by reference in this prospectus but not delivered with this prospectus (excluding exhibits unless specifically incorporated by reference into those documents). Please direct requests to us at the following address: </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">TherapeuticsMD, Inc. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Attention: Corporate Secretary </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">6800 Broken Sound Parkway NW, Third Floor
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Boca Raton, Florida 33487 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(561) 961-1900 </FONT></P> <P STYLE="font-size:24px;margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">45 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:120pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>$20,000,000 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g579833g0730230036492.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>TherapeuticsMD, Inc. </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PROSPECTUS
SUPPLEMENT </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g579833g0730230036492.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g579833g0730230036492.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  G 1$# 2(  A$! Q$!_\0
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MJ?>L/:>[YF[P;=6]_<WMY_Y=3B_"W_)1O$'^Z?\ T):E\&_\CAXG_P"NX_\
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'****0S__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g579833g0730230036773.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g579833g0730230036773.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %> FX# 2(  A$! Q$!_\0
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MT*PB58P< $'.T8':LR/P"EMIVL:;::B8=/U*,#[.(<B&3 #.O/0X^[6EX?\
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MBVC-SI3-<1@9,+??'T_O?SKC""I((((."".E=:=.O'34Y&JN'EKH?8T,\5S
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M6=V+,3W)J!S+YBB/>I[,O!!KT).-"F>9",L15/:/"O@VWT.UCN93%/?RKEI
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M:_8=4NK;M'(0/IVKUKX87AN/"I@8Y-M,R#Z'YA_.NF>JN=6*5X*1VM%%%9'
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M)X?U=;17N);B(QA< 7C,(P6)8]?F(&!S6H?&(D:!;?2[LM+(N5E*(1&03O\
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M8C-ND8E_*QLR<YXP/KWJ[TR+5+;F/)\0;",2LVG:AY48E<R!4P4B?9(P^;.
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MRD!/,\@P/^ CO7H"SV_AS1VTO3H=DLHS+,SY<^YX_*KVI7MAIEM]FM"7N!P
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MA86VF6$%C9Q"*W@0(B#L!55ZBA'DB/#TG.7M)&=XBTXW5J+B(?OH1GCNO?\
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MZW;C^0I&1E8JRD$=01TIM#PT&5'.,0MTC:LI_#FDY^QZ?=DD8)^UM_,U5O\
M59+N3,2O!&.B"9FS]235%(WD<(B,S'H .372Z1X"U[565C:FUA/62X^7CZ=3
M^5"I4J>K)EC<9BO=C^!S(!9@ "2>P[UZ9X*^'[%X]3UF+"C#16S#D^[?X5T_
MASP)IF@E9V'VJ\'_ "UD'"G_ &1V^M=36%;$W]V!WX+*N1JI7W[?Y@  , 8
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M211RC$D:./1E!JN=+L"<FRM\_P#7,5;HH BCM;>'_501)_NH!4M%% !1110
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MHZ;>?:+-Q>2PQVK31Q$*(E8LV[_:9L9^E8]IXBO]+L8;-(AY%O>"[97W+O;
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MOA7PK:^&K':N)+N0?OIL=?8>@KH***R;N<$I.3NPJK-J5C;WD5I-=P1W$O\
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M)&5(/<8KQ_Q-H>KZ)?RRP33FTD8LC*Q(&>W-959-*]COP%*-2;BW9]#HQ-:
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M"1Q]!4-W*6A=M8O*@ [GDU-115DA1110 5B:Q_R'= _Z^9/_ $2];=8FK_\
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M!K.H^=IMW=+=NKQ2VZ!@.,;2<\?C5TVURWC W7D2"$V>W=C@-Z9]:FW>*/\
MGEH__?V7_P")HW>*/^>6C_\ ?V7_ .)J;]=#5025M;)WV.;33-2L_#ME>P64
MK7]G=2.(=I#,K$]OUIMYI%Y9V.@LL-\'29YKE[./?)&S#T(/\JZ;=XH_YY:/
M_P!_9?\ XFC=XH_YY:/_ -_9?_B:KG?D9?5X6LK[+IVMK^"*^N13W_@BXB@B
MNYIGB 59H\2L<CJ,#FL:?0]0AU-&WWMXK:5+'NF"G8Y'"#:!70[O%'_/+1_^
M_LO_ ,31GQ3_ ,\]'_[[E_PJ8R:T5BZE.,W=I].G8YBV34QX2.F00ZNUW*D<
M!6Y@VQP@_>*D <8^M,N=(UBTLM:L#9(Z7=NDD8LU8IO! (Y[D#.*ZK/BG_GG
MH_\ WW+_ (49\4_\\]'_ .^Y?\*KG?D9O#Q:2?-HK;>O^9FW9GU.VT<PV-XG
MV:Z3S!-"4( 7KCT]ZJW^BW]UK7B*>.2]MXY+91$(0NV<[#\O(.?3C'6MS/BG
M_GGH_P#WW+_A1GQ3_P \]'_[[E_PI*36UC25*,OBO]WE8L>'89;?PYI\,T;1
MRI BLC#!4XZ&M.L3/BG_ )YZ/_WW+_A29\4_W-&_[[E_PK-QN[W.B$U&*C9Z
M>1N45AY\5?W=&_[ZE_PHSXJ_NZ-_WU+_ (4N7S*]K_=?W&Y16'GQ5_=T;_OJ
M7_"C/BK^[HW_ 'U+_A1R^8>U_NO[C<HK#SXJ_NZ-_P!]2_X49\5?W=&_[ZE_
MPHY?,/:_W7]QN45AY\5?W=&_[ZE_PHSXJ_NZ-_WU+_A1R^8>U_NO[C<K%U3_
M )&+0A_TTF/_ )":FY\5?W=&_P"^I?\ "FPV&LW.L6=WJ+6"QVN\JMN7)8LN
M/XJ:5M;D3FYI))[K\R2Z_P"1QTWWM)__ $*.MJLG5-,O+F_M;VQNXH)H$=#Y
ML1D5@V/0C^[47V7Q)_T%-/\ _ )O_CE#2:6HTY0E+W6[OR[+S-NBL3[+XD_Z
M"FG_ /@$W_QRC[+XD_Z"FG_^ 3?_ !RERKN5[27\K_#_ #-NBL3[)XD_Z"M@
M/I9-_P#%T?9/$?\ T%K'_P  F_\ BZ.5=P]I+^5_A_F<[JNB:L=4U34K&W;[
M2EQ$]L21B1=NU^_O44GAF^MK#4+>&UD<O:1*&4C+OG+8]\DUT_V3Q'_T%K'_
M , F_P#BZ/LGB/\ Z"UC_P" 3?\ Q=;*HUU7XG%+"Q;;Y9:W[=;^?G^",273
M+B_L=-MS9ZFT<=XC3"_=6(3&"1@GBJ/_  C&LN-4MG3<J11QVLA8?O51MP'Y
M<?A74_9/$?\ T%K'_P  F_\ BZ/LGB/_ *"UC_X!-_\ %TE4:ZK\0EAHRWB_
MP[6[F9)!J.M:A8ROI<UE%9QL7,S+EW*X"K@G(]^*RX/#&IP^&X92;B34%C:&
M&W.T+;AV^9N.O'/)KI_L?B/_ *"]B/I8G_XNC['XB_Z#-E_X G_XNA3MHFOQ
M&\.I-N2DW\O+S\CG'\-ZS#]NL@()8;RS$8>%-B*Z=,@DG)]:NPVVHW^H:?+-
MI,L$=C;-'(LSK^]8C&%P3Q[G%:WV/Q%_T&;+_P  3_\ %T?8_$7_ $&;+_P!
M/_Q='/?JOQ!8=+92M\N]^_<Y=M&U0Z;J=M96-];V,EOA+2YE5L29_P"6>"<#
M\:Z?PTDD5@89(=3C90 ?MSALG'\.">*7[%XB_P"@S9C_ +<3_P#%T?8?$7_0
M:M/_   _^SI2ES*S:_$JE1]G+F47^'^9R:^&]81(%AMR@N99(;L''$>_<#UJ
MW_86JFS73H+988GOC*S2#**B_=R 03GTKH?L/B+_ *#5I_X ?_9T?8?$7_0:
MM/\ P _^SJO:/NOQ,UA8K[,OP_S.<&@ZJEJ^FSVRS0K?K,K1KA"A^]@$DBD3
M1];L+C4H8;<R1BW^SVDH(Y4MW^@-=)]A\1?]!JT_\ /_ +.C[!XA_P"@Y:CZ
M6'_V='M/-?B/ZJNBE^'^9S1\+:Q 9[,&!H;NR$+/ A0(R_=R"QZ^M7((M;GU
M"U L[^UC2$I<QO,I@.%P-@!_I6S]@\0_]!VV_P# #_[.C[!XA_Z#MM_X ?\
MV=+VE]VOQ&L,HOW5)?-?YG,V>EWZ^&K_ $\V>J_:7A8!9I%,.<_P#=Q^5(_A
MC4C=3V_DDZ<(6GC3(YF9,;?SS73_ &#Q#_T';;_P _\ LZ/L'B'_ *#MM_X
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<B@ HHHH **** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g579833g0730230036991.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g579833g0730230036991.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "D DP# 2(  A$! Q$!_\0
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M-+]L;47MII5C0B0KVR1D+@=N<UYK3BH2Z"G*<-.8ZS_A9OC/_H/3_P#?M/\
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M./!>GR""7[:'N)=UF-]PR[N"^<A0>,<@X%>>VGBZ]MM'BTN6UL;N"#=]G-U
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MBA*G()!QP?2F5+<+&EU,L,ADB61@CD8++G@_B*BK<YF%:\/_ "*%Y_U^P_\
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M4K<PK'YG^KZ<].:+U&*U);,I7?@77K&PDO)K>$I'&LKHDRLX1NC;>N.:;?\
M@O6-,TJ34;I;9(8RH=1.I="W0%1T/M6R_CN"ZO[YGLVC2]LH;(DOGR]A&6/'
M(XZ5O?$&^TN_T"4P:PA*O&88(9583\8RP"@C'N31S3328^2FTVCR>D/0TM(>
MAK8YS9\4?\AZ7_<3_P!!%8];'BC_ )#TO^XG_H(K'J8[(J?Q,#R*ZI?'5ZFO
M66JQVT*O;6HM3'D[9$Q@Y^M<K71:/X<MKK1)]:U6_:ST^*40J8X][R.>P&:)
M<O4<'+:)9'C7R;FXEM-+BA6>U>V93,[_ 'NK98FDM_'%S;O PLX6\G3&TX9)
MY4_Q?6H[SPK!_84>J:5?M?1M>?96!BV[2?NG\:VO^%>V$3ZAY^J73+92Q0/]
MGM@[>8X!(QGH#Q6;=,T2JO8R;SQJ^H:5';76G1/<QPK"MR)77Y1T)4':3^%+
MJ'CFYU#^U]]G"O\ :<$4#X)^01]"/KBLW6O#L^E^)I-$A<7<P<)&4&"^>@QV
M-._X0[Q$+O[*=)N%FV>9M; PI. 22<"JM#<ENI>QM2?$.6XDOOM6D6L\%[%#
M#+$[-C;&,#!!SDTA^(UY-=7QNK""6TNP@^S*[((]@PNUE.>E8EMX2U^\>5+?
M2KAVAD\J08 VMZ')IEYX9US3X(YKO3+B*.1_+4LO5O3'7-'+3#FJ%B]\3R7F
MB76E+:1Q03WGVL$,S%#C&T9/(^M7M3\=W6IP7T3V<*"\6!6()^7R@ ,?7%9T
MO@_Q##+;QR:3.KW#;(AQ\S8SCKP<=C5>V\.ZO>*C6]A*ZO(T:G@ LOWAR>U%
MH"O4/1]!\=:9>0:A-J5U'87-U<HTB!I%_=J@7Y63G/'0\5YEJYLFUB[;3FE:
MS,K&$RGYBN>,UM:?X.N7_MA-42:SGL;/[2B8!W\\<^GTKF*(1BF[#J2DTN8*
M='_K4_WA_.FTZ/\ UJ?[P_G6AD:?B7_D9M1_Z[M_.LJM7Q+_ ,C-J/\ UW;^
M=95*.PY?$PK>M_!VM76B0ZO#;QM:S';%^]&^1MVW 7J3FL&NHC\8/;Z=X;@@
MML2Z+,\NYFRLNY@<8[>E*7-T'#E^T-G\ >(;>XM('MHBUU*8$*2A@) ,[6/8
MX%1W'@?7[>6TC^R),UW*88_(E5P''56(Z$5U=EXXM-6\8Z/+))>VT"WIGF^U
M7>^)/E8?*,<=:J'X@6FD7MM%H^FE;6"]FN9A+-O\XN"IVG' P>*SYJFUC;DI
M6O<PCX#U[[;:6L<,$[79=87AG5T+(,LNX=",5;?X?7T&@:CJ-Q>6<<UE*J-
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ME6K\-&1?B%I7F$#+.%S_ 'BC8_6M_1-:M]-\*PZ??RK]FO=3N;:]B)^94=0
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M6YP&]B>U<H?"4\]M?/Y<=K-*B)!%YID"[6#<L?7%:04&O>.6O*LI?N^W^?\
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$&C__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g579833g0730230037444.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g579833g0730230037444.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "X FX# 2(  A$! Q$!_\0
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MU1D_KBO)*Z:4$XW9R5JDE*R9V?\ PL[7_P#GG9?]^F_^*H_X6=K_ /SSLO\
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MMK9%*J(1,SMM/\7WN/J?RH]SL%JG<HGXE^(556:"S"MT)A;!^GS4W_A9VO\
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MZA/':9B9(X0(R 6/7///%><5O:C_ *)X5TNTQA[AFN7^G053A'L0JD^YJ_\
M"S]>_N6/_?IO_BJ/^%GZ]_<L?^_3?_%5:2^L-/\ "5BMV583VS@6XMU/F-GA
MB_48J_J$,K>;#=6D8T==/5Q(T*J%DV\;6QG.:CW>QI[_ /,8W_"SM>_YYV/_
M 'Z;_P"*H_X6?KW]RQ_[]-_\56C/9?\ $RN-0%LHT\Z5A9MHV;MH'7US4MU#
M!=WNEZ<9BD:0QW$T7D((PJC)8O\ >H]SL.T^YD_\+.U[_GG8_P#?IO\ XJC_
M (6?KW]RQ_[]-_\ %57\9VT4GV/5+=K=XYT,<C6WW-Z^G [8KH-0@FD>Z@N[
M2-='6P5DE:)5"R[1C:V,YS1:%D[$^_=JYC_\+.U__GG9?]^F_P#BJ/\ A9VO
M_P#/.R_[]-_\56O#X8TNP?3;F6Q^8W*Q.KR,R/N7.?F !Y].*JVOA?3+JTNK
MB>SFAD,TB&-6<FW"CC@#OU^;%%Z?8=JG<@L_B+XAO+ZWMDCLMTTBH/W3=S_O
M5ZTN=HSUQS7BG@*P^V>+X"1N2W#2G\.!_.O;*SK))V1K0<FFV%%%%8FP4444
M %%%% !1110!YI\0]+UC5]:MUL]/GFMX(<!UQ@L3D]_85R'_  B/B'_H$7'Z
M?XU[!KNJ2:9&DB#<"0N,XZ@_X5B?\)9=?\^X_P"^C_C6BQ'(K!' 3K>_$\Z_
MX1'Q#_T"+C]/\:/^$1\0_P#0(N/T_P :]%_X2RZ_Y]Q_WT?\:/\ A++K_GW'
M_?1_QI_6BO[)J]OR/.O^$1\0_P#0(N/T_P :/^$1\0_] BX_3_&O1?\ A++K
M_GW'_?1_QH_X2RZ_Y]Q_WT?\:/K0?V35[?D>=?\ "(^(?^@1<?I_C1_PB/B'
M_H$7'Z?XUZ+_ ,)9=?\ /N/^^C_C1_PEEU_S[C_OH_XT?6@_LFKV_(\Z_P"$
M1\0_] BX_3_&C_A$?$/_ $"+C]/\:]%_X2RZ_P"?<?\ ?1_QH_X2RZ_Y]Q_W
MT?\ &CZT']DU>WY'G7_"(^(?^@1<?I_C1_PB/B'_ *!%Q^G^->B_\)9=?\^X
M_P"^C_C1_P )9=?\^X_[Z/\ C1]:#^R:O;\CSK_A$?$/_0(N/T_QH_X1'Q#_
M - BX_3_ !KT7_A++K_GW'_?1_QH_P"$LNO^?<?]]'_&CZT']DU>WY'G7_"(
M^(?^@1<?I_C1_P (CXA_Z!-S^G^->B_\)9=?\^X_[Z/^-'_"677_ #[C_OH_
MXT?6@_LFKV_(\Z_X1+Q%_P! FY_3_&C_ (1+Q">NDW/Z?XUZ+_PEEU_S[C_O
MH_XT?\)9=?\ /N/^^C_C1]:0?V35[?D>=_\ ")>(O^@5<_I_C1_PB7B+_H$W
M/Z?XUZ)_PEEU_P ^X_[Z/^-'_"677_/N/^^C_C1]:0?V35[?D>=_\(EXB_Z!
M-S^G^-'_  B?B+_H%7/Z?XUZ)_PEEU_S[C_OH_XT?\)9=?\ /N/^^C_C1]:0
M_P"R:W;\CSK_ (1+Q%_T";G]/\:/^$1\0_\ 0(N/T_QKT7_A++K_ )]Q_P!]
M'_&C_A++K_GW'_?1_P :/K0O[)J]OR/.O^$1\0_] BX_3_&C_A$?$/\ T"+C
M]/\ &O1?^$LNO^?<?]]'_&C_ (2RZ_Y]Q_WT?\:/K0?V35[?D>=?\(CXA_Z!
M%Q^G^-'_  B/B'_H$7'Z?XUZ+_PEEU_S[C_OH_XT?\)9=?\ /N/^^C_C1]:#
M^R:O;\CSK_A$?$/_ $"+C]/\:/\ A$?$/_0(N/T_QKT7_A++K_GW'_?1_P :
M/^$LNO\ GW'_ 'T?\:/K0?V35[?D>=?\(CXA_P"@1<?I_C1_PB/B'_H$7'Z?
MXUZ+_P )9=?\^X_[Z/\ C1_PEEU_S[C_ +Z/^-'UH/[)J]OR/.O^$1\0_P#0
M(N/T_P :/^$1\0_] BX_3_&O1?\ A++K_GW'_?1_QH_X2RZ_Y]Q_WT?\:/K0
M?V35[?D<GX3\)ZM'XGLIK[3YH;>%C(SOC&0.._KBH?$.@^(-4\0WUXNE7+))
M*=AX^Z.!W]!79?\ "677_/N/^^C_ (T?\)9=?\^X_P"^C_C4_65>Y7]EUK6L
M>=KX3\1HP9-*N58=", C]:4>%/$BEBNEW0+#!P1R/SKT/_A++K_GW'_?1_QH
M_P"$LNO^?<?]]'_&J^M(7]E5NWY'GZ^&?%"G*Z?> X"Y##H.W6FMX8\3,FQM
M-O"N<[2PQGUZUZ%_PEEU_P ^X_[Z/^-'_"677_/N/^^C_C2^M(/[*K=CSV3P
MOXFEQYFFW;XX&X@X_6G/X:\42)L?3[QD_NLP(_G7H'_"677_ #[C_OH_XT?\
M)9=?\^X_[Z/^-'UI!_95;L>=KX0\0LP']DW R<9../UJQJ'A;7YK^9H])N#&
M"$0\?=48'?VKO/\ A++K_GW'_?1_QH_X2RZ_Y]Q_WT?\:/K2#^RJO;\CSL>$
MO$2L&72;D$<@C''ZTH\*^) Y<:7=!CU;(R?UKT/_ (2RZ_Y]Q_WT?\:/^$LN
MO^?<?]]'_&G]:0?V56['GR^&/$ZD%=.O 0-HPPZ>G6@^&/$[*5;3KPJQR06&
M"?SKT'_A++K_ )]Q_P!]'_&C_A++K_GW'_?1_P :7UI!_95;L>>OX7\32*JO
MIMVP7H&(./UIQ\->*6C\MM/O2G3:6&/RS7H'_"677_/N/^^C_C1_PEEU_P ^
MX_[Z/^-'UI!_95;L>>1^#_$#2(K:5<*I8 DXX_6M3Q)X<UR[UE_L^F7#V\*)
M#$PQ@JHZ]?7-=?\ \)9=?\^X_P"^C_C1_P )9=?\^X_[Z/\ C1]:5[A_956U
MK'G7_"(^(?\ H$7'Z?XT?\(EXBSG^R;G/X?XUZ+_ ,)9=?\ /N/^^C_C1_PE
MEU_S[C_OH_XT_K0O[)J]OR/._P#A$O$7_0)N?T_QH_X1+Q%_T";G]/\ &O1/
M^$LNO^?<?]]'_&C_ (2RZ_Y]Q_WT?\:/K2#^R:O;\CSO_A$O$6,?V3<_I_C1
M_P (EXBQC^R;G'X?XUZ)_P )9=?\^X_[Z/\ C1_PEEU_S[C_ +Z/^-'UI#_L
MFMV_(\[7P?X@9@ITFX )P3QQ^M:WB3PYK=SJBI;:7.]O;PI#&RXP<#GOZUUW
M_"677_/N/^^C_C1_PEEU_P ^X_[Z/^-+ZTKW#^RJUK6_(\[/A3Q&RJK:5=$+
MT!(X_6GOX9\3R($?3KQD'12P(_G7H/\ PEEU_P ^X_[Z/^-'_"677_/N/^^C
M_C1]:0?V56['GO\ PB_B;RO*_LV[\O\ N[AC\LT?\(OXFSG^S;O.-N=PZ>G6
MO0O^$LNO^?<?]]'_ !H_X2RZ_P"?<?\ ?1_QH^M(/[*K=CSO_A%/$>S9_95U
MM!SMR,?SI[^&?$\B!'TZ\91T5F!'\Z]!_P"$LNO^?<?]]'_&C_A++K_GW'_?
M1_QH^M(/[*K=CSX^&?%#*%.G7A"] 6''ZTO_  C7BCYO^)?>?/\ >^8?-]>:
M]#B\62^:GG1%$)Y8'.*ZRVN4N8E=&!R,\52Q%]C&I@94G[]T</\ #CP_>Z6;
MVYO[5X)'VH@?&<#D_P Z[ZBBLY2<G=CA%15D%%%%24%%4KO4H+7Y2=\G]T=J
MSFUN=CE4"K]*3:0[,WJ*PX]:DS\P!'?BM.VO8K@#!PWI0F@LRS1113$<MXQ_
MX]8_^NB_R-<M74^,?^/6/_KHO\C6!8V$NH3&*)D4C^^<5C5U9[>7R4:#;VN5
M:*DBB,MPL.Y5+-MRW059DTJZC4DIEO,,80#+,1U(]JRLSO<XIV;*5%3K973N
MZ+;RED^\ O(IHMIS$THA?RUSEL<#'6BP^:/<BHJY;Z=)/;^>98HHRVU3(V-Q
M]JA^R7!C:00N8U)!<#(X]Z+,7/&]KD-%3_8[H('-O)L.,-MXYZ5)-I=[#-Y3
M6[EL9^49XHLPYX]RI14SVES'%YKP2+'_ 'BO%!L[D;,V\@\S[GR_>^E%F/FC
MW(:*G^Q77F&/[/+O'5=O(J1-,O'AEE$#!8CAP1R/PHLQ.<5U*E%6;FR>%AL#
MNA ^8ICD]J;]CN=KM]GDVIPQV]*+,%.+5[D%%3I:R26<ERI4I&P##OSWJ633
M+N/&(FDR@<[!G;GUHLPYXWM<IT5.EG<R1^8D$C1CJP7BI)-/F$Q2".28 #)"
M$=:+,.>-[7*E%3):7,@<I!(P0X;"]*?<69@AMI-^?/7=C'3G%%@YXWM<K45H
MS:/-"K,98GV;=ZH22H-0R:?.)G2&*655.-P0BBS$JL'LRI14T=G<RJS1V\C*
MO!(7I3X+0S07$Q?:L(';J3VHLQN<5U*U%:,FBW44ZQ,4RT9D# \8'4?6F2:8
M\<,;M/#OD4,D>3N.:=F2JT'LRC15N\L'LR%>6)Y,X*(>5/O5E]&(+@7$:B)%
M,IDZ GMQ19A[6%D[[F715Y=-)MS.;J!8]Y0$D_,1Z<5%<VOD0V\H?>DR;@<=
M#W%*S&JD6[(K4444BPHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MC^XYRBNC_P"$$\1?\^:_]_!1_P ()XB_Y\U_[^"CVL.X?4\1_(_N.<HKH_\
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MX-_PG'B'_G^'_?M?\*/^$X\0_P#/\/\ OVO^%'(P^JU#WGY/]FCY/]FO!O\
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M8 H1%C4*HXIU8MW/+G-S=V%%%%(D**** "BBB@ HHHH **** "BBB@ HHHH
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M_P")H_X5;J__ #]VWY/_ /$T44<[#ZS4[A_PJW5_^?NV_)__ (FC_A5NK_\
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I44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g579833g96q94.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g579833g96q94.jpg
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M 0$! 0$! 0'_P  1"  Q :(# 1$  A$! Q$!_\0 '@   @(# 0$! 0
M      D("@8'"P4$ P'_Q !,$  !! (! @0"!08&$ <!   % @,$!@$'"  )
M"A$2$Q05(3EXMK<6(CAV=[47&B,Q.M<8)"4T-T%76')SD9:7L[35)C(V5F*!
MF,'_Q  = 0 " @,! 0$             !P4& P0( @$)_\0 4Q$  @(! P(#
M P0+"@H+ 0$  0(#! 4 $1(&$P<A,10B0391=;0(%2,R-V%Q<W2!LQ<S-4)2
MH;&RM=06)#1#4U5B=I25.%16<H*2HK;$TM.1P?_:  P# 0 "$0,1 #\ _?\
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M1NT['X*Z1*?@^Y U(8;Q:@FL+6SN/]@#-P-RL[R0Q,3M]WK2+WHT7^,\<DS
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MMN05E5KX2K<EFC[4Y7\?'I\F13C&OZKN0>+==6N&*LU:L<6DEY\%G.?;8DV
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MS-D-./UT+6A$V$/L3 MYO\I+,P2)D9$N$V$ABZ]UAU%9S&2L5UE=<=4F>"O
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M\I!]KLQ//2?R\RRRV9^!]?=V!\AM;+94M;32W$>VXMM"EMY^GT+4G&5(\_\
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M&[AELQ2QCBI;=UF@=BHVW/&1#M_&&E!>$W_38Y$?9:(?BSK'JT^)_P#!./\
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MBM6?09VDC).4J^'4=HNPS)TZPE?EZ?>1 V+77'$^?J]#C>?+RZT/"^5#C<E
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M+^'G6&5LY*3IO./)/.J3BM/8!%R.:IN9ZEECLTI")(P>3>9'C='9PR]MGGB
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M6<3)[-HLHVX3,60K?+G,66-5UF_&R#!210YL$R3J\M) U+C"SIHR 54.M+F
MMY&%</"J]A!#:M5@JUY@G%(UAB'%)#"B\1.&19!L@Y(BOJ\= 4.IJ.+G?.V'
M?VES/2I6V=[==I.3R/8G8N\8L.P<UV61XCRD8)(\D>D;WSNI]ZSM><EMGD.9
M>K?X1]7;*V"8L,*KV>,5?T[&BS'\X@C>.>Z <>6BN"(H>,/BPZL8^?K'14*G
MV6CP;<2+3W[E!TUTAU'CZZXFS[/:KP(C21E1;) ]YK]-R#(Q8L3(A0$^[',T
M2JHH5CJ[KGI3*6FS=3VJI:LO(L4H<T@"?=7&7HP1$@C"A8G[A4>]+ LS.QD_
M8/%P:ZS2)CU5X9W1&R78#B1XZP;5!N4B$4<:REI^8:&U9H\4@1'LI><BL@ \
M@@TWF,F8,4]B4Q')X76.\!)EH?9^7O,E9^\5^8(TG!6(^)D8+Z[-Z:E9?&.M
MV"8<)/[25]U9;<?85B/4ND/<=5/GL(T+#RY)ZC5'AZ.'?(C>G-'9/=6W]62%
M6KAZ5MBU4LN1$2*^C:.U]XSBF;?8J<)E8]UR@ 0MBM4;)A'J&22Y<6+"S"3@
MBP8&[77>5H4L17Z9HR++)&*L<JJPD]GJTU411RN/(3N\<1X^3!59G"ATY:GA
MOA<E?SEKJ[(Q-#%(UR:!V0Q^UW+[/WY($;S]GC264<_O2[HD;/PEXN@\0%^A
M-3/M%T;[A;3ZA_"[Y16/HFS]:I:7OV9OX*<5_OQB?[&ZBU._MP?H(\5?V-U/
M_I5=5GJWY39OZ0G_ *VG!X&_@@\._P#=?&_LSJ;'5=TUM'1HTH?OB?5^7O\
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M1?O410BKN23LJ@ ;DD^0]23KU.O.O6L'L>L=;7 @V7MVO:/:2S,9J&R3L=3
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MVTRRTWA+;333:4H;;0E*$(3A*<83C&.M$DDDDDDG<D^9)/J2?B3J2
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g579833txmd-riders.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g579833txmd-riders.jpg
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M<" S+C  .$))300$       /' %:  ,;)4<< @   @ " #A"24T$)0
M$/SA'XG(M\EX+S1B- =8=^O_[@ .061O8F4 9,     !_]L A  ! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! @(" @(" @("
M @(# P,# P,# P,# 0$! 0$! 0(! 0(" @$" @,# P,# P,# P,# P,# P,#
M P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P/_P  1" %D H8# 1$
M A$! Q$!_\0 ]P !  $#!0$!              4&!P@! @,$"@D+ 0$  @,!
M 0$              @0! P4&!P@0   & 0(" @@)$A$)!@4"!P$" P0%!@<
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MFUAH.&9'=/F[4'4C*/4D2"HH0@&.',8H<1U8G.)C0OD3A5AC4LQ(Z*H))_@
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MD@  7)-JN<?B\CRF:F!A[FR9#H-P'07)N2   "2218 DZ"KI16V#<S-U"\9
MB)6!D:/C;#M3SG>;4RSE1W4+6J5>Y9]!4R+DW:%P4!OD:RR\>JW:U8P!8#*<
MH&:%YR<U1N5XM)H\9@PGEF:)5[3W9E%V(\ON*#<O[G^U5Y>&Y=\>3*5E.-%
MLKMW([*&-E4^?1V.@C]^_P";6+H6:TB4#A8+$)!."0'[[2G(*HEYNB W6.45
M.4>/+V^&NKVH;VVK?YA7$[N1UW-;YZT\9K1V/_,-B[)>8/JO*=DO,).8/W1V
M2\X<./:X]C6>U#]5?H%.]/UW-;YZU&S6@.;C8;$'()BGXR\H'()/DP/^Z/4"
M3T>/#AK':A^JOT"G=R+VW-?YZ#9;2'R5@L9>!"*#S2TH'!-3];4'BX#@0_\
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MKI''.T+$GI(@!93[;@,/IJS V6U!R\;!8PYQ "<9:5#G,( (%)^Z/5"(&#@
M=OCJ]VH?JK] KF]Z?ZS?35R,0T7.>>\C57$F(&=PO.1KLM((56KQT^9DZF#Q
M,6^FI,4'DQ+1L6BBPBHQPNJHLNFF1-(PB;T-5<W(P./QGR\PHF/';<Q%[7(
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M[<]B=*VG5F3I$/&PL#E;!-ZP?D'-I;$F@J4[."N%@QV_,+MV=Z9^0Y"<$R&
MH;(O1<Q7'7(5-<G*:<AB24E69([?*JNN@L!4)_7>+]O\*[AUQ\18+JNU6B;'
M>2]CT+1R$]6-['2P%#[\]S^VJB?"1;/8["Q&3+:UL\R3C_+\^G0'\'=P"[Y:
MS6UW/9\) S%===Y[4[JA[ VKC0K=T=$G>(K8BH@03C8X#BN3G]-YKYMSRF9$
M\8W KY4B,$5P1==UBYTOYR;53]2\UQ,'JG CP"/PG"FCD.TJ]F>43RA6!LVW
M=VP+V'; OI>JXOGPIFU3(</D!^Z@[#3920P[\)+B"!QU3,51,3C>=FMRV5Z;
M?L.9V>1B$GT,%E2WP$2>.NKPQEUA6BVJR? #&*-?&])\MC/&H9743X<A9G)<
M"%&62*]M44G=&-/>8&K>;ZSX?-BF9@RR''S8E4(H4F5D:*2V[1F4;)#K?MH5
MTTK+S&_PD.U7=3N>O2<O;YB-C8C.^Y++^WI[?F5%Q3+5'$]DV./L8QE(Q1=;
M1/P\#CS*L]FWEDHAH>3C2$DBEDNO)N>(FX^1Z:Y;BN,CVH"S00QR[=[AI%R0
MY:154ET$=PQVL=OEVD5V\?U3PO,\J]Y-JID3O%N,<;"-L5D"Q,6"HYEVE?,J
MAP&W!NN([G-5,<?#87>SW+.F,+-!Y7V\9'PU6<EL[,Q1HF+;+DK9].X[H]3M
MEU<VJU5HD]5+(Z1B[%,,II[%JR[UTZ(N!3J$)V!@SCT3'%#!*CPY"2,FT[I%
M3(#LRKM5K,H+(I4-M"BUZX;<CCGUU))/DPO'/C/&LFX;(V?%:-0SEF6X9E1V
M5RN[<U[=+-9 ^$CQ4?9-?]MM"L>4:Y;K+L1V([<EXR-AAA:J_P J8*R5?7V?
ME)&0C9OH'4)/X_GFL>E(F24--(E,W4*5(H"-S$],Y@YN+DLE8FA3/RIKDW8)
M*B"*P(ZAP3;\WJ-:J<EZLP).#GXW%>599,#$BL+ %XY7,M[-T:,@7M<C1@!5
M>[/]Z^S:C;0L?;;9RR93<Y3M$QA]A*0.06<G)8EH^287>92<GK7JJ2*]L:XW
MH]12QHQ7!:2-"GL8NUG2;E\#+D2'1S'"<U/S,G)(D7PJ+)8I8.R'&9-K#;O9
MMY&F_98 A=VM;>"Y[@H>"CXLR2_%.T=Q(?(CKE)(67SA%7M@B^S>6+ MLTKZ
M"V#?/M:FMPFZ2A,MR"DC,8[J?PK5NJNY23IM+CF&*J_DEA1(K#V#]NJ:EK69
MYB2I\]4G<] =279)R"ZR?>\A555#%\]'P7*IQV+.<;:LCX"M"&8ERA8R2S>7
M[/<&"/<&UCNZ5Z5_4'#MR>7",L,T:\BZS$( BR;1%##Y_M A0NEBM]P*=2:P
MWO/PONWF/:V5M1(N\VYM;]S^RZ?S>C.XZJT$KNHP%A+ D5C[<4XNG?)S.D@)
MO.%X@F[E6-54.X>MRE.[<@)UB#VL?T=R+%3.40IBY(BL['L2RREX=M@+B)20
M#[#[HZ&N#E>MN+C5U@WR*V9BF:Z)_P"HAAAV3;KDV[SJ";7N#=FO<5VW?PGV
MS>QW2!QEFVVYEW$8(R<QWD5G<%EB9Q#!5/),!B;-]NH^1=O>):' J3LW)R;;
M ]SQT@NFL=TFR8A,.D8Y+JQ>0T$]+<U%CME820X^?$<=HHP[,ADC#I*[G:!]
MJCVZ7.T%C>M\_J_@)\V/$S'FGXZ5)UFD*(KA).V\2)YC^JDBWZD!>XP30:]#
M)GPOFW;*>"\JQ3F@,(2Z7^W;D!NN+9S&MCGZAE2J9'R/7YC#LJP?5S)-7H<!
M<<;8RK$7 -7]AAI=W7^]1#1HJ).%D33QO1_)8N?"XD+0QI#M<. R,B$2 [D+
M%7<LY"LH;=9N@-:\KUQQ&7QDZ"-5FDDFWHR7#AW!C*[9  8D"H&9&*A 4ZD5
MDA6OA)]L&:=RNV-U#YONSBI8AWT[@=[#U3,=)KV(JIAK;@&VZ3:0&W2FN$K7
M(,;&^K;N#-!1;)JFB$BJ_33:HG W _+F],<KA\=D!H$$TN#%C?9LTC23=W69
MO*"-V[>Q)-@"2:[.+ZMX?*Y&$C)<PQYTN3]H$18H>VK+ MG-]HC** !<L% U
MKR5OG*;U\^>I)"@D]>O'B2!@ #().G*JZ:(@'$ %(B@%$ ['8U]@0%5 /4"O
MA$I!D)'2]9?WC^P'MM_O3[L_Z.=K&N-C_P#_ $&3_98/]_(KOY/_ /S.+_:L
MC_AXM8;:[=><II2FE*:4K+_8#FJA;<=Z.V_.F41F@QWC#)#*SW#Q<C>^\[WE
M2C)1FN$5&=:8]==B=X4 )TR?8XCS!PUQ?46#D<GPF3@XFWXB6,A;FPO\IL?\
ME>B]*<CB\3SV/GYF[X:-P6L+FUP=+D?Y17V1A_A8-JU[Q9B6)RS&Y"KF7;97
M]U]0W1W.'HK&TPKJR96VHI[6\:YWB8KOU&+62=D:_68!W9&)%$'9GZ+MPFH8
MQR\_C'])\MCY<SXAC;#1L=H%+%2%CR.^\1-C8 LP0ZBQ (ZU[R+UCPV5A0)F
M;TSI$R4R'"J06DQACI, 6%SM5"X-KL&()N+RL+\*SLOKUEM(.H"_WFO8=POM
M1O.T:3E<:1$0\-O+VS[;KE@47=V@^_DJG#4&WN9^,DW"G6G104ATA$IC@41U
MOZ4YR6-2#'&\\TZY #D_^GGF66RG:+LH!4:#WC[*W1^L/3T+N"))!CX^.^/=
M$ ^)Q\<P@L-Q\KE@S"YML4VO5:8_^%9V'T"%VGD).9\N<MAS*]?R'-RF1:9(
MW.V5B)>[-\AX<R#68V4E;DM6214OF">9+$AZRPA(-6&*DNLFN\36.;3D>D^>
MR),RZP(LT3( C;58C)21&(";KB,$;G+-NN 0I%;\;UCZ=QH\&S3N\,RN2X#,
MH.+)&ZW,E@#*1Y45%V@7!8&K:8U^%2VBMH''4U=8.S5:=:X[^#RJ%@P]1<41
M),1XMDMI^[I?*F638<8H2;9K"U+)=!4-.%CR )U)]RY;**<AR"2QD>D^8#R1
M0,C1[\MA(SG>XGQ^W'W#;5D?R7^H 0+]=$7K3A)=F1.'$C+AAD"K9#!E]R0K
MYA82)]H1:_<9[FQ%LH-I&_;;WN$LUDLESOLJGF?'E9W;$K-BLLUCC#>0GV/L
MN[RL.7O"-*Q9D"XW.@QC=.CXQB)4)6+;S$::-@E7C%OUA-<4AY7*^G^2XZ)8
MHHP<.1X+@!Y$#)CRK(SHJL?,Y6Q*M=PK&Q%Z['&>I>(Y28Y#2E<J.*< EHXI
M"&G@9 C,Z@;5$A(WK9"ZK<&U?&7=QOOW(0^3]Y6!ZKN$I>2</9-SAEV5D[9C
MBOM J5HCKQ8GTC,I8[EY8\O.Q5,62D'+)HF5Z[ZJT<.TV;GH'BQU_;\/P'&R
M8N%GS8[Q9D4$8"N?,I50!O L"V@)T%R 2+J+?/>=]2\G#EYW'09,<V'-/(Q9
M -K!V).W<"=IN=HW$!20"06W?*O7K:\+32E-*4TI0>T/Z6LUD=:S,WL_A;MZ
M_N1;/_Z&H+7"X+]3D?VW(_XC5Z7U-^MQ?[%!_P %*PSUW*\S32E-*4TI32E-
M*5]T(7?EMDL>W2K[9KA.Y#I;&R_!F5[:'=,DL,>!;F] RU3=U<SN BWI*FC9
M(61M]*FX55%DL[9N$W+5=7F!!0"F / 2>G^4CSWY*%8W=>3;(5"VW>C8XA/F
MVG:P-S8BQ ZBOJ4'J;AI<6/CYVD2-^,6!G"@[73*:<:;A=2MEOU!-]I -5-D
M_>WLRS_B7.>W.RY)RQC&@NH;X-V@8MR2IA0+C8[;3]D>-KM2+I8I2G0UY8H5
M*R762L_6H=JM(*HH)"4KA4IBFX:H.#YO R\?DHHH9<C=F.Z=PJJMDR(Z@,4.
MX*%LQL#?4 UM?U#P.=C97&2S2Q8W:PXHWV*69<:&6)F*[P 6+[@H8C;Y20=:
M4#X5+'MB^$:SEN0R5/9%I6W#(-9DZ-5ZBO&VJYY)KE'>.L5QTX^QU.TF_4Y;
M#>;+S$XT1E7D\Q5>L%Y(3,GZ+IDNHH$LCTIDQ>FX.-QEC?DHW#,P*JA;[0C>
M&1NY$I<J%-B%LRD,!6K%]98D_JG(Y/):2/BY$*A3<N$)C!*,LB=N5Q&&+J2"
MUU8,K$U\+KI(0TM<KA+5PLR6O2EKL<E %L:S-S8@A'\R]=Q(6!S'(MH]Q. P
M63ZV=!--$[CG$A0*(!KWL"ND")+M[@0 [;[;@:VOK:_2^MJ^:Y<D4N2\D.[M
M%B1NMNM[+VTOXVTJFM;:KTTI32E-*4TI5V]O_P#_ !\P7_\ F?%7_P"_:_JE
MR?\ =V1_]E_]TUT^%_O;'_\ NK_EJ7W/_P!IG<=_^?<S?TD674.(_NK&_P#L
M1_[HJ?/?WUE?_??_ 'C5C=="N3656QO<+$;3MW^W;<A8*VYMT!A[)T';YVNL
M1;%DI*%1*YCY7O0+TZ3/OVS8/U'#+I3IIB[13 QR!Q,'(Y_C7Y?A\CC8V"23
M1%03T!]E[:VOH?DO7=]-<M'P?.8_*2IW(HI%8@=2 1>U]+VZ7TO:OKEM.W_[
M+ME3FJT>I77*V;*=.;O;[NJNM^L>$X^LK49FUV\99Q/BVHQ%&E[A91MUTEK-
MD5)U89'I4(Y)JV*FD#@!-KQO*^GN;YL29$L<4$PQ%@5%D)W$S1R.Q8*NU0J6
M06)N;FU?0.+]3\#P;0XL4LN1!\69V=D7R!8)8XU"EV!8L]V)(  "C=J:JO$/
MPI&V%CMM@H_-U\SYDG<+9+9@7(^3PN%:>VB!B<M8YWA5C,5UO&.DF-GB,:U:
M.D<51:Z+-1A HV)X_57:O'O53I$UJR_2O*MR1.''CQX"I*B;3M)C?&:-5?RE
MV(D()N^P  JM[UMQ?6'"CC/_ %,F1)G/+%(V^QLZY:R,RC>%4&(6%D#DE@S;
M36&%8WB[?I[*?PK59O$C=:9B/X0J0M2](RU#T9*UVS'BD;N$-FNDA::&2PP[
MU[6;:S2*QF6S-\=PU4%,Y2+ F8-=N;A>1CQ.)E@$;Y?'JH:,L0KWA[3;6L=5
M.JW%CKTO7G\7U!QCYW+X^0TD>'R,CLDB@%DM.)DN-PT8+M:S$@D$ VJ]6&=\
M&T'!&VICA.#NV3[=!46F[TJ;<L4'P;#URD;UYW<-3F\-AG(F0Y-6[2JM(#"L
MJL!$D9,LF]9M8E!>/Z)=RJF2CF\%S&?R9SGCC1Y'QF5^X2V,(FO(B#:-W<'A
MM!+$-< $]/"]1\'Q_$_ I+(XB7(5U[:@9)E39&[_ &A([9L==[*$!0@LP&6%
M;^&AV[5_,M2NKB2R[)5#&^XG9-<L<L6M+81LE3\6T':?.84W4MJ^FE*IBP5N
M5ZF"/%HX5@+8T&Y5%3$,! +RI?17(R83P 0B:7&RE<EB0TC9 E@OIKM06!MY
M+Z5THO7?&1<@F06E,$.7AL@ 4%8UQC%D;?-IN<W(O9[>8@U8*E?"6X4AZIM>
MPO;L^;BYJDXYG=ZUUS5DNJUB2IUIR3EC(]JLTMMJR!8YIC8PS \A&#&R.BS;
M>+G&,PQ2>JD;N!4,)POS^F,YY<K-AQ\=9I%QEC1CN"1HJB9%!7MWT&TLI4D"
MXM5*#U9QT<&'QTV1D-'$^2TDBV4R2,6[,C,'[EC?S .K $[6OK4SN?\ A)-I
M>6X[/C?#MRREAMQ><M8[R9:21&&F9$MW=(B-K=$Q-;<)9.D270\]4X]YDBN3
M#P[N4<R[=VC85I!;IY!(O-KXSTSS&(V,<M(IA'$Z"\A^P8SO(LB#99CL*BP"
MD; HLIK;R?JS@\M,Q<5Y(C)(CFR"TZ_#I&T;D2;A:17;4N#W"Y!<6.7T!\)-
MM7SUFO)<C4,BPN&J3![7=]-KQ]9[+C23@\B8.<WS%F.XFCXPI+F\Y;GJG;G=
M3F:OUFN5&I,X6*!^S%=B":SM1,G(?TURN!A1)-$T\[9>*KJKW24)(Y=VVQAE
M#!K/)(6:QLVBZ]=?5/#\AFRR0S)!C+AY;(Q7SQ%XT"1KNE96V%;QQ1A%#"ZZ
MM86&D_A<]N$Z1Y539!S=$UJN[IO@\LURTZ- 4.EN;A=N- @*7N,E[E3F%N*U
MJ5DRM9X9M8C-WYWZ<H:-;]:'K8\2=!/2')1VF[4)E;$S(@-WZ@S.6A"L5NRQ
MJ2EQ;;N-M*YLGK/BY-V/WIA%'FX,K-M%L@0($G++OL#(P$GYP:PW'=TA8_X6
MO9PQK[&WV#%5IR!EUON&7QG/,).F0*=<MOP=Z.\>3W8LH5P+]VHR#(2J+AO7
M#12Y>KGCTNA45Z$Q^:9](\TTAA25(\0XV\$,UUR_AQCWZ>[U>XUW:@7J'^,_
M3R1C(:)Y<L97:8%4LV'\2<DBU_>)^S /EV]3:]5!_P!6#:](YDM#^XW"=D<6
M3>&K'CR;N="POE6M[E+1#RF5[9DNO5:!S':<]V2?K=BJCB3;H)C().Z@O&.5
M(A1D=BT;<=?^$^47"184 RQ.'"O(AA4B-4+&-80"K6)TM(& <,&)K:?6/$-R
M$AGDOAMC%"Z(RSL#(T@596G8AEN!8WC*G85*J*\Q*O0]*KU<JI6_2J=7*N9,
MZY4.<W0E7.D1-(ZQ4N '$I2E$W$0  [&OJ0O87ZU\;?:7)2^V_MK9K-1J:BO
MWG9?M"E_^Y:YK6_OI_&/^Z:W)^K?YA_E%?KUGWB[14SG34W3[<2*)G,10A\X
M8R*<AR&$IR'*:S@8IRF 0$![(#K\=_@O,'48F3;_ .T_Z-?N0\]P8-CFXE__
M +T?Z5;?QR-H?OJMM_\ /CC'^5&L_@O,?=,G^J?]&L?CW!??<3^NC_2I^.1M
M#]]5MO\ Y\<8_P J-/P7F/NF3_5/^C3\>X+[[B?UT?Z5/QR-H?OJMM_\^.,?
MY4:?@O,?=,G^J?\ 1I^/<%]]Q/ZZ/]*GXY&T/WU6V_\ GQQC_*C3\%YC[ID_
MU3_HT_'N"^^XG]='^E3\<C:'[ZK;?_/CC'^5&GX+S'W3)_JG_1I^/<%]]Q/Z
MZ/\ 2I^.1M#]]5MO_GQQC_*C3\%YC[ID_P!4_P"C3\>X+[[B?UT?Z5/QR-H?
MOJMM_P#/CC'^5&GX+S'W3)_JG_1I^/<%]]Q/ZZ/]*GXY&T/WU6V_^?'&/\J-
M/P7F/NF3_5/^C3\>X+[[B?UT?Z5/QR-H?OJMM_\ /CC'^5&GX+S'W3)_JG_1
MI^/<%]]Q/ZZ/]*GXY&T/WU6V_P#GQQC_ "HT_!>8^Z9/]4_Z-/Q[@OON)_71
M_I4_'(VA^^JVW_SXXQ_E1I^"\Q]TR?ZI_P!&GX]P7WW$_KH_TJ?CD;0_?5;;
M_P"?'&/\J-/P7F/NF3_5/^C3\>X+[[B?UT?Z58+_  D6+L7?"D[0<B;5<$;J
M-OK>WRTWC^X.IIO>J[?&4)$5*Y14HNO*Q-.GG4HW;OE4BMDEC 5(%U2@(\1
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MZ-:_FJ&;/?R;:?<];?OKI^]S ^YS_2M/W)YWWR'^=^C6@_DIV:C (&WQ[:#
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MS_2M/W)YWWR'^=^C6@_DIV:Q[>^/;0/9 >S7;8/9 >(#V93M@.G[W,#[E/\
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MGA&KP5LOE/P?#Q5VW%7\R[^VPT@YM-'K"LW@_#L-*S24!&KJ]*J=!)NT4(!
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M565Z/A8^*905608(PU>0) ,8V'.FNTAT89,C(L.4B"BPMCQB:94C)''I$N'
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MUJ>C%(6=K]>?O9Q=U"PLW#*F9O&K8Z:+EJ84E"F3'EUH3C>.C5DCQX51V#,
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M9A&/ (BNTKVUL5!+!2+6*AB2!TN2>IK)YCEC*)CDY!F#%@W<>X8@*6!O<,5
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MO(LKJ2P)<*J':2;;KA"" .7DYG/PM) 6GV1M-VY%@#M(X2)H490A41LS2#>
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M_<D_KQ^A3\-].??Y/ZH?IT\T6S;WZMJ_PD7'^M#3XWF_N2?UX_0I^&^G/O\
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M:/I^3Y:^K?LHQ.+AY>?X#):9SC-<%-MAOBUON/R:>V_R&O5KYET?+-MX ?\
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ML,P\;6Y0;3D\[!?O&]$%>MLX-,4@2ZUS$%'JO$3"(@;F[':'4>[YB;>RG;T
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M\@+<O'E'LE[0CJ*RVOI[:&._M]E4YYET?+-MX ?]V:EW?DIVOEIYET?+-MX
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M_=FG=^2G:^6GF71\LVW@!_W9IW?DIVOEIYET?+-MX ?]V:=WY*=KY:Y"891
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M'[TZ_ 48M!=P4#]%RCSL[DHL)T@(9LN:XB6QL[#\W=T%@=QOT4$^ROGGK?\
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MYRK-W+9=(JR#ANLF)DUD%T3@<ARB)3%$! > ZP05)4Z$&I A@&752+CYJY>
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MK.SG:H6[,;LQL!=F.K,=6.I)KFX#Z0^EVO1UFMM1DG-0T*B#B8F(J)0%W%L
M6DY%FP3Z].R"43!L^=TLD4'4U*KD:M$_DW+@P)I@8X\-32.20V1238G0$Z 7
M)_@&I\!J:UO+'&+R,JBX&I U8V4:^TG0>)T&M2@E,''B40X=OB APX=@>/Z0
MZA6RM. AZ';[7Z.E*TTI32E-*5O+\BI_H!^V)Z4K\CRR_A'8?M[,?=%SK]FQ
M?JE_BC_)7X*G_7-\YJ%ULK53@ \.QVNU^AI6;UMY2\>/*''T^'IAP$?B=C2F
MXVM?2G(3APY0X< #AP[' ! 0^((:5G<W6YO3E+\J'H^AZ?9'XHZ5C<?&M0
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MT9W,PVE&+$G+[F_W;6,!MJ=UKK:I1X7J6#$BP8DE!15.X2(%4#",?;'FO<9
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MLW%E-QN ()-[+U[ ^[R#&KV$MWS:^LC"I8(L<G'3V<7<U7ELIDW+/C9E;2,
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M $ _;$]*5^7U/O?@_P#O].=-6=Z@K=^93I13O. P3%7KSCI!( X\,($$_'@
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MZ*=P>%//!5_)ZQ^%(KN#3M-XCZ*=P>%<A,OU<2J_^7K%ZE(##]5(KLATR)>
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M'(@X".:.15.-3D.5@S<)H3N[QR&=0J[$ 8L6W .P8FXV^4,FHW,+5=XSALC
MSUG&WL#&6-BS]QV*JH7:QC0J!8[O,5?1MBM>LS-<"O2TTI32E-*4TI32E-*5
M6%S_ 'W ?Q*J/W(1U!/;_&-2;V?,*M#D* >VS'U^JD:LW;R5IHUPK,<X=F4(
MT0D+!7)*(9+.SHIK+$:I.7A3*&(0Y@( B!1'@ VL658,J*=[E$D5C;K96!-O
MHJKF0MD8<V.E@\D3J+]+LI O\ES7SU4V2Y#@[;+NZW-T:8QD:K8?-'8HGGTU
M%1<E,P.1&U^S3CB5D&,-(I-L69 FVRDHR_<SGHI!ZN@NT,U-PUZH>HL62!5F
M61<S?+>50"0#'LBD )'VB [3J+J 0VZO&GTMF19#-"T38/;AM$Q8 LL@DFC)
M"FT4C L-#9B05VU>7!6VR<Q5D^OY E8+&[L3X\N-5=K1+N15E\:EE<N7'(M:
MI=&>2=>!U.TN&K5M) E446BQ00CR]&VZ$Y$4N?R7+QYN&V*C3#[56%P+26B1
M&=P&\KEEW]&N3J;ZGI\3PDW'YR9<B0'[%U-B;QWF>140E;LBJ_;ZK8+HMC86
MPD]I>7+(^;05B>X\<42"-:XUF)++:UY2X0ENW74//CP;!$&KS5G"&:TVN.X<
M6Z;MZ"SDP?JA&ZH@2XG.8,2F6(2C);:3Y5LA7&>$;3N)/G8/>PL/82*H2>GN
M2G<13&$XB;P/,]W5\N/(.X;0%\BE+ M<^T*=.R]VE9;B&M@D,?V6D05DJ+N<
ML.WUNX?3R=9J,TVW#V_*%,K\PQ:19A8TXN.[2K!.T&I%@0*L=)%,R2:9M87G
M,&1D7*21HI %GT7<P["1NP).K[U#@FU[7)N34G].\C$KOAO$D\99L>Y;:C#(
M>5%( T3MN8R!>UR + 53Z.QFY0UGE7$9;!F(TN.#5JH6%[<C0TM!2:V#93&L
MQ"3$4ECJ8GINL62[RCJPN"H61BT,Y?G759*.4$SJ;3ZDQY(5#IM?N[F4)<$=
MX2 @]P*&5 $%XR;+8, 3;2/2F3%.QCDW)V-J,7VE3V#$RD=MF96<F0VD478D
MJ6 O5MEVE7&(=0!<+1.**HG&8"6Q;*.;8=:QPKR4-7K D 0-55IZTG5WDE;9
MP[J4F49DZ<TU54+(QCI4J1BZ(N<QY WX@T[WRNX-OE(&Y?>;=9@%%E0KY"!L
M<"]6)_3V3&4'%KCQA</M$OYE)VM[J;+J2[7=P_G!(>-C:H"I[.,F1T3"1TO)
MTH&L?/3CP(;ORM(-(ZO2NYC%>9F]>;*Q-$IT+T#6K4M^U,FSBHYF5ZNF1)$J
M1CJ%VS\_AL[.@DW%0+VL2PQY(MQN['5G4ZLQL#<DZ5IQ_36<D:I(8MH=CMW$
M@*<F*;:+1HNB(PL$5=Q%A;6J_P $88R9 8US^PD7R"5MES6S">$7MX82JK%C
MAO&"5FK.&WEGBS+%D'+:5=3KQX\.F8#/FAD52\0,4-5.2Y#$ER\5D'V"[9I@
MA%S+)M:4*>F@  \#<5<XGC,Z'!S$<CXAM\$!<&PABW+"6%[D$L6-O>%C5"8U
MVE9/ISBL.[-$8MO4-%W+)4PACF=M"Z=:I)KRUQ&:&OE6/ 8J@*ZK;ZJ_HLOT
M;-O!QB)$Y@3(N2*G<G5M9G.8>0'6%IHY&CC'<"^9]G=NC;I&;:P==2['RV(M
M8"I@^G<_&:-IUQY8EDE/;9CMCWB';(FV)5WH8WT"*//HURQ,).[+\D3>/*+3
M7+''J3FHRMA+?'T'='$=(;@G,W69F!994N\G9L1W1K#7V#>2 O44U6,JX36>
MN#(2""B+8P[(_4&)'E29 ,MI%78"EQ  P8QH%E2Z$"Q(*BP%U()K7+Z8S9<.
M+&80[HV;N%7(.064J)7+0N!(I-P"KD%FLX(4U'R&T"]Y#G<NQLA!U:%C%;'D
MJ#99'M\O8YR[Y!K\[MCK&+H.LRL>Z@21\MCP+VN$TM(@YXK/HL52L2N^*I9+
MSN-BQP.K.S[(R8U"A$89#2,P(-P^SR!;:!K;MNE0;TYEYDN2CI&B;Y5$CLS2
M2*V*D2J05L8^YYRU]62^S=K4G<]H&9;?8D9!@AB"B0J>([!CQE$5B57;I1C6
MP8 L6,U:L^69XUCYRPPR&0)9.5*X+),F"; I )%==2ZPI#'YWCX(MK&>23OJ
MY+#KMF63</M"%.P%;;2V[\_:;">5Z<Y/)FWH,:&/X=HP%)T#8[1;3:(,R]P[
M[[E7;:T>X7/(\V793D(6T-(*8H6(QG8F[1D/7*'.V-_!5-S-8CHF/3R\5(.Z
MW&N$W>1)>JN7,V)6@&;(.BG_ ':XZ83E]082R(TJRS[60EG506M*[V(W'2,,
M FNI'YHM66],9[Q2+$T./O5P%C9BJ%H8X[@E0;R%"7TT!OYFO?,/;GBQ[B#'
MKJL/VY8]Q(6V?LXPS:RL;1$PA9GJ11CX-S%4'&</&1AE&AEP9,X=LW1664,
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M2J%,HH8#G$!,8>R/TA!9 +6T&GA7R:9@\K,"2">IKJZE6JFE*:4KTV_DN/\
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MT;REU)LBLQ #%=;"VI&EB1[.NE0EY/!QW=<J1(0C!;NZ*&)4-I=KZ ZW /M
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MO!OE\?-*1%QUH3S4%=MFU6;RP_S/'S[6?)%1\-CRSII(J<D:<HHFX'<(.1;
MMZWC^&Q7Q<?-D$MV&\N2O:W+D",1$$7)==?>Z^PB]O$\ISN9'FY/'Q-"0I[8
M0!N]M?&:4S!@U@(VT]WI[0VV]I9S>OD+"M-; P;L9F?-;(0G4;NC8)M.VP,!
MB3; K,,8VQ63)-<;5VPR$ADMRJ1A#-)AXY435=I19BIOUS78^!QL^<[B5CV'
M5+#:6DGL2%1MR@(!=BH&@+^Z*HR^H\OC<<;+-+O&C[FWJL6-<!FD4*Q,A.U
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M\TXDV_S:75*YDE/'-,;YOS[7J<Y:NJ6MD%4)V=J=<E55ADA58NG*I2I&Z)J
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ML_U33<OB*>,52\LJQX06[DTL_P!4TW+XBGC%4@Y^%PJOZJ %5_=RGZJ4I!3
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M9O$EDIQW"B!A;STPDH8I8_OVF)5FS/DZ5%L)#+&Z0YDT]>'D294?Q!7; VJ
M^\5]C-X;NH7J!:^IL.=Z3YS/]38!Y^2#X;A,FS8:.&&0\&NW(G!L(OB!9XH-
MN](BK2MW'*)6.K=>JII2FE*:4II2FE*:4JKWOX"5S^-%J^Y]9U$>^?F'^>I'
MW1_#5(:E4::4II2FE*:4II2FE*M'FC...MOU58W?*4E(PE4>SJ%<&:90DE-M
MF,J\C)62C$)%.*0<N6P3"D29DS'D-UB070;E#F5#7)YCF^/X'%7-Y-F3%9]F
MX*6 8JQ .T$C=MVKIJY5>IKWW[.OV:>KOVJ\W+Z;]$PPY/.18QR.R\T<+/$D
MD<<C1F5E5NT)1-+J-D"2RGRH:N9$R*<Q%1<NBUDF*,K',I))E,,%XJ79I/FZ
M;E-K*1CD <QTB@14"K(* !TE $INR&NE%()HEE 90Z@V8%6%Q>S*=01[0>AT
MKQF?AOQ^=/Q\CPRR03/&7B<2Q.48J6BD7RR1L1='71ELPT-2&ME5*:4II2FE
M*:4II2FE*K"Y_ON _B54?N0CJ">W^,:DWL^851^IU&FE*:4II2FE*:4II2K(
MWG<+C3'.3*)B"SN;$G?LFH-W%"AXNK3,R2SD-).HZ5[WO(]NJV*6J)M!>3!U
M#$)'L%$UU!X'* \7-Y_C>/Y*#B,DR?'Y(!B549M^I#6(%O);=)>P12&/6OI/
MIG]D_K+U=Z,Y/U_PJ8A]+<*S+G2R9,41QB(UDBWH[!O_ %);M8H4,T\ZO&HN
MI-7O$. B'8[ \.QV0_R#Z(:[5?-AKK6FE*:4II2FE*:4II2I:!^OL']N8KZ?
M;ZPWNGYJR.M<ME_"2Q?;Z9^Z3G1?='S5EO>/SU":S4::4II2FE*:4II2J:M-
MRJE'CTI:XV"-K<6LX,T2?RBPH-E'96CI]U4JO*8O6%&K-4R9!X"H)>4O$XE*
M-?)S,7"C$N7(L<9-KMH+V)M\]@;>/0:UP/4?JOTUZ/PEY+U3FP8''NY023-M
M0N$>38#8C<4C<JO5B-JW8@&U]LSI7<7XT<9DR\1W1<?*RL"W374BI"1?U:$L
M3Q*-AY^^%9$7-$(/73E([@I$A".*LFDH)UA, <S+YO'XSCCR_+7@X\LHOM)*
M*YLK2VOM!)%]/+< W->M_8UZ6]=_MHY*/B_3^ B<UGP2Y&#@R.L65)!#&9=K
M]Q@AS)HP95Q5L8E&QW+J]KJ5&SQ]UJU?M\2UF6<59HEG-1K:PQ#R FTV#],%
MV@R4+(D3?1CA5 Q3]$J4IP*8!$ XZZ>)DQYF+'EQ!UBD0, ZE6L=1=3J#\AU
MJSSW"Y7ISF\O@,]\>3.PYWAD:"5)X2Z&S=N:,E)%!N-RD@D&QJH=6*Y%-*4T
MI32E-*4TI7,E\BX_V ?3+;2LU^899?PCL/V]F/NBYU^PHOU2_P 4?Y*_"<_Z
MYOG-0NME:J:4II2FE*:4II2FE*:4II2FE*:4II2O1A^3>?VA]T?]VZ,_IAH.
MOEG[5O[HQO[4/]QZ^S?L9_OC)_LK?\2*O6OKX97Z*K<)3%X"8HEY@YB\0$.8
MOIAQ[8:5FU<8*)BH9(%$Q5*0JAT04(*I$SF.5-4R0#TA4U#)F IA#@82B #Q
M =+&U_96+B]O;6\ $1   1$1    XB(CV   #MB.E9II6*X^D2Z04>E2Z8$P
M6%#I"=,"(F$@+"CS=("(J )0-PY1,'#CQUFQM?V4N+V]M<FL4J&GX"!M4.]@
M;+%1T[ R)4B2$7*().XYX1LY2=I%<H*<4E"HNFY#@ ]@#$#6J>"')B,&0BO"
MW52+@V-Q<?. :YG-<)P_J/BY>$Y_&@S.'G"B2&90\;A65U#*=#9U5A?V@5,B
M42\ Y>4.4O*'+R@!>'J>4H   4"]KAV.&MM=.UM!H*U$I@ #"4P%-QY3" @!
MN';X#VAX:5FN,ZB:90,JHFD43$3 RIR)E%14X)I)@8XE 5%5# 4I>V8P@ <1
M'2Q/2L$@=:WZ4K32E-*4TI32E5>]_ 2N?QHM7W/K.HCWS\P_SU(^Z/X:I#4J
MC6H (B   B(CP  [(B(]H #TQTK-;N0_JO4F]1\GV!]1V>'JO2[/8TI6S2L5
MH<Q$@3%4Y$@5.5)(53E3!54PB!4DA.)>D5.(< *7B8?0#3KTH=.M: HF)S)
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MB(^K2RK^ONXSONNHG I1TT[$Y7+4B JKF*50YQ*0H<^;A.,R\L<A/C1RYGE
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M,K!K&S*+IJY'F<QJZ2QW1.PJ<4TZS[XU=<A+N9+LRE%!"D/=-AON+(01T<$
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MF^H$RL> K.5$Y5F,8VR1_$.FYML9 80A7+;HEU#*&N170E7>\YIB^KS<??\
M)KF]C@.5R;,QQ\64!<'&6G>0*!&1.-'<,6F%5;1L+4'DHKWO(<DD[Y5%U'
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MB.?S!#+ %39,&!]\D!D"$7+DMH!MW[MIOMM<U,^FL$SPY!:3?"5( $8!*.9
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MXXE$ADA#B.J7G<Z:8SD1B0B0: BW=V[K:^S:-OA\M;X?3G'PP+C@R-$IB.K
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M7\)+%]OIG[I.=%]T?-66]X_/4)K-1K4!$!X@(@/I@/ ?BAI6:W H<!X@<X"
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MW&X$J/>]X@$A/>(UM58>H>':-9A..TY(!VO8[2 Q]WW%) +GR FQ:];7>ZG
M;"1GH=QD5$'M<=QS"4(WK=V>-5'TS;E\?QC2%D&5;<1UH<2-W9+1*98Q5X)G
MZ"B7R1#<"\+R;(L@A.UP2/,@-@N\D@M=;(0WFMY2#[:-S_$([QM,-R$ ^5R+
ML_; 4A2&NX*#;?S CV&JA8[@\02*],(PO;9<<A()JU!X2*LI(^5.N:710CEI
M=2&)&0TVX6@'R)(Y^LU?G6:*I B)R"76IN+SU$A:(_9'S"ZW'36U[D>8'<H*
MV(-[5N3F>-=H@DP)F'D-FL>NE]ME;RL-K$-<$6OI5-L]TNWRR5EU.L<BL9J
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MGD2TJ*:O$Q8L8MBRBXMFVCHR-:-V$='LD2-V;!BT2*@U9M4$P B+=NB0"D*
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MB8^=I:DC'M36>E%G:M),QEN=-J15H8#' %$15NYG 94&:<:)HVB,CHK%UZH
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M@%7,:J"R!F>1%D 5=Q) 5P;^Q=6L;BM?^(L"(LF4Q5D$K,55RBI%(\99FV@
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MM@BW NXFLY'F';F/20,W,1JY4:K'70-RZE%S^?$!I$Q4 *62Y7[,1$KKU9
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M?&C[)5*BT%-R]_I)Z!#4J/3R#=8'"6VXN"8J:=R->D7$^QGK\ULK0I5#$<R
M-5VJRX-TTBE]7AR\.(,<98BD<]A&WECL4RS]T@!A8A-A\%N"!<FO%YL/.&?*
M.$9HT_\ 4.FP(.XZPX_8!)4E@T@D'BUBI-@*IV\/?A A7R]%5D+:WC*$I!2U
M2LS:+A'3[)=<S5D&@V6SQ=38M6ZC]W:-LV-V5EA&J*:97*KAVU.F#IR1,=;<
M=?3=H'EV%I+AE)($;1(ZJ6)T"SN48GI8&]A6K);U7?(2'N!(MI1K*3(LTB,P
M4 7+8T8D0"UR2MMS 5WHR-WK$CX.=5OV899W4ZYAI]$1B%2AZHQNSR?W6V:(
MR"QR! V6%<VB1F*EMN6:&=&,K&JJII)2)T2.AY B[<"6:,1P .\H)W%B@&.I
M0H5.T!I[V]X:E;VJ2IZDV+*9<AFC2$@;0H<ME,)!(K L2F/:^JDZ/;=5MXF
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M#)D,<OR)Q(43E_2,(<0TJ8=PI0$A3[+Z5H"*)0$"I)E 3 <0 A0 3E'B!Q
M^2 >T/;TL*&20ZEF)M;J>GA\U:]$GQ >C)Q*83E'D+Q*<WR1P['8,;T1[8Z6
M%-[]+FQ%NOL\/FK3H4>)AZ)+B?@)QZ,O$X@("',/#U7 0X]GT=+"G<DL!N:P
MZ:G3YJUZ-/B)NC)S")A$W(7B(G  .(CPX\3@' ?3TM3>]K7-M/;X=/H]E:%1
M1*  5),H%$P@!2%  $P<#"' .P)@[ ^F&EA0R2-JS,2?E/LZ4!%(!*8$DP,0
MO(40(4!*3APY"CPX@7@/:#L:6%.Y(006-B;G4ZGQ^>M2)IIARID(F CQ$"%*
M4./I\"@ <=.G2L,[N;N23\IO6_2HTTI7IM_)<?[6FY?^[&G_ $LT/7RG]K/]
MS8W]J'_#>OM/[%?[[R?[*W^_%7MMU\$K](U8.\[BZ!C.XRM6N[T[$&K;&J$.
ME Q-PN5LGK+DYUD%& KS2FU6I2CQ0[U+';PS51NNZ.L=-4JJ3<")F6Z6/Q>3
ME0+-CB]R][E54+'LW,69@--XO<"VEB=;<K)Y?$P\AH,DVL([;0[NS2=S:H15
M)U[9L03?6X&E^@SW;;='T,G8D,HPP0BCFOMN^3EA.,T$RV?',KEN)?K@[BT%
M6\0./("0D7+PY2MF16#E%P=-P@HD63<+RBOVC"W<L=+@^ZXC(Z]=[*H'4W!%
MP0:BO/<0\?=$Z]JZZD,/>C,H.HT';5F)Z#:02""*IMQO>VS-(M&6<7V72246
MLR3E@.-LG'GHA"G5VNW&RREAKB=//.UR"B:9;(Z84?OF[=F:,=%<%4,F!A#:
M. Y4OL$:W\NN^.QW,RJ%;=9B65EL"3N%K7K2?4O"JG<,K6NVG;DW#8JNQ9=F
MY5",K[F &TWO:NXRW@X>77OS=^%[BU*-E5?$#1,,<7F;=Y"LJ%-9WT[C&D=7
M:]*R-TCDJNNL]7,R26%JR;"Z6Y&ZS=16+<)G#ME>V1)#W#YT 1=Q3SEF 4[K
M 7M<FPN00,KZ@X\F4/W5,<_:'V;L9&V!_LPJDN-MV-@;*-QLI!,O [M=OEHL
M4=6:YD 9IW*O<<1C*5CZM<EJ@:4R]%,)O&<4O>!KY:@SE;C&2:"C5LL](N J
M<BA"' 2A"3A>3BB,LL6U5#D@LNZT9(D.R^XA2#<@6\+ULBY_B9YEAAEW,QC
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M+A1XN'K<'6X9Y8;#-SR525?=5:LU#(I]*)A%-$RNM<O%S#,;$QR'*Q*Y8D(
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MXFI:>9STD#6]V5!G&QM?-+P-#D'4.R<MDTU3(2KM,4TTB) :.7SLV9@38T@
MFGRC*Q T ('D6Y+6+@,0=+JIN3>IX7IV#!Y&#+B),&/A"!03J6#'SM8!;JA*
M @7LS"P %9I:X->CJ77^L<=]L93]HC-8'O'^"GLJ(UFE-*5N(82'*<OR1#%,
M''LAQ*("'_\ ,-*=-:PRDMDU&D&DE'H9*R[#Q\S&Y;J$PUB92FHFDL4YMNOG
M#O6)5W;FE.GB=9/;UG3EB_3.2?9$?+HD?BD8A2=U>?R%8,8H693&P)#:21+L
M23WK;MM@1[AL#MO7G7]-XKJ4$V0J,LJ&Q36*9^X\5RA.W=<AO?&XC=;I6^6=
MKM,R[-M)24M=^J\8..6N(K'4ZA)03.N7+&;>UQ]P/4YY.7KTS*-T'4A%HH'<
ML'3)X5F*B1%2]*<PU\+EY\*,HB1N_=,BLP)99-I7<+,!H"38@B]C;2K.?PF-
MR$@=Y)43LB)D0J%>/<'VM=2=2 +J0;7%]35(5+9%A^DO)A6O+R[".D;Y7\@L
M(MK"8X8.(22@,P1N<$XE.W1E%8WRPU]Y=XM,#-YB5D118CT*)DQ(FH3?-S^;
M.JB0*6$;(3=S<-&8K[2Y16"GJJKKJ;ZBJ\'IO QV8Q%@AE60"T8VE91-;>$#
MLI<#1V:RZ"U@19S.OP?S6Y5'%T1B^WS$;)8UA,>T4Q+%;G5:/.8^QZKE*3BV
MK6UURFV-W VA:?R<HHY==ZW;9TQ;=6!% Y^L!>X_U(8)YI,M%*RL[^5=UG?M
M@^5F6ZVCT&X$$WN>E<_D_2JY$$"84C!X5C3S,5W1Q]TBS*C%6W2$D[2"!ML+
MWJ^C_:[XY8NPU5;QD";KU^Q?C2;QH^NV&F-=I;&5KMWI;&DY K<;7)BO3\-#
MUN:BXQIU;J[5NZ8K,D56QFX\R>N>O+]C,GFQXU;&EE#A)2S$%&+HQ8,"6!)O
M<D$$@WZUTWX3XG"QX,J5DRX(6C+PA4!5T".H4JP"D 6L 5(!%NE1Q-E6-D$*
MBR:VB\MHRG7RG9'8M"&IQGSBQT.CXVH$ "5J5J*EPKD>O!XN8$D4X=_'FDTW
M+M!R91LL"))'GLLEV*1EY(V0GS6VN[N?+NVL;R';N!VV4BQ%Z@/3F&!&JO*$
MCE20#R7+(D:+YMF]1:-=VQEW78&X-A:VJ?!W4I7'..X3+%[ME]R+0*GBNNP%
MN>-J+.PU)0Q@UMA&=?J%8LV/W->FZB^=7V7!8EBCY1ZL@NB4RQ3-D3$MS>I\
M@94LF'&D>+(\C%1O!?N;?,S*^X,-BVV%0"#IJ:HX_I'&^$ACSY9)<R*.)5<[
M&"=L-945D*LA+O?N*Q((U\HJ^;?:5CEHDS(RF+2P487'#M[9J1J=1BVK6PX0
MI\K3*@JU@HRJ,ZTSCW+*85</6B+)-JHX*7HR)) *0\\\SE$DLJ&\<J&^XW65
M@S7);<3<  DWMU).M=,<!AK;:S@B2)Q;8 &A0HE@%"@$&Y %KVL -*MK!_!\
M88@9RMVAM+V-Y8X*0F73M_+5C#LO&RS";M4;<U8*/J4EC!W4,>1;"?C16:^*
MS&%61,[=&YS'7,<+4GJ7.DC:(J@B8"P#2 @A2MRPD#.2#8]PL#8>%5(O2?'1
M2),K.9E)))6(@AF#[0AC*1@,+CMJA&YO::NOBS:]4,27AK=8*XY#F$8.GW/'
M])I]DE(%W5*'3;U?F>2IF$KZ;"NQLVZ!&S,P!NXDGKYRFS$J G,1-/EJ9G+S
MYN.<>2.)=SJ[,H.YV1"@+78@>4ZA0!?6VIJ[@\)C\?E#)BDE8+&Z(C%2J([B
M0A;*&/F&A8L0-+Z"LE=<FNU32E-*5,3/Z\P^TT5]*EU@?YZ&H?6:4TI32E-*
M4TI32E-*4TI32E-*4TI32E-*4TI32E=IC^_F7\,:_MZ>AZ4K?(_7&0_ASSZ8
M4T'2AZUTM*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E;R_(J?Z ?MB>
ME*_+]L'P@.]-&?G44]R.1R)I3,JDF0'41P*FF_<$(4/J3VBE  U^LX_3O"&-
M2<:.]A[#_IK\5R^J>=61E^(?0^)J(_Z@N]?WR>2/941]Z=;/\.<)]VC^C_76
MO_%?/?>'^D_Z:?\ 4%WK^^3R1[*B/O3I_ASA/NT?T?ZZ?XKY[[P_TG_33_J"
M[U_?)Y(]E1'WIT_PYPGW:/Z/]=/\5\]]X?Z3_II_U!=Z_OD\D>RHC[TZ?X<X
M3[M']'^NG^*^>^\/])_TT_Z@N]?WR>2/941]Z=/\.<)]VC^C_73_ !7SWWA_
MI/\ II_U!=Z_OD\D>RHC[TZ?X<X3[M']'^NG^*^>^\/])_TT_P"H+O7]\GDC
MV5$?>G3_  YPGW:/Z/\ 73_%?/?>'^D_Z:?]07>O[Y/)'LJ(^].G^'.$^[1_
M1_KI_BOGOO#_ $G_ $T_Z@N]?WR>2/941]Z=/\.<)]VC^C_73_%?/?>'^D_Z
M:?\ 4%WK^^3R1[*B/O3I_ASA/NT?T?ZZ?XKY[[P_TG_33_J"[U_?)Y(]E1'W
MIT_PYPGW:/Z/]=/\5\]]X?Z3_II_U!=Z_OD\D>RHC[TZ?X<X3[M']'^NG^*^
M>^\/])_TU]\?R?S=CN3RKGK<A&Y%S-=+<QA=OT?+13:5=,138R2F5J0P.\0%
MJQ;G*L9DZ42'B(@)3CV-?-OVF<3QV%Q>.^)"B.<D D>&QS_F%?6/V3<SR7(\
MMD)ERLZ+C$@$^W?'K^4_37J)\Y60/*^<]E_.:^,]M/ 5]YWOXFGG*R!Y7SGL
MOYS3MIX"F]_$T\Y60/*^<]E_.:=M/ 4WOXFGG*R!Y7SGLOYS3MIX"F]_$T\Y
M60/*^<]E_.:=M/ 4WOXFGG*R!Y7SGLOYS3MIX"F]_$T\Y60/*^<]E_.:=M/
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M++YLRQC&V,:1(UZB5RLV%"RT)&R%5KLM9)6P=#C6Y!..W;:2N;>GQC2:449
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M"FRIH.R<Z8%EZQ*3E=DBB7L@LR>.6YP'B4XZY\\+8\S0-JR&QT8=/D8!A\Q
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M@9:R.X6>G:N#HP,'SY!PZ;<B?*?BDD)('E,PB0 HIEW;B$139O> 8*"%;\X
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MF[$G4^VKO7/]]P'\2JC]R$=54]O\8U:;V?,*I$O, \Q0XB7@;M<0#@/'B("
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M9QS"5P*I  H6CRF>S$F0DLTA.@U,P"R>S\X #Y/98U4'#\:B@",!56(#5M!
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M2W9C8O*YDZ*NX]P[WL0+V)&ZP-@=1:DG%</BK\1*@2&,1@[F;8!&-D9()VW
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MPW540705(/$BJ*R1B*I*D'M&*("&L$!A8ZBI*S(=RFQKN'EI907YE):44-+
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M*(L;='#<;3)="6#A7WD@1A65V(TWL + (MJJR\9S[39026<!MXCVN I0LG;
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M'Z92W3MB5LD@5X=V<2JHO54P I1+RV#S.23+N[1$R!&NBZ(MMJ)]4+M6UNA
M-5AP6&! $,RG'D,BV=M9&W;G?Z[-N;<3U#$5S--LD:XC*1'W:1RMD<M+582@
MLK78;,XJ]DM$=*2$VTM%BIY5#1$D^82TD=1FBJ*C9J1%N0"&!ND)<-RTH>1\
M9883)<755W*I !56Z@$"Q(U-SKJ:RO"P%(DRGFG[5C9W;8S E@S)>Q()N ;@
M646\HJE)?8U@R1:V=G%8RF*$A<9?'4U8"XR5EZ"5ZYQ5UD](:]! -V[0L/&N
MW/656(I&:NG2**JI#'2((;T]1<HK(SRB4QJX7N /82>_[VMR- >H!(!UJO)Z
M8X9UD6.(Q+(T;-VB8[F*^P>72P)N5M8D D7 JN+=MMA;U3;+1+0^S3)P5Q@X
M"NV=0]]N9968BJ\V?M4TEY'B8Z#B;)(G-++(%25DU$TCKF,9(@A6@Y6;&R$R
M85@$D;,R_9K8%K'I\EO*#<+K;K5O(X?'R\:3$R'R&AE15;[5KD*".O\ M7\Y
M%BQ )Z4B-MD-"Y--EQH^S,M='%>KM6E%)"[VM_"SL#563II#Q\W!.$S,'B)%
MGJSQ8I02(XD5!=*%,MZK1^5FDP_@66#X<,S"R*"K,020W4= !X+Y1I2/A\>+
M._$5?(.445#>1BK*H( 9>AZECXMYCK5[>]$O[4RG@YYZQKG;E\174L:=Z)?V
MIE/!SSUC3<OB*6-.]$O[4RG@YYZQIN7Q%+&N5.)EN5Q]2I3LH=CZG//_ !#<
M?V'TM-P\12QK\WR2W*;J9"WR$/%;B=P;AZ_L[N+C&#?,V1@.X=O)=1FQ9-R#
M9BD ZRZA$R!Q .(@&OUDO&<0L D?&Q[!;D]M/#YJ_%9YGG'R#%%DY!8M8#>W
M^FJ\L%D^$/J:F94[/?\ =O GV[R,+#YT"5R=D]H7%$K9)PM9K\==CJV8$X=Y
M-SYNJM2&$3+J\>3B4!$*T<?IJ40F./#89()BLB>< ;B5TUL-3X5=EE]70F<2
M29@.,P$FLGE);: ?"[:"]K^RK,FW7[ER$ Y]S>>RD, F*8<V9&X& O;$H^,W
MJN'Z&KOX5Q'W;&_JT_T507F/4#-M7(R2P_VGT^?72JXR#F?>3BR=:5J];A\Y
M0\T^KE8MK9JVW$6:?2/ W&%9V&O.S/JW>Y>/2</(F0244:G5*[:',*3A))8I
MDPT8^'P>4ADAQ\<H&9=8@NJDJ=&4'J#KT/4$BK&1G^I<5Q'+D9&XJK>60MHR
MAAJK$#0@V.HZ$ @UICC,^\_+N0Z7BC&^>MPUJR)D.SPU-IE79YQO39[.V:PO
MD8V&B4%I&WLF+=5\]<$3*==5)(HFXF,4.(ZSDX7!8>.^5DX^,L$:%F/;715%
MR=%OH*QB9_J7.R(\;%GR7FE<*@WL+LQ  N2!J3;K5:4"P?"(Y5OMEQAC3(6[
M&]7RFA/J6ZO5K*N29)6KMJN_/%6"0L+]*T]Z(:*BY(G5U';EPFV%8Q2%4$QR
M ;1D1^FL3'7+R8L1,=[;240;MVH %KDD:V&MJL8LOJW,RVPL>7*?(2^X!G.T
M#J6()L!IJ=-0/:*98L/PA."H:G3^8,H;G<>Q=_?WZ*J2MCS3>6SB5DL76@]+
MO[ 6"5R7?Q[JLVA,6BQ'22(G-P.ETB8@<6)'Z;SG=,2+%D:,(6M&N@D7<AOM
ML=RZZ7IF2^K<!$DRI,I5D+A?.UR8VV/I>XVMH;@598=UFYH!X#N9SZ @3I!
M<UY& 0)PX\_#QFX\G#T>UJ]^$\3]UQ_ZM/\ 17/'-<\1<9&3:]O??KX=>M7#
MQ=E'?1FVWL*#B'+FZ3(]SDVDE(,ZY4\KY-E)$\;#,EI&8E%@2LP(,XJ(CVYU
MW3I<Z;=ND43*'*'9U6R\7@,& Y.7#BQP @79$ N38#IJ2= .IJUAYOJ?D,D8
MF)-E/D&^@9R0 +DFW0 "Y/L&O2H:[YTWDXVMM@H=^SMN2J-RJDB:(LE;F\Q9
M':RD-)%(FKU1ZAXT'*10Z2I#D$#&*H0Y3%$2B C.#!X/*A7(QX,5X6%P1&EB
M/HJ&3R/J3#G;&R)\I9E)N"S^SK[>E=>+S]O%FZ_9;9"YRW.R]5I8PA;C98S*
M65W\!4S65\K&5PMEF&L\K'P8S\D@=NRZRHEUI<ADT^8P"&LMQ_!I(L+P8@E>
M^U2D=VMJ;"US8=;=*B.2]2M&TRRYAB2VYKR66_3<>@O[+VO[*IS\:[<QP$WX
MS6>^4#<HF\]F1> &X"/*(^,_ #< [6MOX3Q/W;&_JT_T5K_&>?O;XC)N1?WG
MZ?36XFZO<VH(@GN8SZ<0 !$"9KR,80 >T(@6S#P =/PGB?NV/_5I_HJ+<WSR
M"[Y.2!\KN/\ /7I%_)GLT9ER!NHW&QU^R[E&\Q[#;<F_8L+ED&W6ABR?>=.C
MM^NM&DY+OF[9YU=8Z?2D*4_(<Q>/ 1 ?F'[4\+"QN(QVQH8HV.2 2JJIML?3
M0"OKO['^1S\WF<A<N:611C,0&8D7WQZZGY_I/C7LQ[Z2?MB^]EN/7-?#;"OT
M)<T[Z2?MB^]EN/7-+"ES3OI)^V+[V6X]<TL*7-.^DG[8OO9;CUS2PI<U0RF8
M:<DA(N5,BQA$(B_L<4RB@S*W[@R7)O(IA'45R0#"HG9GSR<9D2;<O,IUI,P>
MI,!M6!AY)( C:[1F0:=8P"2_\4 &Y^0U6.=B@%C*MEE$1UZ2$@!/XQ)%A\HJ
MX'69SGZ/K$J*G+S<@+.Q/R\>'-R@;CR\?1[6JUUZZ5;LU[:WJ&AK4:PDE%(6
M8D7Y(2:E*[*F3&42!E-0JH(RC$_64D!4%HJ/ 5$^=$_;(<P=G4Y(VBMW !N4
M,.FH/0_P_36J.190QC-PK%3UT(ZC7P^BNE:;XSI4?'2MJL+R&CI>PUNIQKIR
MI)*)O+%;YEG7JU%I V(N;I969D$4"'$ 2(90!.8I>)@E#!)D,4A7<RJS'IHJ
M@LQ_@ )J,\\>,BR3MM1G5 ==6<A5'\)('AXU CF:E^<0N) R+'FR:9B61\2$
MY5TK.D:'8K2J9ED4@.W;N5HIN=VFW44*Y4:D%8J8I )];/@\GX7XWMM\)>V^
MVE[V_P NE^E].M:OC\3XOX#NK\;:^R_FM:_^36W6VMK57RDE*)(*NE7[]-L@
MB=PNX4=.2((MTRG.HNJJ)P(FBF1,PB81   HCZ&JX )L.IJT20-Q]T5UX^==
M2\:RF(F9<2<1),F<G'2L?(*O(Y_&R+=)Y'R#-ZW54;.63YHN15%4AC$53.4Q
M1$! =99=CE'%G!((.A!&A!'B/;6$82()(SNC(!!&H(.H(/M!&H/MKNF=39 $
MQW,J4I0YC&,L[* %X\.(B)@  XZCY3X5*S?+7#WTD_;%][+<>N:S85BYIWTD
M_;%][+<>N:6%+FG?23]L7WLMQZYI84N:=])/VQ?>RW'KFEA2YJ56D9 (5@<'
M[P#FD)(IC=:7YA*5&.$I1-S\1 HF'@'H<1U$ ;C6;FU17?23]L7WLMQZYJ5A
M6+FG?23]L7WLMQZYI84N:=])/VQ?>RW'KFEA2YIWTD_;%][+<>N:6%+FH*P7
MN/J;:/>V>V$@6<M/P-5C74I)K-4'MDM$DC#UR$05,?D&0G)9RFV;$$0Z1=0I
M 'B8 '9%!),2L2EF52QL.BJ+L?F U/R5JEGB@4-.X16=5!)M=F-E7YV.@\37
M+$71K8']GBX.S&EY&E2R$#;F;!^Y<+5N;=0T;8F\5+@0W*U?*04RT=]&(\P(
M.4S#PY@UAX7B5'D7:L@NM_S@"5N/DN"/G!K,<T<KO'$P9XVVN!^:Q :Q\#M(
M/S$5S3-J-7DHI::F)%@C.3<97(E10914CV;F5#I1C!,6R:_1F=*$$ 4/R(D[
M9SE#6$C,I(C )52QZ: =3_\ S6I22+$%,A(#,%'74GH-/'Z*F1=3@'!,7,KS
MB F G3.^82@/ 3 7FXB #V..H>6U]+5.S=-;U;F1S/38B)R3/R]^1BH/#[U>
M/R;+R+N2:,*:[:UV$MKE.5752 #%1KMD8NA.@"I.5P4H")P,4+*X>2[Q1)&3
M).+Q@6NPW%=/_$I&MNGA51\_$CCFEDD"Q8YM(3<!"%5]?_"RG2_7QKBIN;:1
MD0(DU%R$A:PFSV9&.&'<RRXF=TU>.;6J/>E.W2/#RL&O+MBKLWH-W0=,42IF
M+Q$,SX63BW^(C*;=M[V_.OM(\0;&Q%QIUK&/R&)E[?A9!)NW6M?JE@P.FA6X
MN#8Z]*N4#J;$3E!S*B9, %0 6=\2 (<P"<.;B4!+V>SZ&JOE^2KEF^6N'OI)
M^V+[V6X]<UFPK%S3OI)^V+[V6X]<TL*7-.^DG[8OO9;CUS2PI<T[Z2?MB^]E
MN/7-+"ES3OI)^V+[V6X]<TL*7-2LO(R!%60%?O2@:(BSB!72X )C-2B8P\#]
MDQA[8]L=8 'Y:R2:BN^DG[8OO9;CUS6;"L7-.^DG[8OO9;CUS2PI<T[Z2?MB
M^]EN/7-+"ES3OI)^V+[V6X]<TL*7-.^DG[8OO9;CUS2PI<T[Z2?MB^]EN/7-
M+"ES4-/75I5X\DK8[/WDC5).%AB/I&17;MCRUCF&-?@(XJ@G$!=2\Y)-VB!?
M\]=8A?1U..%YFV1*6:Q-AX*"Q/S  D_(*URSQP)W)F"IN N>EV(51\Y8@#Y3
M5'/L\8ZC(%C:9#*D&SK<FVO#R/FUYU4D>]:XT9RTAD%PW7XCTB=.8P+U5^(!
M^HD:J#V>76]<#+>0Q+$YE!0$6U!D("?RB1;QN*KMR."D0G>9!"P<AKZ$1@F2
MW\0*Q;PL:[>/LTTG*["1D\;9%8W)G#O48Z9&)DGH.X=^X:)OVK67BWQ&<K%*
MO&*Q5T.L()@NB8#IB8G9U')PLG#8)E1LC,+B_0CI<$7!L=#8Z'0U+$S\3.5G
MPY5D538V.H-KV(-B+C47&HU%5_WTD_;%][+<>N:KV%6KFG?23]L7WLMQZYI8
M4N:=])/VQ?>RW'KFEA2YIWTD_;%][+<>N:6%+FG?23]L7WLMQZYI84N:=])/
MVQ?>RW'KFEA2YKLLI.2%ZS 9!\("[; ("[7$! 5TP$!#I.R AK! M2YK=(24
MB5^_*60>@4KUV4H Z7   '"@   "G   .UH +5DDWKJ=])/VQ?>RW'KFLV%8
MN:=])/VQ?>RW'KFEA2YIWTD_;%][+<>N:6%+FG?23]L7WLMQZYI84N:=])/V
MQ?>RW'KFEA2YIWTD_;%][+<>N:6%+FK3Y)W%8JPZYAV65,P5N@O)]!T[B6MD
ML*C)PZCV*R#9_+J)%%4["!8.72::\@Y!%B@HH4IUBB/#5S%XW.S@S8<+R*I
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M#TUI3ZD_93Z#TUI3ZD_93Z#TUI3ZD_93Z#TUI7(?O;P+TG??AP]1S]5X<O\
M]/-Z'Z6FOR4KC^I/V4^@]-:4^I/V4^@]-:4^I/V4^@]-:5R%[V\I^3OOR</5
M\O5>7A_]?#L</T]-?DI7']2?LI]!Z:TI]2?LI]!Z:TI]2?LI]!Z:TI]2?LI]
M!Z:TI]2?LI]!Z:TJ6E^]?2L>?OCQ[T1?+R=5X<G5B\O-S?Y_#M\.QH+_ ):R
M:B?J3]E/H/36L4^I/V4^@]-:4^I/V4^@]-:4^I/V4^@]-:4^I/V4^@]-:4^I
M/V4^@]-:4^I/V4^@]-:4^I/V4^@]-:4^I/V4^@]-:4^I/V4^@]-:4^I/V4^@
M]-:4^I/V4^@]-:4^I/V4^@]-:4^I/V4^@]-:4^I/V4^@]-:5V67>KKK/AWSX
M];;<.;JG+QZ<G#CP[/#CV^&AO:E;Y#O5U]_S=\N;KKOFY>J<O-UA3CR\>SR\
M>UQ[.@O:LGK73^I/V4^@]-:Q3ZD_93Z#TUI3ZD_93Z#TUI3ZD_93Z#TUI3ZD
M_93Z#TUI3ZD_93Z#TUI3ZD_93Z#TUI3ZD_93Z#TUI3ZD_93Z#TUI3ZD_93Z#
MTUI3ZD_93Z#TUI3ZD_93Z#TUI3ZD_93Z#TUI3ZD_93Z#TUI3ZD_93Z#TUI6\
1O>G@I]=/D _\'^R$TUI7_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
